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Extra-renal synthesis of vitamin D3 has been reported in many tissues and cells 
including barrier sites where it induced immunomodulatory effects. I investigated local 
synthesis of vitamin D3 and its role in the induction of host defense peptides (HDPs) in 
human ocular barrier epithelial cells. I also examined the association between vitamin D 
receptor (VDR) single nucleotide polymorphism (SNP) with intermediate uveitis (IU) in 
Caucasians. 
Human corneal endothelial (HCEC-12), non-pigmented ciliary body epithelial (ODM-2), 
and adult retinal pigment epithelial (ARPE-19) cell lines, expressed mRNA and protein 
for VDR and vitamin D3 pathway elements and can locally synthesise 1,25(OH)2D3 in 
vitro. These cells upregulated mRNA, but not protein expression of HDPs in response to 
vitamin D3. IL-1β and TNF- did not synergise with vitamin D3 to upregulate HDPs in 
ocular barrier epithelial cells.   
VDR single nucleotide polymorphisms BsmI (rs1544410) is significantly associated with 
IU. Allele rs1544410-T and genotype rs1544410-CT were higher in IU patients than 
healthy controls. 
The results show that that extra-renal production of active vitamin D3 occurs in ocular 
barrier cells and may contribute to immune regulation in the eye. The association with 
SNP in the vitamin D3 receptor gene and intermediate uveitis suggests that genetic 
control of vitamin D3 may be linked to ocular inflammatory disease. 
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1 GENERAL INTRODUCTION 
 
1.1 Vitamin D 
1.1.1 Vitamin D metabolism 
Vitamin D is a secosteroid hormone required for bone health and mineralisation. 
Vitamin D can be ingested from diet containing oily fish and fortified food products as 
well as over the counter dietary supplements. Vitamin D exists as two biological forms, 
vitamin D2 (ergocalciferol) which can be obtained from plants and vitamin D3 which is 
synthesised in the skin upon exposure to sunlight. After exposure to solar ultraviolet B 
(UVB) radiation of wavelength 290 to 315 nm, vitamin D3 precursor 7-dehydrocholesterol 
(7DHC) in the skin is transformed into previtamin D3, which is converted into vitamin D3. 
Vitamin D3 is referred to as a secosteroid because it is closely related to steroid 
hormones, composed of 4 fused rings of cyclopentanoperhydro-phenanthrene (A, B, C, 
and D).  
When 7DHC is exposed to UV radiation, the B-ring is broken at 9,10 carbon-
carbon bond to produce previtamin D3. In a heat independent mechanism, the molecule 
undergoes further cis-trans isomerisation around carbon 6,7 single (s) bond to convert it 
to vitamin D3, a process that influences its conformation and stability. The trans 
conformation has been proposed as the preferred ligand for nuclear vitamin D receptor 
(nVDR) to deliver genomic functions while the cis conformation is the ligand required by 
membrane VDR (mVDR) to induce non-genomic responses (Norman, 2008) as will be 
explained later in this thesis (Figure 1.1).   
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Figure ‎1.1. The secosetroid structure of vitamin D. The vitamin D precursor 7DHC is 
formed of 4 4 fused cyclopentanoperhydro-phenanthrene rings (A-D). When exposed to 
UV radiation the B-ring is broken at 9,10 carbon-carbon bond to produce previtamin D3. 
This molecules further isomerises around carbon 6,7 single (s) bond to produce vitamin 
D3 of either 6-s-cis or 6-s-trans conformation. This conformation influences the stability 
and flexibility of the molecules required for its functional activities (Norman, 2008). 
Vitamin D3 produced in the skin is incorporated is stored in adipocytes while that 
obtained from diet (along with vitamin D2) is incorporated into chylomicrons before it is 
released into the circulation via lymphatic drainage (Holick, 2006;Holick, 2007). Vitamin 
D intoxication does not occur as a result of prolonged sun exposure. Vitamin D 
intoxication causes hypercalcaemia which can lead to calcification related complications 
in the gastrointestinal tract, kidneys, central nervous system, skin, muscles, and eyes 
(Ozkan et al., 2012). Excess previtamin D is converted by sunlight into lumisterol or 
tachysterol, components that do not bind DBP and are sloughed off with skin turnover 
(Chen and Holick, 2003;Shroff et al., 2010).  
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To produce the active form, vitamin D from skin or diet is subjected to two 
successive hydroxylations at carbons 25 and 1 (Figure 1.2). It is first hydroxylated to 25-
hydroxyvitamin D [25(OH)D] at carbon 25 in the liver by a cytochrome P450 (CYP) 
enzyme 25-hydroxylase. 25(OH)D is the major circulating form of vitamin D and is used 
as an indicator of vitamin D status. 25-hydroxylation can be a function of six CYP450 
isoforms; one mitochondrial CYP27A1, and five microsomal CYP3A4, CYP2R1, 
CYP2J2/3, CYP2D25, and CYP2C11 (Zhu and Deluca, 2012). The second 
hydroxylation step at carbon 1 occurs in the renal tubules by the mitochondrial enzyme 
25-hydroxyvitamin D-1--hydroxylase; also known as CYP27B1 to produce the 
biologically active form of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH)2D].  
The level of 1,25(OH)2D is downregulated by a renal tubule enzyme known as 25-
dihydroxyvitamin-D-24-hydroxylase (24-hydroxylase) that converts 1,25(OH)2D into 
water-soluble, biologically inactive calcitroic acid (Holick, 2007). In the circulation, 
vitamin D is transported bound to vitamin D binding protein (DBP). DBP can bind both 
25(OH)D or 1,25(OH)2D and it determines their accessibility for cellular uptake through 
the multi-ligand endocytic receptors cubilin and megalin (Chapter 3). DBP belongs to the 
albumin superfamily and is structurally related to α-albumin and α-fetoprotein. These 
proteins have a unique structure with cysteine residues aligned next to each other linked 
by disulfide bonds that link them to each other and to the other cysteines. DBP has a 
shorter half-life than 25(OH)D of 2.5 days (Gomme and Bertolini, 2004). The majority of 
circulating 25(OH)D and 1,25(OH)2D (80-90%) is bound to DBP and to albumin (10-
20%), leaving a small free proportion (0.02-0.05%). To measure serum concentrations of 
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25(OH)D or 1,25(OH)2D, these molecules are either separated from DBP by 
immunoextraction or detected using antibodies against the metabolite to be measured 
and DBP (Gomme and Bertolini, 2004;Wootton, 2005;Zerwekh, 2008). 
Vitamin D3 is more potent than vitamin D2 in delivering the benefits to humans 
and it is the focus of this project. Higher doses of vitamin D2 are required to raise serum 
25(OH)D2 levels to those of 25(OH)D3. Vitamin D3 is converted to 25(OH)D3 five times 
faster than vitamin D2 by liver 25-hydroxylase and 25(OH)D3 has a higher affinity to DBP. 
Microsomal CYP2R1 can convert both forms of vitamin D equally while mitochondrial 
CYP27A1 performs hydroxylation only on vitamin D3. The potential of 1,25(OH)2D3 to 
bind VDR exceeds that of 1,25(OH)2D2 by 40% and this allows 1,25(OH)2D3 to be more 
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Figure ‎1.2. Vitamin D metabolism. After exposure to UVB, 7DHC in the epidermis is 
converted to previtamin D which is further changed by sunlight to vitamin D. Vitamin D 
can also be obtained from diet and supplementation. Vitamin D from the skin is stored in 
fat cells and from the diet is incorporated into chylomicrons. It is released into the 
circulation via lymphatic drainage and circulates bound to DBP. In the liver it is 
converted by 25-hydroxylase (CYP27A1 or CYP2R1) to the major circulating form 
25(OH)D. This is activated in proximal renal tubules by 1-αhydroxylase (CYP27B1) to its 
active form 1,25(OH)2D. 24-hydroxylase (CYP24A1) from proximal renal tubules 
provides a negative feedback and degrades 1,25(OH)2D into calcitroic acid excreted in 
bile. 1,25(OH)2D is endocytosed by target cells where it binds to VDR that 
heterodimerises with RXR. VDR-RXR complex translocates to the nucleus to bind VDRE 
and modulate gene expression (Kitson and Roberts, 2012). 
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1.1.2 Vitamin D3 action  
1.1.2.1 Genomic responses 
Vitamin D3 mediates its action via a nuclear/cytoplasmic DNA-binding 
transcription factor vitamin D3 receptor (VDR), a member of the nuclear receptor 
superfamily. Upon binding to 1,25(OH)2D3, VDR heterodimerises with retinoic acid X 
receptor (RXR) to form a complex. This complex translocates to the nucleus, binds to 
vitamin D response element (VDRE) in target genes, and recruits regulatory protein 
coactivators (CoA) to induce gene transcription (Figure 1.3) or corepressors (CoR) to 
repress transcription (Carlberg and Campbell, 2013;Haussler et al., 2011). 
 
Figure ‎1.3. VDR activation. When 1,25(OH)2D3 is locally synthesised or supplied from 
the circulation, it enters the cell and binds to VDR in the ligand-binding pocket. VDR 
heterodimerises with RXR to form VDR-RXR complex. The complex translocates to the 
nucleus to bind VDRE and recruits coactivators to stimulate RNA polymerase II and 
initiate gene transcription (Kalb et al., 2012). 
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1.1.2.2 Non-genomic responses 
While genomic vitamin D3 actions take place within several hours to days, non-
genomic actions are rapid and can be generated within 1–2 min to 15–45 min. It has 
been reported that VDR can be localised to a lipid-raft caveolae (plasma membrane 
vesicle involved in signal transduction) in many cell types to which 1,25(OH)2D3  can 
bind. On binding of 1,25(OH)2D3 to caveolae-associated VDR, one or more second 
messenger systems can be activated (Figure 1.4).  
These second messenger systems include G-protein coupled receptor, 
phospholipase C (PLC), protein kinase C (PKC), and phosphatidylinositol-3′-kinase 
(PI3K). This can result in rapid responses like the promotion of calcium influx from 
extracellular space, enhanced insulin secretion and the generation of cyotosolic kinases 
required for rapid responses (Campbell et al., 2010;Haussler et al., 2011). 
1.1.2.3 Classical vitamin D3 action 
The primary role of vitamin D3 is calcium and phosphorus homeostasis, through 
which it maintains a healthy skeleton and ensures sufficient serum levels required for 
biological functions. Vitamin D3 maintains serum calcium and phosphorus by increasing 
intestinal absorption and facilitating bone mineralisation/demineralisation. Both the 
intestine and bone express VDR. In the intestine, 1,25(OH)2D3 induces the expression of 
calcium channel [transient receptor potential cation channel, subfamily V, member 6 
(TRPV6)] and a calcium binding protein, calbindin 9 K. This causes an increase in 
intestinal calcium and phosphorus absorption up to 30-40% and 80% respectively (Laird 
et al., 2010;Shroff et al., 2010).  
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Figure ‎1.4. Vitamin D3 genomic and non-genomic actions. Most vitamin D3 actions 
are mediated through the classical binding of 1,25(OH)2D3 to nuclear VDR (nVDR) to 
induce downstream signalling that will activate or repress gene transcription. Through 
this signalling pathway, vitamin D3 plays a role in calcium metabolism, 
immunomodulation, and tumour suppression. Alternatively, caveolae-associated 
membrane VDR (mVDR) binds 1,25(OH)2D3 to activate G-protein coupled receptor, 
phosphatidylinositol-3′-kinase (PI3K), protein kinase C (PKC), and phospholipase C 
(PLC) to induce rapid responses (Shin et al., 2010). 
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Renal production of vitamin D3 is under tight regulation by several factors. Low 
serum calcium levels are sensed by the calcium sensing receptor (CaR) in parathyroid 
gland which triggers the release of parathyroid hormone (PTH). PTH stimulates renal 
production of 1,25(OH)2D3 and increases intestinal absorption and renal reabsorption of 
calcium and phosphorus. It increases the expression of the receptor activator of nuclear 
factor-B ligand (RANKL) on osteoblasts to bind to its receptor RANK on 
preosteoclasts. This interaction induces the transformation of osteoblasts into mature 
osteoclasts which release calcium and phosphorus from bone to stabilise serum levels. 
The bone secretes fibroblast growth factor 23 (FGF-23) that downregulates 1,25(OH)2D3 
to reduce phosphorus and calcium absorption. Finally, 1,25(OH)2D3 provides its own 
negative feedback by inducing the expression of CYP24A1 (Holick, 2006;Shroff et al., 
2010).   
1.1.2.4 Non-classical vitamin D3 action 
Many cells and tissues express VDR, CYP27B1, and CYP24A1. This allows 
these cells not only to respond to VDR, but also to endogenously convert inactive 
25(OH)D3 into active 1,25(OH)2D3. Vitamin D3 has a range of functions beyond calcium 
homeostasis and can regulate more than 200 genes directly or indirectly (Ramagopalan 
et al., 2010). It can inhibit cell proliferation and induce differentiation, inhibit 
angiogenesis and enhance apoptosis. Vitamin D3 controls blood pressure by reducing 
renin and induces insulin production from β-islets in the pancreas. A major role played 
by vitamin D3 is the immunomodulation and induction of antimicrobial peptides (Holick, 
2011). Extra-renal vitamin D3 signalling pathway components expression has been 
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described in human epithelial cells of the lung, gingiva, urinary bladder, intestine, breast, 
endometrium, placenta, prostate, and skin (Chen and Holick, 2003;Hansdottir et al., 
2008;Hertting et al., 2010;Kemmis and Welsh, 2008;Kong et al., 2008;Liu et al., 
2009a;McMahon et al., 2011). Moreover, vitamin D3 expression has been identified in 
monocytes, macrophages, dendritic cells (DC), neutrophils and activated T and B cells 
(Hewison, 2012;Van Belle et al., 2011).  
1.1.3 Vitamin D3 status 
Vitamin D3 status is determined by serum concentration of 25(OH)D3 as 
sufficiency (30-100 ng/ml or 75-250 nmol/L), insufficiency (21-29 ng/ml or 52.5-72.5 
nmol/L), and deficiency (<20 ng/ml or 50 nmol/L). Vitamin D3 intoxication only occurs at 
levels above 100-200 ng/ml (Holick, 2009). Vitamin D3 production varies with different 
factors such as geographical location, skin colour, the use of sunscreens, lifestyle, and 
age. As we move away from the equator (e.g. latitude above 35º), UVB light decreases 
and so less vitamin D3 synthesis is expected. Factors that affect the angle at which the 
sun hits the earth (e.g. cloud cover, ozone, and air pollution) can reduce sunlight 
available for vitamin D3 synthesis. A sun protective factor of 15 (SPF) in sunblocks can 
significantly reduce vitamin D3. It has been suggested that people with darker skin have 
more melanin content and need longer UVB exposure to obtain sufficient vitamin D3 
(Kimlin, 2008;Laird et al., 2010). However, recent intriguing results negated the role of 
skin pigmentation effects on vitamin D3 synthesis after exposure to UVB. Vitamin D3 
synthesis correlated with baseline serum cholesterol and vitamin D3 levels but did not 
correlate with skin pigmentation. There was no difference in 25(OH)D3 increase between 
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people with dark skin and people with fair skin when exposed to identical periods of UVB 
(Bogh et al., 2010).  
In Tanzania, people from two tribes, the Maasai and Hazabe had serum 
25(OH)D3 levels of 115 nmol/L which is optimal for bone health and is aimed for by 
supplementation. These people are moderately covered with clothes and spend most of 
their time outdoors, but they try to avoid the sun at hot times (Luxwolda et al., 2012). 
Another study in Johannesburg measuring 25(OH)D3 in 10-year old black and white boys 
showed that vitamin D3 deficiency was not prevalent among the study population. 
Although the white boys had higher levels of 25(OH)D3, only 8% of black boys were 
deficient compared to 1% of white boys (Poopedi et al., 2011). African-Americans have 
low serum 25(OH)D3 (Liu et al., 2006), this may be because the amount and angle of 
sun light near the equator is optimal for sufficient vitamin D3 synthesis or that these 
people acquired genetic changes by moving north or by marriage with Western people.  
1.1.4 Vitamin D3 and the immune system 
The immune system comprises cells and tissue that protect the body against 
invading pathogens. The immune defence can be divided into three components, 
anatomical and physiological barriers, innate immunity, and adaptive immunity. Vitamin 
D3 has several effects on cells of both innate and adaptive immune responses. Unlike in 
the kidneys, in immune cells vitamin D3 is controlled by signals from the immune system 
and is not under calcium regulation (White, 2008). 
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1.1.4.1 Innate immunity 
Innate immunity acts as the first line defence and is composed of cellular and 
humoral components. Cells of the innate immune system include macrophages, 
dendritic cells (DCs), eosinophils, neutrophils, mast cells, natural killer (NK) cells, and 
NKT cells. Innate humoral components include complement proteins, antimicrobial 
peptides (cathelicidin and defensins), C-reactive protein, and lipopolysaccharide (LPS) 
binding protein (LBP). Innate immune cells do not show specificity to pathogens and do 
not have memory. They limit pathogen replication and set the scene for the development 
of specific adaptive immunity. When barriers are breached, innate immune cells rapidly 
arrive at the site of injury or infection in response to locally produced proinflammatory 
cytokines such as interleukin-1 (IL-1), tumour necrosis factor-α (TNF-α), and IL-6. Type I 
interferons (IFN-α and β) function to limit viral spread until more specific response is in 
place. The function of innate immune cells starts with the recognition of pathogens 
through the conserved pathogen associated molecular patterns (PAMPs) (Basu and 
Fenton, 2004;Turvey and Broide, 2010). 
1.1.4.1.1 Pathogen recognition receptors (PRR) 
PRR are germline encoded receptors expressed by innate immune cells (such as 
DCs, macrophages, and neutrophils) that sense conserved PAMPs. Engagement of 
these receptors with their cognate ligands activates the immune response through 
intracellular signalling pathways that eventually result in the elimination of the assaulting 
pathogen. Several PRR have been identified and characterised including Toll-like 
receptors (TLRs), retinoic acid inducible gene I (RIG-I) like receptors (RLRs), nucleotide 
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oligomerisation domain (NOD)-like receptors (NLRs), and DNA receptors  (Kumagai et 
al., 2008). 
1.1.4.1.2 TLRs 
To date, 10 TLRs have been identified in humans and 12 in mice. TLRs 1-9 are 
conserved in both humans and mice. TLR10 is only expressed in humans while TLR11 
is limited to mice (Kumar et al., 2011). TLR1, 2, 4, 5, and 6 are expressed on the cell 
surface and recognise products from bacteria, protozoa and fungi while TLR3, 7, 8, and 
9 are contained within endocytic compartments and recognise bacterial and viral nucleic 
acids. TLRs belong to type I membrane glycoproteins with an extracellular leucine rich 
domain and intracellular Toll/interleukin-1 receptor (TIR) required for the induction of 
downstream signalling. TLR2 heterodimerises with TLR1 or TLR6 to form two 
functionally distinct receptors, TLR2/1 or TLR2/6. TLRs build a signalling cascade by the 
recruitment of multiple adaptor molecules that will lead to the induction of 
proinflammatory cytokines (Yang and Seki, 2012) (Figure 1.5).  
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Figure ‎1.5. TLR ligands and signalling pathway. All TLRs except TLR3 signal through 
myeloid differential factor 88 (MyD88). Activation of MyD88 by TLR1, 2, 4, 5, and 6 
results in the recruitment of other adaptor molecules such as interleukin-1 receptor-
associated kinase 1 (IRAK1) and 4, tumour necrosis factor receptor-associated factor 6 
(TRAF6), and transforming growth factor-beta-activated kinase 1 (TAK1) that leads to 
the activation of the inhibitor of kappa B kinase (IKK) complex. IKK activates p38/JNK1/2 
and transcription factor nuclear factor-kappa B (NF-B) to induce the transcription of 
proinflammatory cytokines (TNF-α, IL-6, and IL-12). TLR7, 8, and 9 recruit MyD88 and 
the adaptor molecules IRAK1 and 4, TRAF6, and TAK1, which activate interferon 
regulatory transcription factor 7 (IRF-7) to induce the transcription of IFN-α. TLR3 
recruits TIR-domain-containing adapter-inducing interferon-β (TRIF) and TLR4 also 
recruits an adaptor molecule TRAM to use the TRIF signalling pathway. TRIF signalling 
pathway recruits TRAF3 and 6 that activate the IKK complex to induce the transcription 
of IFN-β. TRIF can also induce the transcription of proinflammatory cytokines through 
the adaptor molecules TRAF6 that induces downstream signalling of the TAK1 and IKK 
complexes (Yang and Seki, 2012). 
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1.1.4.1.3 RLRs 
RLRs are intracellular sensors of single stranded ribonucleic acid (ssRNA) and 
double stranded RNA (dsRNA). This group of PRR consists of three members, RIG-I, 
MDA5 (melanoma-differentiation-associated gene 5) and LPG2. RIG-I and MDA5 
contain N-terminal caspase recruiting domains (CARDs), a central helicase/ATPase 
domain, and a C-terminus regulatory domain (Figure 1.6). LPG2 lacks the CARDs 
necessary for signalling and plays a regulatory role in the RIG-I/MDA5 signalling 
pathway (Kumar et al., 2011).  
1.1.4.1.4 Antimicrobial peptides 
Antimicrobial peptides (AMPs) are positively charged amphipathic small cationic 
peptides [12-50 amino acids (aa)] rich in cationic and hydrophobic residues. They are 
produced by cells of the innate immune system and other cell types. They act as natural 
antibiotics killing many Gram negative as well as Gram positive bacteria, fungi, parasites 
and viruses. AMPs have roles to play in wound healing, immunomodulation, 
angiogenesis, and cell growth (Figure 1.7). Because they have multiple actions besides 
antimicrobial activity, they would be more appropriately called host defence peptides 
(HDPs) and this term will be used throughout the rest of this thesis. There exist two main 
classes of HDPs; α-helical structures lacking disulfide bonds (cathelicidin) and β-sheets 
with disulfide bonds (human α and β defensins). HDPs can be constitutively expressed 
or induced by microbial products, injury, or inflammation (Lai and Gallo, 2009;Yeung et 
al., 2011). 




Figure ‎1.6. RIG-I/MDA5 signalling pathway. Upon activation, CARDs recruit 
mitochondrial adaptor protein interferon-beta promoter stimulator 1 (IPS-1) (also known 
as mitochondrial antiviral signalling adaptor [MAVS]) that activates the IKK complex. IKK 
activates NF-B and IRF3/7 to induce the transcriptional activation of proinflammatory 
cytokines and type I interferons (IFN-α and IFN-β) (Poeck and Ruland, 2012). 
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1.1.4.1.4.1 Cathelicidin 
Human cathelicidin (LL-37) is a 37-aa long linear peptide that consists of a 
conserved N-terminus with two leucines (LL) and a variable cationic C-terminus cathelin 
domain. The active peptide is located in the C-terminus and is released after cleavage of 
its inactive precursor human cationic antibacterial protein 18KD (hCAP-18, encoded by 
the gene CAMP) by serine proteases. LL-37 is mainly produced by neutrophils but also 
by other cells such as monocytes/macrophages, T cells, mast cells, and epithelial cells. 
LL-37 is also present in human sweat and alveolar lavage (Tjabringa et al., 2005).  
Besides its role in antimicrobial killing, LL-37 is a multifunctional molecule that 
can neutralise LPS, induce chemotaxis for neutrophils, monocyte/macrophages, mast 
cells, and T lymphocytes, and induce IL-6 and IL-8 production. LL-37 plays a role in DC 
differentiation and maturation and mast cell degranulation as well as promoting wound 
healing and modulating angiogenesis (Pistolic et al., 2009;Schiemann et al., 
2009;Tjabringa et al., 2005;Yeung et al., 2011). LL-37 is constitutively expressed in 
some tissues such as gastrointestinal, respiratory, and reproductive tract epithelial cells, 
salivary glands, and immune cells (such as neutrophil granules, monocytes and 
macrophages, mast cells, NK cells, and lymohocytes). Expression of LL-37 can be 
induced or enhanced by inflammatory stimuli, injury, and microbial products (Jager et al., 
2010;Steinstraesser et al., 2011). Induction of LL-37 expression is mediated through 
MEK1/2 and p38 MAPK signalling pathways (Mendez-Samperio et al., 2008;Schauber 
et al., 2003). 
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1.1.4.1.4.2 Defensins 
Defensins are 29-45 aa long peptides divided into two main classes, α and β 
defensins classified according to the arrangement of cysteine residues. They function as 
antimicrobial molecules, selectively inhibiting proinflammatory responses, and inducing 
chemotaxis and wound healing (Steinstraesser et al., 2011;Yeung et al., 2011). Human 
α-defensins (HD) are constitutively expressed and are mainly present in neutrophilic 
granules and Paneth cell granules of the small intestine. They are composed of six 
members. Human neutrophil peptides (HNP) 1-4 are mainly expressed by neutrophil 
azurohilic granules and to a lesser extent by monocytes, lymphocytes, and NK cells, 
while HNP5-6 are expressed by Paneth cells and the genitourinary tract of females.  
Human β-defensins (hBD) are predominantly expressed by epithelial cells in the 
skin and mucosal surfaces and are secreted in a mature form to the outside of the cells 
(Lehrer and Lu, 2012;Tecle et al., 2010). HBD-1 is consititutively expressed as the gene 
lacks the regulatory element for NF-B while hBD-2 and hBD-3 are inducible by bacterial 
components such as LPS (through TLR stimulation) and proinflammatory cytokines IL-
1β and TNF-α through the activation of NF-B pathway. The expression of hBD-4 is 
more limited to epithelial cells of testes and epididymis as well as monocyte, 
macrophages and DCs and can be induced by bacterial products such as bacteria 
phorbol myristate acetate (Hazlett and Wu, 2011). 
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Figure ‎1.7. Multi-functional HDPs. HDPs show antimicrobial properties and are 
involved in direct microbial killing. They also have a range of immunomodulatory effects 
including the recruitment of T cells and DCs, mast cell degranulation, anti-endotoxin 
activity,  neutralisation of proinflammatory cytokines release by macrophages and 
monocytes, and promotion of wound healing and angiogenesis (Lai and Gallo, 2009). 
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1.1.4.1.5 Antigen presentation 
DCs attracted to sites of inflammation by molecules induced by the  innate 
response process, degrade and present antigens as peptides to naïve T cells of the 
adaptive response bound to major histocompatibility complex class I and class II (MHCI 
and MHC II). These are human leukocytes antigens (HLA) class I (A,B, and C) or class II 
(DR, DP, or DQ) produced by genes located on chromosome 6 in humans. MHC I 
antigens are found on all nucleated cells of the human body, while MHC II are limited 
mainly to professional antigen presenting cells (APCs) such as DCs and macrophages 
(Ryan and Cobb, 2012). Extracellular antigens are presented by MHC class II to CD4+ 
helper T (Th) cells while intracellular antigens are presented by MHC class I to CD8+ T 
cells. This induces the activation and differentiation of T cells, thus bridging innate 
immunity to adaptive immunity.  
In addition to DCs and macrophages, B cells and epithelial cells can also act as 
APCs under certain conditions, but DCs are considered as the primary professional 
APCs. After activation through TLR, tissue resident DCs mature into professional APCs 
and migrate from tissue to peripheral lymph nodes to activate T cells. They upregulate 
the expression of costimulatory molecules (CD40, CD80 and CD86) necessary for T cell 
activation as well as chemokine receptor (CCR) CCR7 (receptor for homing to lymph 
node), and downregulate CCR2 and CCR5 (receptors for homing to inflammatory sites) 
(Toebak et al., 2009;Villadangos and Schnorrer, 2007). 
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Vitamin D3 has been shown to increase phagocytosis and chemotaxis in 
macrophages, decrease their expression of TLR2 and TLR4, and  induce the production 
of HDPs (Baeke et al., 2010). On the contrary, it prevents DCs maturation and reduces 
the expression of MHC II, co-stimulatory molecules (CD40, CD83 and CD86) turning 
them into tolerogenic DCs (Figure 1.8).  One study has shown that vitamin D3 inhibited 
chemotaxis of DCs, reduced IL-12 and TNF-α, but increased IL-6 and IL-1β production. 
Interestingly, these effects were induced by local conversion of 25(OH)D3 into active 
1,25(OH)2D3 (Bartels et al., 2010).  
1.1.4.2 Adaptive immunity 
Adaptive immunity provides a more specific response against an infection, and 
memory which allows a robust (high-affinity) and rapid response to future infections of 
the same pathogen. Cells of adaptive immunity are T and B lymphocytes which divide 
adaptive immunity into cellular and humoral components respectively. The activation of 
naive CD4+ T helper (Th0) cells causes differentiation into several effector and 
regulatory subtypes influenced by the microenvironment and cytokines (IL-12 and IL-4 
secreted by APCs) present during activation (Figure 1.8). Th1 cells secrete IFN- and 
activate macrophages and NK cells to kill intracellular bacteria, fungi and viruses. Th0 
cells differentiate into Th2 type in response to parasitic infections and allergies. Th2 cells 
stimulate mast cells, neutrophils and B cell production of immunoglobulin (Ig) G1 (IgG1) 
and IgE.  
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Th0 cells can also differentiate into Th17 and Th22 subsets in response to 
extracellular bacteria. Inducible regulatory T cells (Treg) produced from Th cells include 
Tr1 producing IL-10, Th3 producing transforming growth factor-β (TGF-β), and 
CD4+C25+Foxp3+ Tregs preventing the differentiation of effector T cells through direct 
cell-cell contact (Hesslein et al., 2011;la Sala A. et al., 2012). For T cell activation, CD28 
on T cells bind the costimulatory molecules CD80/CD86 whereas engagement of 
CD80/CD86 by cytotoxic T lymphocyte antigen-4  (CTLA-4) is inhibitory for T cell 
activation (Rudd et al., 2009).  
Vitamin D3 prevents B cell differentiation and proliferation and reduces IgG and 
IgM production. It directs the polarisation of Th cells towards Th2 and Treg phenotypes 
and not Th1 or Th17 by inhibiting IL-12 and IL-23 production by DCs. It reduces Th1 
cytokines IL-2 and IFN and Th17 cytokines (IL-17 and IL-21). It induces the 
development of Tregs expressing of CTLA4 and Foxp3 (Figure 1.9) (Baeke et al., 
2010;Jeffery et al., 2009). The promoter region of Foxp3 gene has VDRE through which 
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Figure ‎1.8. Effector and regulatory T cell differentiation. Naïve CD4+ T cells 
differentiate into different subtypes according to the cytokines present in the 
microenvironment in which the stimulation occurs. IL-12 and IFN- causes the 
polarisation of T cells into Th1 whereas IL-4 induces Th2 differentiation. IL-6 with TGF-β 
and IL-6 with TNF-α, lead to the differentiation into Th17 and Th22 respectively. Tregs 
are IL-10 producing Tregs, TGF-β producing Tregs, and IL-10 producing 
CD4+C25+Foxp3+ Tregs (la Sala A. et al., 2012). 
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Figure ‎1.9. Effects of vitamin D3 on immune cells. Vitamin D3 increases chemotaxis 
and phagocytosis of macrophages, induces cathelicidin production and reduces the 
expression of TLR2 and TLR4. It converts DCs into tolerogenic phenotype by preventing 
their maturation and reducing the expression of MHC class II and co-stimulatory 
molecules. It reduces plasma cell differentiation and proliferation. Vitamin D3 inhibits the 
differentiation into Th1 and Th17 and directs the polarisation of Th2. It also induces the 
differentiation of Tregs by upregulating the expression of CTLA4 and Foxp3 (Baeke et 
al., 2010). 
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1.1.5 Extra-renal vitamin D3 synthesis 
The interest in the effects of vitamin D3 on the immune system started with the 
discovery of extra-renal expression of CYP27B1 in monocytes and macrophages in 
studies on Myobacterium tuberculosis (Mtb). Stimulation of TLR2/1 by 19 kDa triacylated 
lipopeptide of Mtb upregulated mRNA expression of VDR and CYP27B1. To understand 
the downstream signalling of VDR in these cells after TLR2/1 stimulation, monocytes 
were stimulated with TLR2/1L in the presence or absence of 25(OH)D3. 25(OH)D3 
synergised with TLR2/1 in the upregulation of CYP24A1 and cathelicidin mRNA.  
Stimulation of TLR2/1 alone in medium containing human serum (HS) also 
upregulated CYP24A1 and cathelicidin mRNA without the addition of exogenous 
25(OH)D3. This induction was not seen when cells were stimulated in the presence of 
fetal calf serum (FCS) and this could be due to the high levels of 25(OH)D3 in HS 
compared to FCS. VDR, CYP27B1, CYP24A1, and cathelicidin were all upregulated at 
mRNA level when TLR2/1 stimulation was performed in 25(OH)D3  sufficient sera from 
Caucasians, but not in serum from African-Americans which was found to have low 
serum 25(OH)D3 (Liu et al., 2006).  
Further work by the same group has demonstrated that TLR2/1L induced IL-15, a 
cytokine necessary for CYP27B1 and VDR induction, and cathelicidin production, with 
the latter two processes due to conversion of 25(OH)D3 to active 1,25(OH)2D3.  
Moreover, macrophages primed by IL-15 produced HDPs activity against Mtb when 
stimulated directly with 25(OH)D3 (Krutzik et al., 2008). TLR2/1L also led to the induction 
of IL-1β from monocytes. TLR2/1L needs IL-1β and VDR signalling to induce hBD-2 
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(encoded by DEFB4 gene) (Liu et al., 2009b). Finally, IFN- produced by T cell signalling 
through STAT1 induced IL-15 in monocytes, leading to increased vitamin D3 metabolism 
as discussed above, in synergy with signalling via TLR, leading to the uprergulation of 
cathelicidin and DEFB4. Moreover IFN- induced an autophagy pathway in Mtb-infected 
monocytes leading to increased phagosome maturation.  
Finally, only vitamin D3 sufficient sera could support IFN- induced HDPs 
production, which has implications for the effect of infection in different ethnic groups 
(Fabri et al., 2011). In monocytes and macrophages, vitamin D3 is not regulated by PTH 
and calcium, but by signals from the immune system. In macrophages, a splice variant 
of CYP24A1 was identified that limited the availability of 25(OH)D3 and 1,25(OH)2D3 for 
degradation by CYP24A1. The splice variant lacks a 150 aa sequence at the N-terminal 
containing mitochondrial targeting domain. This absence of negative feedback allows 
more synthesis of 1,25(OH)2D3 which may result in hypercalcaemia in inflammatory 
conditions (Ren et al., 2005).  
These interesting findings have encouraged many researchers to investigate the 
presence of extra-renal vitamin D3 production in other cells and tissues including those 
at barrier sites, and whether it affects the induction of HDPs. Local vitamin D3 synthesis 
and induction of cathelicidin have been identified in many epithelial cells including 
respiratory, urinary bladder, gingival, sinonasal, and colon epithelial cells,  as well as 
trophoblasts and skin keratinocytes (Hansdottir et al., 2008;Hertting et al., 
2010;Lagishetty et al., 2010;Liu et al., 2009a;McMahon et al., 2011;Schauber et al., 
2003;Schrumpf et al., 2012;Sultan et al., 2012;Sultan et al., 2013;Welsh, 2011). In skin, 
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placental, and respiratory epithelial cells, TLR synergised with VDR to induce HDPs 
expression whereas in urinary bladder, gingival, sinonasal, and colon epithelial cells 
local vitamin D3 synthesis alone induced HDPs.  
A genome wide analysis (GWAS) from peripheral blood mononuclear cells 
(PBMCs) revealed the presence of VDRE in more than 200 genes, including many 
identified related to autoimmune disease, including type 1 diabetes mellitus (T1DM) and 
systemic lupus erythematosus (SLE). Genes with VDRE including IRF8, PTPN2, CTLA-
4 and CD40 showed increased expression after vitamin D3 treatment. Therefore many 
single nucleotide polymorphisms (SNPs) identified as associated with autoimmune 
disease are located within VDR binding intervals, suggesting that vitamin D3 influences 
several pathways involved in immune responses (Ramagopalan et al., 2010).  
Other genes regulated by vitamin D3 are those of tight junction (TJ) proteins. 
Upon treatment of colonic carcinoma epithelial cell line (Caco-2) monolayer with 
1,25(OH)2D3, there was an upregulation of TJ proteins zo-1, caludin-1 and occludin. 
1,25(OH)2D3 increased transepithelial electric resistance (TEER) upon  treatment with 
dextran sodium sulfate (DSS) used to induce acute colitis in vivo and reduced their 
permeability to fluorescein isothiocyanate-D (FITC-D) dye. These findings were 
replicated in the C57BL/6 mouse model of inflammatory bowel disease (Zhao et al., 
2012). 
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1.1.6 Vitamin D3 deficiency 
The importance of vitamin D3 starts from early stages in life. In pregnant women, 
vitamin D3 deficiency can cause increased risk of gestational diabetes and preeclampsia 
(gestational hypertension). It can cause a delay in lung and bone development. Vitamin 
D3 deficiency can reduce body size and shape at birth and impair bone mineralisation. 
During childhood vitamin D3 deficiency can cause rickets (growth failure and bone 
deformities), growth retardation, increased risk of T1DM, asthma, respiratory tract 
infections and central nervous system disorders (Principi et al., 2013). In adults vitamin 
D3 deficiency has been linked to osteoporosis, osteomalacia, and increased risk of falls 
and fractures (Lips and van Schoor, 2011).  
Low serum vitamin D3 levels have been linked to many autoimmune conditions 
such as T1DM, inflammatory bowel disease (IBD), and systemic lupus erythematosus 
(SLE) as well as infectious diseases such as tuberculosis and seasonal influenza (Van 
Belle et al., 2011) . There is a geographical association where there is an increase in the 
incidence of multiple sclerosis (MS) in countries far from the equator. It has been 
suggested that the decrease of UVB in northern regions leads to less vitamin D3 
synthesis. This was further supported by low serum vitamin D3 found in MS patients 
(Summerday et al., 2012). HLA-DRB1*1501 has been associated with susceptibility to 
MS and recently VDRE have been found in the promoter region which indicates it is 
regulated by vitamin D3 (Ramagopalan et al., 2009).  
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However, if MS is an example of autoimmune disease linked to low UVB 
exposure and vitamin D3 levels, it is intriguing that MS prevalence is increasing in Arab 
countries (although still lower than Western countries) and it remains more frequent in 
females than in males (Benamer et al., 2009). One possible explanation is that 
difference in prevalence is related to differences in sex hormones, as autoimmune 
disease (such as RA and MS) onset appears in females as early as after puberty (18-
40), while in males the onset is delayed to the age of 30-40 years and could be as a 
result of the decline in testosterone (Voskuhl, 2011). It has been noticed that MS 
symptoms are suppressed during pregnancy and during contraceptive pill usage 
indicating a protective role for estrogen. Estrogen and vitamin D3 influence each other, 
as in murine studies estrogen downregulates CYP24A1 and vitamin D3 upregulates 
CYP19, the enzyme required for estrogen synthesis (Disanto et al., 2011;Holmqvist et 
al., 2010).  
An alternative hypothesis proposed by Albert et al. suggests that both 25(OH)D3 
and 1,25(OH)2D3 should be measured in the serum of patients with autoimmune 
diseases. According to them, low levels of 25(OH)D3 are due to increased consumption 
and that conversely serum 1,25(OH)2D3 would increase, which makes it a better marker 
of the disease than 25(OH)D3. They also believe that the relief of symptoms upon 
vitamin D3 supplementation is a temporary silencing of the innate immune response, and 
that bacteria use VDR to downregulate the immune system and inhibit HDPs, leaving 
them to grow over time eventually causing autoimmune diseases. Based on an in silico 
model, they suggest the following: (i) bacterial ligands bind to LBP of VDR and disable 
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CYP24A1 causing a rise 1,25(OH)2D3, (ii) supplementation with 1,25(OH)2D3 will not be 
able to activate VDR which has been dysregulated by bacterial ligands, (iii) and the high 
levels of 1,25(OH)2D3 will interfere with other nuclear receptors (such PPAR [the 
peroxisome proliferator-activated receptors] - and α, the GR, and the androgen 
receptor) involved in the induction of HDPs through binding to their natural receptors 
(Albert et al., 2009;Marshall, 2008).  
The authors suggest that bacterial dysregulation of VDR in women is the reason 
they are more susceptible to autoimmune diseases. Early during pregnancy, women 
with MS and RA will have a 40% increase in 1,25(OH)2D3 which will dysregulate VDR 
and other nuclear receptors and a temporary immunosuppression. After pregnancy 
when 1,25(OH)2D3 goes back to its previous levels, inflammatory symptoms of 
autoimmune disease will return (Proal et al., 2009). However it should be stated that the 
alternative hypothesis has little solid laboratory data to support it and remains highly 
controversial.  
1.1.7 VDR polymorphism 
Variations in DNA in the human genome are mostly SNPs. About 7 million 
common SNPs have been identified with a minimum allele frequency (MAF) of at least 
5% across the human population but in common SNPs MAF might vary between 
different populations (Hinds et al., 2005). SNPs are positions on the genome where 
there is variation of two alleles expressed by different populations. A person can either 
be homozygous or heterozygous for a certain SNP as each allele is inherited from one 
parent. Information on SNPs are collected by  organisations such as the International 
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Haplotype Map Project (Hapmap) Consortium including genomic location and allelic 
frequencies among different populations (LaFramboise, 2009). A database for SNP 
(dbSNP) is available for SNP genotyping assays at the National Center for 
Biotechnology Information (NCBI). The database has reference SNP (rs) numbers to 
identify each SNP assay (Hinds et al., 2005).  
The vitamin D3 receptor (VDR) gene extends over 100 kb (kilo base pair) located 
in the long arm of chromosome 12 locus 13.1 (12q13.1) downstream of collagen II-alpha 
1(COL2A1) (Uitterlinden et al., 2004b). VDR polymorphism has been associated with 
susceptibility to or protection from many conditions and diseases and varies among 
different ethnic backgrounds (Valdivielso and Fernandez, 2006). More than 470 VDR 
SNPs have been identified in the human VDR gene. Some SNPs can be associated with 
each other in certain populations and this is called linkage disequilibrium (LD). LD can 
be inherited as blocks referred to as haplotypes with an average of 10-20kb (Rukin and 
Strange, 2007). VDR polymorphisms were first identified using restriction fragment 
length polymorphisms (RFLPs) with the aid of restriction enzymes including EcoRV, 
BsmI, TaqI, and Tru9I (Uitterlinden et al., 2004b). VDR has been divided into three LD 
blocks A, B, and C where A is towards the 3’ exon 9 and C in the non-coding region 






















Figure ‎1.10. VDR gene polymorphism. VDR is located on 12q13.1 and SNPs are 
shown as LD block A,B, and C with the most commonly studied SNPs. Cdx2  and GATA 
(A1012G) is in the 5’ promoter region, FokI is between blocks B and C while BsmI is 
closely associated with TaqI and ApaI in block B in the 3’UTR (Rukin and Strange, 
2007). 
 
A start codon polymorphism FokI (rs2228570) does not have an LD association 
and is located at the breaking point between LD blocks B and C. It is a T to C 
substitution (T/C) that alters the start codon resulting in a different size protein. The 
presence of FokI site (T allele) results in a 427 aa protein and the absence of FokI (C 
allele) results in a shorter 424 aa protein. FokI modulates transcription factors in the 
immune system. The C allele increased transcription by NF-B, nuclear factor of 
activated T-cells (NFAT), and promoter for IL-12 p40 subunit (IL-12p40) more than the T 
allele. Human PBMCs homozygous for the C allele expressed higher mRNA for IL-12 
(A1012)
G 
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and proliferated stronger upon stimulation with the mitogen phytohemagglutinin (van 
Etten et al., 2007). Patients with T1DM that were homozygous for FokI TT allele or 
heterozygous for FokI CT allele had lower pancreatic β-cell function (Mory et al., 2009). 
The most commonly studied LD SNPs in block B (intron 8 and exon 9) are the closely 
linked BsmI (C/T; rs1544410), ApaI (C/A; rs7975232), and TaqI (T/C; rs731236). No 
functional consequence has been reported for these SNPs but they are located in the 
3’untranslated region (3’UTR) that can influence mRNA stability and protein translation 
efficiency (Arai et al., 2001;Rukin and Strange, 2007;Uitterlinden et al., 2004b). Cdx2 
(G/A; rs11568820) is a promoter region SNP, a known binding site for the Cdx2-
intestinal transcription factor. It modulates intestinal VDR transcription and calcium 
absorption. The A allele increases while the G allele reduces VDR transcription and 
calcium absorption respectively (Arai et al., 2001). A1012G (rs4516035) SNP is (A to G) 
located in 1012 bp close to the exon 1a transcription start site. It is associated with the 
transcription of GATA3, a transcriptional factor for the differentiation of Th2 cells. The A 
allele of A1012G downregulates Th1 responses (Halsall et al., 2004).  
1.2 The human eye 
The human eye is a unique structure that receives and transmits light signals to 
the brain to be translated as images. It is in constant contact with the environment which 
renders it vulnerable to injury and infection. The eye has specific anatomical and 
physiological barriers to protect against potential damaging pathology that could lead to 
loss of visual acuity or even blindness.  
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1.2.1 Eye structure 
The human eye is a spherical structure with a diameter of 2.4 cm. It is composed 
of a three-layered outer compartment and an interior compartment (Figure 1.11). The 
three outer layers are the outermost corneosclera (cornea and sclera), the uveal tract 
(iris, ciliary body, and choroid), and the inner neural retina. The retina is supplied by the 
central retinal artery and the outer and middle layers are supplied by ciliary vessels. The 
inner compartment contains aqueous humour (AqH), lens, and vitreous. The AqH is a 
clear fluid secreted by the ciliary processes. The vitreous comprises two-thirds of the 
eye volume and it is a transparent avascular inert gel that gives the eye its shape. Vision 
is reflected by the integrity of a transparent visual axis that starts from the cornea and 
passes through the anterior chamber (AC), lens, and vitreous, to the retina (Caspi, 
2010;Chen et al., 2008). 
The cornea forms the outer avascular fibrous coat of the ocular surface acting at 
the front line to protect the eye against offending environmental and infectious factors. 
The cornea is made of corneal epithelium, stroma, and corneal endothelium. Corneal 
epithelium is composed of flattened stratified non-keratinised squamous epithelium. This 
layer is in continuity with the conjunctiva at the limbus (at corneal edge) from which stem 
cells arise to replace old or dead corneal epithelial cells. Corneal epithelium is separated 
from the stroma by Bowman’s layer (BL), an avascular basement membrane-like 
structure rich in collagen fibres. Corneal stroma is made of densely packed transparent 
regularly oriented collagen bundles. Next to the stroma, exists a thick Descemet’s 
membrane, a basement membrane secreted by the corneal endothelium. The corneal 
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endothelium consists of a monolayer of hexagonally oriented epithelial cells with a high 
density of mitochondria and functions to provide nutrients and dehydrates corneal 
stroma. Corneal endothelial cells do not undergo mitotic division and do not regenerate 
(Di Girolamo, 2011;Takacs et al., 2009).  
 
 
Figure ‎1.11. A schematic presentation of the human eye. The human eye is 
composed of an outer corneoscleral layer, uveal tract (iris, ciliary body, choroid), and 
retina. The AC is filled with aqueous humour produced in the posterior chamber by 
ciliary processes. The vitreous is located at the posterior of the eye, a gel substance that 
provides support and maintains the shape of the eye (Asadi et al., 2012). 
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In the uveal tract, the iris is a circular disk that acts as a diaphragm to regulate the 
amount of light that passes through to the retina by altering the size of the pupil through 
contraction of circular sphincter muscles (constricts the pupil) and radial dilator muscles 
(dilates the pupil). Surrounding the muscles is a stroma, an outer non-pigmented 
epithelium layer and inner pigment epithelium. The stroma is rich in melanocytes which 
determine the eye colour (Forrester et al., 2001). The ciliary body is a triangle shaped 
structure with two regions, anterior pars plicata where the ciliary processes are located 
and posterior pars plana at which it joins the choroid. The ciliary processes are made of 
two layers of epithelium that have their apical surfaces opposing each other, an inner 
non-pigmented ciliary body epithelium (NPE) in contact with AqH in the posterior 
chamber, and an external pigmented epithelium in contact with ciliary stroma. NPE 
secretes AqH and is the continuation of iris pigmented epithelium anteriorly and neural 
retina posteriorly while the pigmented epithelium is the continuation of retinal pigmented 
epithelium (RPE) (Goel et al., 2010).  
The AqH has a unidirectional flow (Figure 1.12) passing from posterior chamber 
(between the iris and the lens) through the pupil to the AC (between the cornea and the 
iris) and circulating towards the angle of the AC (trabecular meshwork). The blood 
supply to the iris and ciliary body is provided by anterior and posterior ciliary arteries as 
well as choroidal branches (Forrester et al., 2001). The choroid, the outermost region of 
the uveal tract is a vascular, highly pigmented tissue which provides a network of blood 
vessels that carry nutrients to the retina (Regatieri et al., 2012).  




Figure ‎1.12. Aqueous humour flow. AqH is secreted in the posterior chamber (1) by 
ciliary processes. Some of it can pass through the vitreous cavity (2) and it is also 
released to fill the AC through the pupil (3). AqH causes fluid exchange with the cornea 
(4) and iris (5). The AqH drains into trabecular meshwork into Schlemm’s canal and to 




The retina is located at the posterior of the eye and can be divided into outer 
retina and neuroretina. The outer retina is made of a monolayer of RPE and sits on the 
multilayered Bruch’s membrane, which allows the transfer of nutrients and oxygen from 
fenestrated choriocapillaries to RPE and waste from RPE to choriocapillaries. The apical 
surface of RPE faces the outer segment of photoreceptors (Mettu et al., 2012). RPE 
cells do not regenerate and decrease with age and their dysfunction could threaten 
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visual acuity such as in age-related macular degeneration (AMD) (Del Priore et al., 
2002).   
AMD is a chronic disease that occurs with aging and starts with the accumulation 
of drusen (extracellular deposits). Within drusen are amyloid-β (Aβ) and proinflammatory 
complement components that contribute to the pathogenesis of AMD. At later stages the 
degeneration of photoreceptors and RPE cells occurs (Ambati and Fowler, 
2012;Anderson et al., 2004). RPE has several functions including transport of nutrients 
and water to the inner retina, preventing light scatter and photooxidation, reisomerisation 
of retinoids necessary for vision, and phagocytosis of dead photoreceptors. Neuroretina 
is formed of photoreceptors (rods and cones) and a ganglion cell layer which transfers 
the visual signals to the optic nerve. The central retinal artery and choroidal capillaries 
supply nutrients that diffuse through RPE to the retina (Erickson et al., 2007;Simo et al., 
2010). 
1.2.2 Antigen presenting cells in the eye 
At the external surface of the eye, murine and human studies have shown that 
bone marrow (BM)-derived cells, mostly immature APCs, are recruited to the cornea 
from the limbus, the area between the vascularised conjunctiva and avascular cornea. 
Immature DCs express very low levels of MHC II and lack the expression of co-
stimulatory molecules (CD80, CD86, and CD40) which can result in T cell tolerance 
(Lutz and Schuler, 2002).  
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In mice, three groups of APCs exist in central corneal stroma; 
MHCII+CD11b+CD11c- monocytes/macrophages, MHCII-CD34+ myeloid precursor cells, 
and a small group of B220+CD11clo plasmacytoid DCs. CD11b+ cells are suggested to 
have the potential to form lymphatic vessels during corneal inflammation by 
differentiating into lymphatic vessel endothelial receptor 1+ (LYVE-1 +) cells. The corneal 
stroma expressed MHCII+CX3CR1
+CD45+ (CD45 is lymphocyte common antigen) cells 
with cellular processes that bridge MHC II+ cells in vitro (Forrester et al., 2010). CX3CR1 
is a receptor for chemokine CX3CL-1 (fractalkine) and is expressed on myeloid cells 
such as monocytes, macrophages, DCs, NK cells, and microglia to recruit them to the 
site of inflammation (Chinnery et al., 2008).  
The cornea expresses soluble vascular endothelial growth factor receptor-1 
(sVEGFR-1) which neutralises vascular endothelial growth factor-A (VEGF-A), an 
angiogenesis stimulant. Moreover, the constitutive corneal expression of VEGFR-3 (the 
receptor for VEGF-C and VEGF-D), thrombospondin-1 (TSP-1), endogenous IL-1 
receptor antagonist (IL-1Ra), as well as tissue inhibitor of metalloproteinases-1 (TIMPs-
1) in tear film prevent hemangiogenesis and lymphangiogenesis (Barabino et al., 2012). 
TSP-1 is a potent anti-angiogenic factor and is also produced by mouse iris and cultured 
RPE  (Cursiefen et al., 2004;Zamiri et al., 2005). 
 MHCII+CD11c+Langerin/CD207+ langerhans cells (LCs) that also express CD1a 
(marker for LCs) and CD45 are present in human peripheral and paracentral corneal 
epithelium while human peripheral and paracentral anterior regions of corneal stroma 
contain DC-SIGN/CD209+ interstitial DCs (Mayer et al., 2007). BM derived DCs 
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(BMDCs) from CD45 knockout mice (CD45-/-) showed decreased cytokine production of 
IL-12, IL-6 and TNF-α after LPS (TLR4 ligand)-stimulation. In contrast, CD45-/- DCs 
showed increased IL-12, IL-6 and TNF-α production in response to stimulation of TLR2 
and TLR9. The lack of CD45 reduced IFN- producing Th1 cells in response to 
stimulation with LPS-activated DCs (Cross et al., 2008). MHCII+CD11b+CD11c-CD45+ 
monocyte/macrophages are also found in human corneal stroma (Mayer et al., 2007). 
Another population of APCs that was detected in mice corneal stroma is 
MHCII+CD11b+CD45+F4/80+ macrophages (Forrester et al., 2010). F4/80 is a marker of 
tolerogenic APCs mainly expressed on macrophages and on a small subset of DCs 
(Stein-Streilein, 2008). 
The uveal tract (iris, ciliary body, and choroid) of all mammalian species contains 




+ DCs are present in the ciliary 
body epithelium. CD11b+CD11c+ DCs and macrophages are present in rat choroid as 
well as F4/80+ macrophages. Choroidal MHCII+CD11c+ DCs are localised at the basal 
surface of RPE where shed photoreceptors accumulate, a possible source of 
autoantigens. The retina in rats contains CD11c+CD45loF4/80+ microglial cells that are 
immunosuppressive and a small population of MHCII+ DCs and macrophages lining the 
blood vessels in meningeal extension that could play a role in inflammation (Forrester et 
al., 2010).  
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Under normal resting conditions, APCs in human and rat eye (e.g. ciliary body 
and choroid) are tolerogenic, but are motile and can be activated with proinflammatory 
cytokines during inflammation (Forrester et al., 2005). APCs from mouse retina could 
present antigen to antigen-experienced T cells, but failed to activate naïve T cells which 
is in agreement with the tolerogenic ocular environment (Gregerson et al., 2004). 
1.2.3 Immune regulation in the eye 
The eye has evolved to protect itself against injury including infections. The eye is 
provided with a set of anatomical and physiological barriers to divert or suppress 
destructive inflammatory responses. This renders the eye in a state referred to as ocular 
immune privilege. Other sites of the body that are considered immune privileged are 
testis, hair follicle, placenta, and the brain (Niederkorn, 2012). Immune privilege of the 
eye is a concept first introduced by Sir Peter Medawar in 1940 after the survival of a skin 
allograft in the AC of a rabbit eye. This was explained as immune ignorance that was a 
result of the lack of draining lymphatics that did not allow the escape of the antigen into 
peripheral lymph nodes to stimulate an immune response.  
More recently, it was revealed that ocular immune privilege is a product of many 
active immunosuppressive mechanisms in the ocular environment to limit ocular 
damage by innate and adaptive immunity (Hori, 2008;Taylor, 2009). These mechanisms 
include the lack of lymphatic drainage and physical barriers, immunosuppressive 
microenvironment, and regulation of systemic immune response (Zhou and Caspi, 
2010).  
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1.2.3.1 Lack of lymphatic drainage and physical barriers 
The cornea is avascular and lacks lymphatic vessels. Lymphatics are also absent 
in the AC and the retina. Lymphatic drainage is only available for the conjunctiva, sclera, 
and choroidal capillaries (Barabino et al., 2012;Streilein, 2003;Yucel et al., 2009) . 
Recently using fluorescent tracers for lymphatic markers such as LYVE-1  in human and 
sheep eyes, lymphatics were identified in the ciliary body (Yucel et al., 2009). The 
contribution of this pathway to AqH drainage is still unclear (Kim et al., 2011;Yucel et al., 
2009). By injecting a fluorescently labelled antigen into rat AC, Camelo et al. 
demonstrated that soluble antigen can leave the eye to regional lymph nodes of the 
head and neck, as well as in the marginal zone of the spleen, without being associated 
with ocular APCs (Camelo et al., 2006). 
The eye is designed with external barriers to protect it against traumatic damage 
such as the bony orbit, eye lids, and eye lashes. The tear film flushing foreign particles 
and containing antimicrobial substances (such as lysozymes and lactoferrin) as well as 
IgG and IgA, can neutralise bacteria and viruses to protect the ocular surface (Akpek 
and Gottsch, 2003). Additional ocular physical barriers are present which include 
corneal endothelium, blood-aqueous barrier, and blood-retinal barrier. These barriers 
not only physically prevent passage of immune cells, but also have an active role in 
suppressing the immune response. Corneal epithelium represents an essential physical 
barrier with immunomodulatory properties (Akpek and Gottsch, 2003;Hori, 2008) but 
only structures which are critical to this project will be discussed. 
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1.2.3.1.1 Corneal endothelium 
The role of corneal endothelium is to keep a state of dehydration in the cornea to 
preserve its transparency. It works as an active fluid pump between the cornea and 
AqH. Fluid leak to corneal stroma is tightly controlled by the integrity of tight and 
adherens junctions in corneal endothelium. This integrity might be weakened or lost in 
inflammatory conditions such as uveitis (Srinivas, 2012). Rauz et al. have identified the 
mRNA expression of apical epithelial sodium channel (ENaC) and the enzyme serum 
and glucocorticoid regulated kinase isoform 1 (SGK1) in human corneal endothelium. 
These molecules might support the function of  corneal endothelium in sodium transport 
and maintaining corneal transparency (Rauz et al., 2003).  
Moreover, human corneal endothelium expresses the enzyme 11β- 
hydroxysteroid dehydrogenase 2 (11β-HSD2) as well as glucocorticoid receptor (GR) 
and mineralocorticoid receptor (MR) (Rauz et al., 2001;Stokes et al., 2000). MR is also 
known as aldosterone receptor while GR is a receptor for cortisol. These two receptors 
have 90% aa homology in the DNA binding domain (DBD) and about 50% in the ligand 
binding domain (LBD). The enzyme 11β-HSD2 acts to prevent binding of glucocorticoids 
(such as cortisol which is present in high concentrations in plasma) to MR leaving it 
available for aldosterone (Odermatt and Kratschmar, 2012). Cortisol and aldosterone 
may induce the expression of SGK1 which in turn activates ENaC to facilitate sodium 
pumping across the apical surface of corneal endothelium (Rauz et al., 2003).  
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1.2.3.1.2 Blood-aqueous barrier 
Blood aqueous barrier (BAB) is composed of TJs between NPE cells and TJs 
between vascular endothelial cells of the iris. Leakiness of BAB could allow access of 
inflammatory cells as well as plasma proteins into the AC (Chen et al., 2008). GR, MR, 
and 11β-HSD1 are expressed in the non-pigmented ciliary body epithelium (Rauz et al., 
2001;Stokes et al., 2000). 11β-HSD1 is the enzyme that catalyses the interconversion 
between inactive cortisone and active cortisol (Odermatt and Kratschmar, 2012). The 
production of AqH requires a metabolically active process that involves the transport of 
water and ions (Kiel et al., 2011). 11β-HSD1 may play a role with GR and MR in sodium 
transport and AqH production by ciliary epithelium (Rauz et al., 2001). 
1.2.3.1.3 Blood-retinal barrier 
Blood-retinal barrier (BRB) is made by TJs between retinal pigment epithelial cells 
and TJs between endothelial cells of retinal vessels. Only small molecules such as 
glucose and ascorbate are allowed to diffuse through these TJs. A breach of this barrier 
may occur in conditions such as uveoretinitis, diabetic retinopathy, and AMD (Crane and 
Liversidge, 2008). 
1.2.3.2 Immunosuppressive microenvironment 
Breakdown of ocular barriers can occur and can cause the infiltration of immune 
cells into the eye resulting in a sight damaging inflammatory response. In addition to 
barriers the eye is rich in soluble and membrane bound molecules that can affect innate 
and adaptive immune cell activation.    
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1.2.3.2.1 AqH 
AqH contains a range of neuropeptides that diffuse from sensory nerve endings 
to the eye and cytokines, including alpha-Melanocyte-stimulating hormone (α-MSH), 
vasoactive intestinal peptide(VIP), somatostatin (SOM), TGF-β2, calcitonin gene-related 
peptide (CGRP), macrophage migration inhibitory factor (MIF), all can regulate immune 
cells to suppress inflammation in the AC (Taylor, 2009).  
α-MSH is a peptide mainly expressed in the hypothalamus, pituitary gland, and 
skin with antiinflammatory properties that range from the suppression of proinflammatory 
(TNF-α and IL-1β) and upregulation of antiinflammatory (IL-10) cytokines (Brzoska et al., 
2008). α-MSH binds to melanocortin-1 receptor (MC-1R) on macrophages and dendritic 
cells differentiated from human monocytic cell lines and neutrophils to mediate the 
suppression of their production of proinflammatory cytokines, nitric oxide (NO), and 
reactive oxygen intermediates (Manna et al., 2006). When murine lymph node primed T 
cells were incubated with α-MSH, there was an 80% reduction of IFN- production. 
APCs treated with α-MSH caused a reduction in IFN- by T cells (Taylor et al., 1994a).  
In another murine study, AqH inhibited the maturation of LPS-stimulated DCs. 
AqH downregulated the expression of MHC II, CD80, and CD86 and inhibited their 
ability to activate T cells. These inhibitory effects on DC maturation were reversed upon 
blocking TGF-β2 (Wang et al., 2011). Recently, Denniston et al. showed that human 
naïve CD4+T cells failed to proliferate when co-cultured with noninflammatory AqH. AqH 
treated DCs had a significant reduction in the expression of CD86. Endogenous cortisol 
and TGF-β both contribute to the suppressive activity of AqH (Denniston et al., 2011).  
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VIP is a neuropeptide present in the nervous and endocrine systems as well as 
the lungs and intestine. It posseses immunomodulatory properties as many cells in the 
body including immune cells such as monocytes and lymphocytes expressed receptors 
for VIP. In murine studies, VIP has been shown to inhibit macrophage proinflammatory 
cytokine production (Chorny et al., 2006;Delgado et al., 2004) and in the eye it is 
produced by human corneal endothelium, iris, ciliary body, and has been detected in 
AqH (Koh, 2012). VIP in AqH inhibited in vitro poliferation and IFN- production by 
antigen stimulated lymphonuclear cells (LNC) in rabbits. Absorbing VIP reversed the 
inhibitory effect on LNC (Taylor et al., 1994b). The injection of liposome containing VIP 
into rat vitreous suppressed endotoxin (LPS) induced uveitis (EIU). There was a 
reduction in the EIU clinical score, the number of infiltrating inflammatory cells to the 
anterior segment, and mRNA expression of IFN-, TNF-α and IL1β (Lajavardi et al., 
2007). 
The release of some neuropeptides is affected by light/dark conditions which in 
turn modulate the immune response in the eye. Mice reared in the light (diurnal) showed 
high levels of VIP in the iris and ciliary body and low levels of another neuropeptide, 
substance P (SP). In contrast, mice reared in the dark, showed low levels of VIP and 
increased amounts of SP. This effect seemed to be an adaptation process and could be 
reversed by putting mice under diurnal conditions (Ferguson et al., 1995). CGRP is 
present in the AqH of humans and other species and at concentrations present in AqH, 
inhibited NO production from mouse macrophages (Taylor et al., 1998). MIF is a 
multifunctional molecule that plays a role as a proinflammatory cytokine and contributes 
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to the immune privilege of hair follicles by suppressing cytolysis by NK cells (Calandra et 
al., 2003;Ito et al., 2007). Recombinant murine MIF (rMIF) and rabbit AqH both inhibited 
macrophage migration in vitro and NK-mediated lysis of murine corneal endothelial cell 
line (Apte et al., 1998). 
1.2.3.2.2 Corneal endothelium 
Like many cells in the cornea, corneal endothelial cells lack MHC II and only 
weakly express MHC I. They express CD95L, which upon binding to CD95 on T cells 
induces T cell apoptosis (Hori, 2008). In mice, corneal endothelial cells constitutively 
express B7-H1 (programmed death-1 molecule ligand; PD-L1), a member of the 
CD28/CTLA-4 family and a ligand for programmed death-1 molecules (PD-1) on T cells 
that downregulates T cell receptor signalling (Hori et al., 2006). When cultured in the 
presence of human corneal endothelial (HCE) cell line, there was a reduction in the 
proliferation of all T cells, specifically CD4+ T cells, and Th1 T cells. This inhibition was 
cell-cell contact dependent. HCE cells suppressed proliferation and IFN- production 
from infiltrating Th1 T cell clones (TCC) prepared from AqH of patients with different 
inflammatory eye diseases (Behçet’s disease [BD] and uveitis). HCE express PD-L1 and 
PD-L2 and when incubated with Th1 TCC, there was an increase in PD-1 expression on 
T cells. The ability of HCE to reduce IFN- production by Th1 cells was blocked by anti-
PD-L1 but not anti-PD-L2. Interestingly, HCE incubated in IFN- containing Th1 cultures 
supernatants upregulated PD-L1 expression indicating the role of inflammation in the 
expression of these molecules on HCE (Sugita et al., 2009).  
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When co-cultured in the presence of HCE, human CD8+ T cells had a reduced 
proliferation. Unlike CD4+ T cells, CD8+ T cells had a poor expression of PD-1 which 
suggests another molecule is involved. It appeared that the cell-cell contact dependent 
inhibition of CD8+ T cell proliferation was mediated by membrane bound TGF-β2, highly 
expressed by HCE. TGF-β2 not only enabled HCE to suppress T cell proliferation, but 
allowed them to convert both CD4+ and CD8+ T cells into CD25+Foxp3+ Tregs. CD4+ 
and CD8+ HCE-induced Tregs inhibited the proliferation of CD4+ and CD8+ effector T 
cells respectively, via TGFβ1 in both cases (Yamada et al., 2010). 
1.2.3.2.3 Intraocular compartments 
A suppressive microenvironment is created in the intraocular compartments by 
pigmented epithelium of the iris, ciliary body, and retina. These tissues although in 
different locations and functions in the eye, all have immunomodulatory properties that 
play a role in ocular immune privilege (Zamiri et al., 2007). Murine iris and ciliary body 
pigmented epithelium (I/CBE PE) inhibited ovalbumin (OVA) stimulated T cell 
proliferation and reduced production of IL-2, IFN-, IL-4, and IL-10 in vitro. This inhibition 
was dependent on direct contact between these cells. This inhibition was not mediated 
by Fas (CD95)-Fas ligand (FasL; CD95L) interaction and T cell apoptosis was not 
induced. When cultured with T cells, I/CBE PE produced TGF-β which mediated the 
inhibitory effect on T cells (Yoshida et al., 2000b;Yoshida et al., 2000a).  
Subsequent experiments by Sugita et al. have demonstrated the expression of 
soluble and membrane bound TGF-β (TGF-β1 and TGF-β2) in B7+ (CD80/86) iris PE 
(IPE). Through membrane bound TGF-β, IPE cells increased the expression of B7, 
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TGF-β and CTLA-4 on CD8+ T cells and converted them into Tregs (IPE Tregs). IPE 
Tregs used cell-cell contact and membrane bound TGF-β to inhibit bystander T cell 
proliferation. By comparison, CB PE cells were not able to convert either CD4+ nor CD8+ 
T cells into Tregs (Sugita et al., 2006;Sugita et al., 2008) 
Murine RPE and ARPE-19 (human adult retinal pigment epithelium cell line) 
express PD-L1 and PD-L2. In the supernatants of mixed cultures of ARPE-19 and T 
cells, PD-L1 mediated a reduction in the levels of IFN-, IL-8, and monocyte chemotactic 
protein-1 (MCP-1) produced (Usui et al., 2008). Immortalised murine RPE cells 
upregulated MHC II expression after treatment with TNFα and IFN- and constitutively 
expressed CD80 but they could not process the antigen β-galactosidase (β-gal) and 
present it to naive T cells from β-gal-TCR transgenic mice. When these T cells were 
stimulated with irradiated APCs with β-gal on a monolayer of RPE cells, RPE cells 
induced T cells to become anergic by inhibiting their proliferation and the production of 
IFN- and IL-2. Anergic T cells recovered from RPE co-cultures and activated with 
splenic APCs on a monolayer of RPE cells in the presence of β-gal failed to proliferate 
and showed suppressed IL-2, IFN-, and IL-17 production. Although Foxp3 expression 
was induced on these T cells, they did not become Tregs (Gregerson et al., 2007).  
Sugita and colleagues were able to show that RPE cells can induce Tregs. CD4+ 
T cells cultured in the presence of murine RPE cells showed reduced proliferation, and 
converted into Tregs. RPE induced Tregs were CD4+CD25+Foxp3+ and were 
suppressive of bystander T cell activation. A novel inhibitory factor CTLA-2α discovered 
on murine RPE cells was essential for RPE conversion of Tregs in vitro (Sugita et al., 
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2008). Ocular pigment epithelial cells constitutively express FasL (Sugita, 2009). In 
ARPE-19 cells, the expression of FasL was increased after treatment with IFN- or 
infection with cytomegalovirus (CMV). ARPE-19 express both Fas ligand in soluble and 
microvesicle membrane bound forms but it is not clear how FasL is released with 
microvesicles to induce target cell apoptosis (McKechnie et al., 2006).  
Murine primary RPE cultured cells secrete immunomodulatory molecules 
including TSP-1, TGF-β, SOM, and pigment epithelial derived factor (PEDF). TSP-1 and 
TGF-β produced in RPE cell supernatants cause the suppression of T cells activation 
and reduced IFN- production. TSP-1 is required for the activation of TGF-β and both 
are important for the induction of T cell suppression (Zamiri et al., 2005). PEDF 
suppressed IL-12 and augmented IL-10 production in LPS-stimulated macrophages. 
PEDF and SOM synergised to suppress NO produced by murine macrophages. When 
injected simultaneously with LPS into mice ears, PEDF reduced the inflammatory 
response (Zamiri et al., 2006). PEDF contributes to the prevention of angiogenesis and 
the survival of retinal stem cells and may contribute to therapeutic treatments of 
neovascular disease or AMD (Liu et al., 2012a). A murine study (Kawanaka and Taylor, 
2011) showed that α-MSH and neuropeptide Y (NPY) produced in supernatants of 
primary RPE upregulated the expression of Arginase1 (ARG1) and nitric oxide 
synthetase (NOS2) in primary murine macrophages. These are called alternatively 
activated macrophages (M2) which are usually induced by Th2 cytokines IL-4 and IL-13 
rather than classically activated macrophages (M1) induced by Th1 IFN- (Gordon and 
Martinez, 2010).  
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1.2.3.3 Regulation of systemic immune response 
AC associated immune deviation (ACAID) is a phenomenon characterised by the 
development of antibody and suppression of cell mediated inflammatory responses after 
the soluble antigen is injected or shed from tumour in the AC in experimental animals. 
For ACAID to occur it requires the eye, thymus, spleen, and sympathetic nervous 
system where removal of any of them within 72 hours after injection inhibits ACAID. It is 
believed that within 48 hours F4/80+ macrophages in the iris and ciliary body pick up the 
antigen, transport it to the venous circulation, and lead to the generation of CD8+ T cells 
that can suppress inflammation. F4/80+ macrophages induce the development of CD4-
CD8-NK1.1+ thymocytes which migrate to the spleen where they participate with CD1d+ 
B cells, CD4+ NKT cells, and CD8+ T cells in the generation of ACAID by inducing CD8+ 
the development of regulatory T cells that inhibit Th1 and Th2 inflammatory responses 
and the production of antibodies IgM and IgG1 (Camelo et al., 2005;Niederkorn, 2006). 
 T cells also play a role in the process by producing IL-10 necessary for the induction 
of ACAID (Ashour and Niederkorn, 2006). As it is vital for the eye to maintain clear 
vision, ACAID is an example of how the eye can induce systemic immune tolerance.  
1.2.4 Uveitis 
Uveitis is a group of inflammatory conditions in the eye. Uveitis does not only 
affect the uveal tract, it may involve the sclera, retina, and optic nerve. It is a cause of 5-
20% of legal blindness in the United States and Europe and 25% in the developing 
world (de Smet et al., 2011). Uveitis is classified anatomically according to the primary 
site of inflammation as anterior (AC), intermediate (vitreous, pars plana), posterior 
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(retina or choroid), and pan (AC, vitreous, and retina or choroid) uveitis (Jabs et al., 
2005). Patients with uveitis may present with photophobia, red eye, floaters, and blurred 
vision (Guly and Forrester, 2010). 
In intermediate uveitis (IU) inflammation can involve AC, ciliary body, and the 
retina. It can either be infectious or non-infectious (idiopathic or autoimmune). Infectious 
IU can occur in toxoplasmosis, tuberculosis, lyme disease, human T lymphotropic virus 
Type 1 (HTLV-1), and syphilis. Non-infectious IU can be associated with systemic 
diseases such as sarcoidosis, intraocular lymphoma, and multiple sclerosis. When IU is 
not associated with an underlying infection or systemic disease but with the presence of 
snow banks (white exudates) at pars plana, it is referred to as pars planitis (Babu and 
Rathinam, 2010;de Smet et al., 2011).  
Anterior uveitis has been linked to be ankylosing spondylitis and birdshot 
choroidopathy while posterior uveitis has been linked to sarcoidosis, BD, and Chron’s 
disease. IU has been associated with MS and sarcoidosis (Barisani-Asenbauer et al., 
2012). Uveitis has been associated with MHC antigens. Of class I, HLA-B*27 is 
associated with anterior uveitis, HLA-B*51 with BD, and HLA-A*29.2 with birdshot 
retinochoroidopathy. With regards to MHC class II, HLA-DRB1*03 has been linked to 
anterior uveitis whereas HLA-DR2, HLA-DR51, HLA-DR17, and HLA-DRB1*15 have 
been linked with intermediate uveitis (Du et al., 2009;Tang et al., 1997;Zamecki and 
Jabs, 2010). 
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The antigens inducing uveitis have, in most cases, not been identified but 
experimental autoimmune uveitis (EAU) can be induced in animal models using retinal S 
antigen or interphotoreceptor retinoid binding protein (IRBP) (Caspi et al., 2008). 
Humanised models of EAU have been established where mice are made transgenic (Tg) 
with human MHC II antigens after deleting mouse class II antigens. Several Tg human 
MHC molecules have been created (e.g. HLA-DR3, HLA-DR4, HLA-DQ6 and HLA-DQ8) 
and are injected with IRBP or S antigen to induce EAU. This will allow a better human 
relevant understanding of immune mechanisms and therapeutic targets for the treatment 
of uveitis (Levy et al., 2011). EAU involves inflammation in the iris, ciliary body, retina, 
and choroid (Babu and Rathinam, 2010), and involves breakdown in ocular barriers 
which allows the infiltration of immune cells to the eye. Animal studies and samples from 
AqH, vitreous, and peripheral blood from patients have allowed an understanding of the 
cellular types and mechanisms involved in uveitis.  
In EAU models, Th1 and Th17 cell mediated responses have been observed but 
with Th1 IFN- being the predominant cytokine locally and in the peripheral lymph nodes 
(Caspi et al., 2008). In humans, both Th1 IFN- and Th2 IL-4, IL-10, and IL-13 cytokines 
play a role in the pathogenesis of uveitis (Horai and Caspi, 2011). CD4+ CD25+ Tregs 
induced during the recovery from EAU play an important role in the resolution of 
intraocular inflammation. They are regulated by IL-10 and other suppressive inhibitory 
molecules in AqH (Ke et al., 2008). While treatment of PBMCs from patients with BD 
uveitis with IFN- increases NO production, IL-10 reduces NO suggesting its protective 
role in uveitis (Belguendouz et al., 2011). In humans, myeloid DCs have been isolated 
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from AqH samples of uveitic patients and showed high MHC I and II expression, but 
decreased CD86 compared to DCs from peripheral blood of the same patients, a 
combination which led to reduced activation of naïve T cells (Denniston et al., 2012). 
Interestingly, this did not involve endogenous cortisol, which was responsible for a 
similar effect of noninflammatory AqH (Denniston et al., 2011). 
TNF-α plays an important role in uveitis and high levels can be found in AqH and 
serum from patients with uveitis. It is one of the molecules targeted for immunotherapy 
of uveitis (Khera et al., 2010). TNF-α and its soluble receptors TNF-α receptor I and 2 
(TNF-α R1 and TNF-α R2) are significantly elevated in AqH and vitreous fluid from 
patients with active uveitis compared to controls. Soluble TNF-αRs stimulated  increased 
TNF-α production by infiltrating T cells present in ocular fluids increasing inflammation in 
this model system (Sugita et al., 2007). Neutralisation of TNF-α reduces retinal 
inflammation in uveitic patients and the EAU model (Dick et al., 2004;Murphy et al., 
2004).  
TNF-α represent an important therapeutic target for the treatment of uveitis and 
ocular inflammation in BD. Monoclonal antibodies against TNF-α such as infliximab and 
adalimumab have been shown to be effective in treatment of uveitis and BD (Deuter et 
al., 2008;Gueudry et al., 2012). AqH from patients with idiopathic uveitis had significant 
increase in the concentrations of IL-6, IL-8, IFN-γ, and CCL2/MCP-1 (chemokine ligand 
2 or MCP-1) compared to noninflammatory controls. IL-8 and CCL2/MCP-1 were higher 
in AqH from BD and herpes-viral uveitis while TGFβ2 and CXCL12 (chemokine ligand 
12) were reduced (Curnow et al., 2005). In the AqH of patients with IU, TNF-α, IL-6, IL-8, 
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IL-1β, IL-12 p70 subunit (IL-2p70), IL-10, and CCL2/MCP-1 are higher than in controls. 
IL-6 and IL-8 levels in these patients were even higher in AqH samples than in sera 
(Valentincic et al., 2011).  
Cytokine polymorphisms play a role in susceptibility and pathogenesis of uveitis. 
Polymorphisms in IL-10 and TNF-α have been associated with uveitis in patients in the 
UK, these SNPs were in loci previously linked to immune mediated inflammation (Atan 
et al., 2010;Haukim et al., 2002). Another study in Austria has shown an association 
between a SNP in IL2RA and the risk for intermediate uveitis where G allele is protective 
(Lindner et al., 2011). A meta-analysis study has shown an association of one SNP in 
IL10 and a variant between IL23R and IL12R β2 and BD. Monocytes from individuals 
expressing A allele of IL-10 variant express less mRNA and produce less IL-10 protein 
compared to those with the G allele (Remmers et al., 2010).  
1.2.5 The role of vitamin D3 in the eye 
Very early studies have shown the presence of VDR, calcium-binding protein 
(vitamin D-dependent), and plasma membrane calcium pump by immunostaining of 
sections of the different layers of the human eye (Johnson et al., 1995). Treatment with 
vitamin D3 reduced the growth of human retinal blastoma cell line Y-79 in vitro (Saulenas 
et al., 1988). Topical treatment of mice cornea with 1,25(OH)2D3 reduced LC migration 
into the cornea and neovascularisation (Suzuki et al., 2000).  
Later research has demonstrated some of the immunomodulatory effects of 
vitamin D3 in the eye. When a human corneal epithelial cell line was infected with 
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Pseudomonas aeruginosa in the presence of 1,25(OH)2D3, the expression of IL-1β, IL-6, 
and IL-8 was suppressed (Xue et al., 2002). Oral treatment with vitamin D3 abrogated 
inflammation and reduced proinflammatory cytokines in lymph node supernatants from 
mice with EAU. Treatment with vitamin D3 in vivo reduced the expression of RORt 
(transcription factor for Th17) and the production of IL-17 when CD4+ T cells from mice 
lymph nodes were stimulated in vitro (Tang et al., 2009). 
 Similar results were seen in  humans where the addition of vitamin D3 to naïve 
stimulated CD4+ T cells from patients with BD, upregulated IFN regulatory factor 8 (IRF-
8), a transcription factor that negatively regulated Th17 in vitro. This was reflected by 
suppressing the expression of RORt, IL-17, and CCR6. It reduced the production of 
IFN- by CD4+ T cells cultured in Th17 polarising conditions and to the contrary, it 
increased IL-10 production. Vitamin D3 suppressed the production of IL17 and IFN- by 
CD4+ T cells co-cultured with DCs pretreated with Vitamin D3 compared to those co-
cultured with untreated DCs (Tian et al., 2012). Vitamin D3 genes were recently identified 
in human, mouse and rabbit corneal epithelial cells. 25(OH)D3 and 1,25(OH)2D3 were 
detected in rabbit tears, AqH and vitreous. 25(OH)D3 and 1,25(OH)2D3 increased TEER 
and upregulated the expression of occludin in human corneal epithelial cell line (Lin et 
al., 2012;Yin et al., 2011).  
Vitamin D3 rich food and supplement intake correlated inversely with the onset of 
early AMD in a survey among 40 years and older participant (Parekh et al., 2007). In a 
recent study, vitamin D3 intake in women younger than 75 years correlated with 
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decreased odds of early AMD which suggests a protective role of vitamin D3 (Millen et 
al., 2011).  
Interestingly, the protective effect of vitamin D3 has been confirmed in vivo. A 
group of twelve-month old C57BL/6 mice injected with vitamin D3 emulsified in safflower 
oil was compared with a group injected with safflower oil alone and were followed for 6 
weeks. Vitamin D3 treatment significantly reduced the number and morphology of 
inflammatory macrophages and decreased complement deposits in the subretinal 
space. Vitamin D3 markedly reduced Aβ along Bruch's membrane and other neurotoxic 
oligomers and this was reflected by an improved visual function of mice treated with 
vitamin D3 (Lee et al., 2012). By comparison, analysis of sib pairs found that while UV 
exposure was protective for the development of AMD, serum levels of 25(OH)D3 were 
not significantly different between patients and controls. After controlling for known risk 
factors, such as smoking a SNP in CYP24A1 was associated with onset of disease 
(Morrison et al 2011). 
Low serum 25(OH)D3 levels were associated with an increase in BD (Karatay et 
al., 2011). This was associated with decreased Treg and predominating Th1 responses 
indicating an immunomodulatory role of vitamin D3 in the eye (Hamzaoui et al., 2010). 
There was an association between VDR SNP FokI and BD in a group of Tunisian 
patients (Karray et al., 2012;Morrison et al., 2011). 
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1.2.6 Hypothesis and aims 
The eye is constantly exposed to the environment and inflammation as a result of 
a physical assault or infection can lead to blindness. The eye is protected with epithelial 
physical barriers (corneal endothelium, BAB, and BRB) at the front and the back to 
prevent the entry of inflammatory cells to the eye. It is also equipped with physiological 
molecules to maintain an immunosuppressive environment and clear vision. One 
potential molecule is vitamin D3. Vitamin D3 has many immunomodulatory properties 
and many epidemiological studies suggest an association between low serum vitamin D3 
levels and a range of inflammatory and autoimmune diseases. 
A vitamin D3 extra-renal system has been characterised in 
monocytes/macrophages and many epithelial cells. It promotes barrier function at 
different sites in the body and modulates both the innate and adaptive immune 
responses by suppressing inflammation and inducing antimicrobial peptides. Thus 
vitamin D3 appears to provide a mechanism by which the cells/tissues can still defend 
themselves against pathogens and at the same time limit the damage caused by 
inflammatory responses. Gene polymorphisms of VDR and related genes have been 
linked to different inflammatory and autoimmune disorders and they determine with other 
factors individual responses to inflammation. 
Previous studies of vitamin D3 in the eye have demonstrated extra-renal 
expression of vitamin D3 in ocular cells, but did not show the ability of ocular cells to 
endogenously produce 1,25(OH)2D3. Ocular cells can produce HDPs that can also be 
detected in ocular fluids where they mediate antimicrobial and immunomodulatory 
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properties (Garreis et al., 2010a;McDermott, 2009). To date there is no evidence if the 
ocular HDP production is mediated by endogenous vitamin D3. VDR SNPs were studied 
in BD and AMD (Karray et al., 2012;Morrison et al., 2011) but no information on VDR or 
related genes in IU was available. 
It is against this background that I hypothesise that extra-renal vitamin D3 exists 
in ocular barrier epithelial cells, it induces HDPs production, and that genetic control of 
this process contributes to uveitis.  
Therefore to address the hypothesis I aim to:  
1. Investigate and characterise the expression of vitamin D3 machinery in ocular barrier 
cells and if they can convert inactive to active vitamin D3. 
2. Study the role of vitamin D3 in the induction of HDPs in the eye and if vitamin D3 
synergises with Toll-like receptor signalling to upregulate proinflammatory cytokine 
production. 
3. Study the association of genetic variation in VDR with intermediate uveitis in 
Caucasians. 
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2 MATERIALS AND METHODS 
2.1 Cell lines 
All cells were grown in a humidified chamber at 37°C with 5% CO2 and passaged 
by trypsinisation. Penicillin (100 units/ml) and streptomycin (100 µg/ml) solution were 
added to all growth media (PAA Laboratories, Yeovil, UK). All cells were grown in 10% 
heat inactivated fetal calf serum (HIFCS) except human corneal endothelial cells and 
HKC-8 which were grown in 5% HIFCS (Biosera Ltd, Ringmer, UK). 
2.1.1 Human conjunctival cell line (CCL-20.2) 
The work described using this cell line was from the project done by a Medical 
student (Deepali Patel) in our group in 2011, whom I was involved in supervising. CCL-
20.2: clone 1-5c-4 previously charachetrised (Chang, 1954) and obtained from American 
Type Culture Collection, ATCC (Manassas, VA, US) were grown in medium 199 
(Invitrogen, Paisley, UK) containing Earle’s Balanced Salt Solution (Sigma-Aldrich, 
Dorset, UK) and 2.2 g/L sodium bicarbonate (Sigma-Aldrich).  
2.1.2 Human corneal endothelial cell line (HCEC-12)  
  HCEC-12 were purchased from the German Resource Centre for Biological 
Material; DSMZ, Germany. The cell line was established by simian virus (SV) 40 
transformation and characterised as immortalised corneal endothelial cells (Bednarz et 
al., 2000). HCEC-12 were cultured in flasks (Sarstedt,Leicester, UK) precoated with a 
mixture of laminin and chondroitin sulfate (Sigma-Aldrich, Dorset, UK) in F99 basal 
medium (Gibco, Invitrogen, Paisley, UK) supplemented with 20 g/ml ascorbic acid,  20 
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g/ml human recombinant insulin, and 10 ng/ml basic fibroblast growth factor (bFBF) (all 
Sigma-Aldrich, Dorset, UK) 
2.1.3 Adult retinal pigment epithelial cell line (ARPE-19)  
Adult retinal pigment epithelial (ARPE-19) a spontaneously immortalised human 
RPE cell line, were obtained from American Type Culture Collection (ATCC number: 
CRL-2302, Middlesex, UK). These were developed and characterised as a model of 
retinal pigment epithelial cells (Dunn et al., 1996). Cells were cultured in Dulbecco's 
Modified Eagle Medium:Nutrient Mixture F-12 (DMEM/F12), with glutamax (Gibco, 
Invitrogen, Paisley, UK).  
2.1.4  Non-pigmented ciliary body epithelial cell line (ODM-2) 
ODM-2, an SV40 transformed cells originally established and described as a cell 
line for non-pigmented ciliary body epithelium (Martin-Vasallo et al., 1989), were a kind 
gift from Dr. Coca Prados (Department of Ophthalmology and Visual Sciences, Yale 
University, US). Cells were cultured in DMEM, high glucose (4 g/L) (PAA Laboratories, 
Yeovil, UK).  
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2.1.5 Human kidney cell line (HKC-8) 
HKC-8, an SV40 transformed cell line was established and characterised to be 
used as a proximal renal tubule cell line (Racusen et al., 1997). The cell line was kindly 
provided by Dr. Rosemary Bland from the University of Warwick, UK. Cells were grown 
in DMEM/Hams F12 (PAA Laboratories, Yeovil, UK).  
2.2 Macrophage isolation and differentiation 
Donation Component cones from healthy donors were obtained from National 
Blood Services (NBS), Birmingham, UK. Cones containing 10-15 ml of blood were 
emptied into a 50 ml centrifuge tube (BD, Oxford, UK) and topped up with phosphate 
buffered saline (PBS) to 50 ml. PBMCs were separated using density-gradient 
centrifugation. In two 50-ml centrifuge tubes, diluted blood was layered onto 15 ml of 
density-gradient centrifugation medium (GE Healthcare, Buckinghamshire, UK), and 
centrifuged for 30 min at 400g. PBMCs were collected and washed a few times with 
RPMI 1640. Monocytes were isolated using a commercial CD14+ cells separation kit 
(MACS CD14 MicroBeads; Miltenyi Biotec, Surrey, UK) according to manufacturer’s 
instructions.  
Briefly, PBMCs were incubated with anti-human CD14 magnetic microbeads in a 
column placed on a magnetic separator. CD14+ cells were retained in the column while 
others were washed through. CD14+ cells were eluted in MACS buffer and washed. 
Cells were counted and placed in 12-well plates with a density of 1x106 cells per well in 
RPMI 1640 supplemented with 10% HIFCS. Granulocyte-macrophage colony-
stimulating factor (GM-CSF) (10 ng/ml) and macrophage colony-stimulating factor (M-
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CSF) (50 ng/ml) were added to monocyte cultures to differentiate M1 and M2 types 
respectively (Peprotech, London, UK). Medium and cytokines were replaced on day 3 
and after 6 days, M1 and M2 differentiated cells were used for experimental purposes. 
2.3 Isolation of RNA from primary human corneal endothelial cells 
(PHCend)  
Primary human corneal endothelial cells were generated from redundant donated 
corneo-scleral tissue following corneal transplant surgery. Donor peripheral corneal rims 
and central corneal buttons (transplant waste) from penetrating and lamellar 
keratoplasty surgical procedures, where the donor had given consent for research were 
used. According to the United Kingdom Guidelines for Organ Donation, only those 
patients with normal eyes in the absence of absolute exclusion criteria including active 
transmissible disease or infection, Creuzfeldt-Jakob Disease, intravenous drug abuse, 
and neurodegenerative disorders, are suitable to donate organs and tissues for 
transplantation. Additional exclusions include previous ocular surgery, inflammation and 
tumours such as retinoblastoma. The study was undertaken after formal ethics approval 
from the Black Country Research Ethics Committee (incorporating the Dudley Research 
Ethics Committee (LREC 06/Q2702/44)), and all experiments were carried out in 
accordance with the Tenets of the Declaration of Helsinki. Under a dissecting 
microscope, Descemet’s membrane and corneal endothelial cells were stripped from the 
posterior surface of the peripheral corneo-scleral region and placed into lysis buffer.  
Lysate was stored at -20º C until RNA extraction.  
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2.4 Cell stimulation  
Cells were plated in 12-well plates and allowed to grow to confluence. Cells were 
then washed and placed in fresh serum free medium. Cells were either left untreated 
(control) or treated with the different TLR1-9 ligands (Axxora Ltd., Exeter,UK), or RIG-I 
and MDA5 (Invivogen, San Diego, US) or cytokines (Peprotech, London, UK) alone or 
together with 25(OH)D3 or 1,25(OH)2D3 for the required time points (Table 2.1). Cell 
culture supernatants were collected in 1.5 ml Eppendorf tubes and stored at -20 C until 
analysis. Adherent cells were washed with PBS and RNA lysis buffer or Trizol were 
added and stored at -20 C for RNA extraction.  
Table ‎2.1. TLR ligands and concentrations. 
TLR Ligand Receptor Concentration/ml 
Pam3cys TLR2/1 1 µg 
Poly I:C TLR3 10 or 100 µg 
LPS TLR4 10 µg 
Imiquimod TLR7 1 µg 
ODN 2216 TLR9 3 µg 
Poly (I:C)/LyoVec RIG-I 1 µg 
Poly (I:C)/LyoVec MDA5 1 µg 
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2.5  RNA extraction 
RNA extraction was initially performed using RNeasy Mini Kit but Trizol reagent 
was used subsequently to obtain better RNA yields. 
2.5.1 RNeasy Mini Kit 
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Crawley, UK) according 
to manufacturer’s instructions. Briefly, RNA was lysed in a guanidine isothiocyanate 
containing lysis buffer and vortexed. One volume of 70% ethanol was added and mixed 
carefully by pipetting. The mixture was transferred to an RNeasy Mini spin column with 
silica-based membrane to ensure better RNA binding to the column. RNA was subjected 
to several washes to remove contaminants before it was resuspended in RNase free 
water and stored at -20º C. 
2.5.2 Trizol extraction 
Cells were lysed in 1 ml Trizol (phenol and guanidine isothiocyanate) reagent 
(Sigma-Aldrich, Dorset, UK) and stored at -20º C until RNA extraction. Lysates were 
transferred to 1.5 ml Eppendorf tubes. Chloroform (Sigma-Aldrich, Dorset, UK) was 
added (200 µl) and vortexed for 15 s. Tubes were allowed to stand for 10 min followed 
by centrifugation at 12,000g for 30 min at 4º C to separate RNA containing aqueous 
from organic phase. Aqueous phase was transferred to fresh tubes and 1 µl of 
Glycoblue (Invitrogen, Paisley, UK) was added to bind and precipitate RNA. 
Isopropanaol alcohol (Sigma-Aldrich, Dorset, UK) was added (200 µl) to the aqueous 
phase to facilitate RNA precipitation and stored at -20º C. Tubes were centrifuged at 
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12,000g for 30 min at 4ºC and supernatants were carefully removed by vacuum suction. 
RNA was further precipitated by the addition of 70% ethanol (500 µl), vortexted and 
centrifuged at 12,000g for 5 min at 4º C. Supernatants were removed and RNA was 
resuspended in 12-20 µl of RNase free water and stored at -20º C. 
RNA obtained from both methods was quantified and checked for purity using 
Nanodrop spectrophotometer (Thermo Fisher Scientific, UK).  
2.6 Reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA (1 µg) was reverse transcribed to cDNA using Taqman Reverse 
Transcription Kit (Applied Biosystems, Warrington, UK) following manufacturer’s 
instructions. PCR was performed using GoTaq Flexi DNA polymerase system 
(Promega, Southampton, UK) in a total volume of 20 µl containing cDNA (1 l for 18S 
and 2 l for all other genes), 0.8 mM MgCl2, 0.25x GoTaq Green Flexi Buffer, GoTaq 
DNA polymerase (0.01 U/l), 10 mM dNTP mix ((Promega, Southampton, UK), 1 pmol 
(0.05 µM) of 18S and 2 pmol (0.1 µM) of other forward and reverse primers (Alta 
Bioscience, Birmingham, UK). PCR was performed using Gene Amp PCR System 2700 
(Applied Biosystems, Warrington, UK) as follows: 5 min at 94 C, followed by three 
temperature cycles of 1 min at 94 C, annealing for 60 s for vitamin D3 genes (Table 2.2) 
and 40 s for TLRs1-10, RIG-I and MDA5 (Table 2.3), and extension at 72 C for 1 min. 
For cubilin and megalin, pre-amplification was carried out at 95 C for 5 min followed by 
cycles of denaturation at 94° C for 45 s, annealing for 45 s, and extension at 72° C for 
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45 s. All PCR reactions ended with a final extension step at 72° C for 7 min. Primer 
sequences and cycling condition were as shown in Table 2.2 and Table 2.3. 













VDR CGCTCCAATGAGTCCTTCACC GCTTCATGCTGCACTCAGGC 33 61 421 
CYP27B1 CACCTGACCCACTTCCTGTT TCTGGGACACGAGAATTTCC 35 58 302 
CYP24A1 CCCACTAGCCACCTCGTACCAAC CGTAGCCCTTCTTTGCGGTAGTC 35 60 485 
CYP2R1 AGAGACCCAGAAGTGTTCCAT GTCTTTCAGCACAGATGAGGTA 40 62 259 
CYP27A1 GGCAAGTACCCAGTACGG AGCAAATAGCTTCCAAGG 40 62 292 
18S GTTGGTGGAGCGATTTGTCT GGCCTCACTAAACCATCCAA 20 55 400 
Cubilin GCGGCTTCACTGCTTCCTA GAGTGATGGTGTGCCCTTGT 35 53 518 
Megalin TAAGTCAGTGCCCAACCTTT GCGGTTGTTCCTGGAG 35 53 290 
 
*VDR and CYP24A1 (Lechner et al., 2007), CYP27B1(Bland et al., 2004), CYP2R1, 
CYP27A1 (Blomberg et al., 2010), cubilin and megalin (Tsaroucha et al., 2008). 
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TLR1 ACC AAG TTG TCA GCG ATG TGT T GAT TGT CCC CTG CTT TTA TTG A 35 61 659 
TLR2 GAG TGA GTG GTG CAA GTA TGA GGG CCA CTC CAG GTA GGT CT 35 61 168 
TLR3 TCC CAA GCC TTC AAC GAC TG TCC TGA AAG CTG GCC CGA AAA 35 61 470 
TLR4 TGC GGG TTC TAC ATC AAA CCA TCC GAA ATT ATA AGA AAA 35 55 412 
TLR5 CTC CTT TGA TGG CCG AAT AGC CCC AAA TGA AGG ATG AAG GTA 35 61 429 
TLR6 CAA GGC CCT GCC CAT CTG TAA TTG GGC CAA AGA AAT TGA AAG 35 61 428 
TLR7 CCC CAG CGT CCT TTC ACA GA CGA GGG CAA TTT CCA CTT AGG 35 61 543 
TLR8 ATG CGT GCC TTG TGA TGG TG GCA ATG CCC GTA GAG ACA AAA 35 61 319 
TLR9 CTA CAA CCG CAT CGT CAA AC ATC GAG TGA GCG GAA GAA GA 35 61 456 
TLR10 ACC CCA GCC ACA ACG ACA C ATC ACG CAA AAG AAC CCA GAA 35 61 488 
RIG-I GAT AGC AAC AGT CAA ACA CAA TCG GAC ATT GCT GAA GAA GT 35 55 411 
MDA5 GCC ACG AAG CAA GCC AAA GTT CTT TGC GAT TTC CTT CT 35 55 306 
18S GTTGGTGGAGCGATTTGTCT GGCCTCACTAAACCATCCAA 20 55 400 
GAPDH CCA CCC ATG GCA ATT CCA TGG CA TCT AGA CGG CAG GTC AGG TCC AC  35 61 350 
2.7 Real-time PCR 
Reactions were performed in 96-well plates using reagents and primers (Table 2.4) 
from Applied Biosystems (AB). Each reaction was carried out in a total volume of 20µl 
containing 10 µl Taqman Universal Master Mix (2x), 1 µl endogenous control 18S primer 
(VIC/TAMRA 20x), 1 µl specific primers 20x TaqMan gene expression assay (Applied 
Biosystems, Warrington, UK)  and 7 µl RNase free water. Relative gene expression was 
measured and analysed using a LC-480 PCR system (Roche, West Sussex UK). Gene 
expression was obtained as Ct values (the cycle number at which the log PCR plots 
intersect with a calculated threshold value) and ΔCt was calculated (Ct of target-Ct of 
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control gene) and relative gene expression of treated samples compared to untreated 
controls was calculated as ΔΔCt values (2^-(Ct treated sample-Ct untreated sample). 










2.8 Cytokine and HDP enzyme linked immunosorbent assay (ELISA)  
ELISA was used to measure cytokines in cell culture supernatants. IL-8 was 
measured using Human CXCL8/IL-8 DuoSet ELISA Development Kit (R&D Systems, 
Abingdon, UK), IL-6 using Human IL-6 ELISA Set OptEIA (BD, Oxford, UK), and HDPs 
with Standard ELISA Development Kits for hBD-1, 2, and 4 respectively (Peprotech, 
London, UK). Briefly, 96-well plates were coated with antihuman capture antibody 
overnight at room temperature (RT) for IL-8 and hBDs and at 4º C for IL-6. Plates were 
washed several times and blocked with blocking buffer at RT for 1 h. After washing, 
biotinylated antihuman cytokine was added for IL-8 and hBDs for 2h at RT. This was 
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followed by several washes and streptavidin conjugated to horseradish peroxidase 
enzyme (HRP) was added and incubated for 20 min at RT. For IL-6 the detection system 
(biotinylated antihuman cytokine mixed streptavidin-HRP conjugate) was added for 1 h 
at RT. At the end of the incubation, the plates were washed and tetramethylbenzidine 
(TMB) substrate was added for 20 min in the dark. The reaction was stopped with 2N 
H2SO4 and absorbance was measured by spectrophotometry at 450 nm for IL-6 and IL-8 
and 405 nm for hBDs. Standard curves were constructed and sample concentrations 
were extrapolated from a standard curve. 
2.9 1,25(OH)2D3 enzyme immunoassay (EIA) 
Cells were grown to confluency in 12-well culture plates. Cells were placed in 
serum free medium and were either left untreated or treated with a physiological 
concentration of 25(OH)D3 (10
-7 M) with or without pre-treatment with itraconazole or 
ketoconazole (10-6 M), chemical inhibitors of 1α-hydroxylase (CYP27B1) (both Sigma-
Aldrich, Dorset, UK) for 2 h. After 24 h cell culture supernatants were collected for the 
measurement of 1,25(OH)2D3 and cells were processed for protein extraction and 
quantification.  
1,25(OH)2D3 concentration was measured by 1,25-Dihydroxy Vitamin D EIA  
(Immunodiagnostics Systems Limited, Tyne & Wear, UK) according to the 
manufacturer’s instructions. Briefly, supernatants were delipidated and centrifuged at 
2000g for 15 min. Immunoextraction of 1,25(OH)2D3 was performed by transferring the 
delipidated samples to immunocapsules containing gel coated with specific antibody for 
1,25(OH)2D3. Samples were placed in a foam rack on a blood tube rotator (5-20 
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revolutions) at RT for 90 min. After several washes (1000 g for 1 min), 1,25(OH)2D3 was 
eluted with an elution reagent containing ethanol into glass tubes. Tubes were placed in 
a heating block at 40º C for 20-30 min to evaporate the elution reagent. Immunopurified 
1,25(OH)2D3 residues were dissolved in assay buffer and used for ELISA. Antisheep 
1,25(OH)2D3 antibody was added to calibrators and samples and incubated at 4-8º C 
overnight. Part of the mixture was transferred to a 96-well plate coated with antisheep 
1,25(OH)2D3 antibody and incubated at RT for 90 min with shaking. Biotinylated 
1,25(OH)2D3 was added to the plate and incubated with shaking for further 60 min. After 
several washes, HRP-labelled avidin conjugate was added and incubated at RT for 30 
min. Unbound conjugate was washed several times and TMB substrate was added and 
incubated for 30 min. Reaction was stopped with 0.5M HCl and absorbance with 
measured by spectrophotometry at 450 nm. Concentrations from 1,25(OH)2D3 were 
obtained from a standard curve of the calibrators. 
2.9.1 AqH Samples 
 AqH (50-150 μl) and serum samples (500 μl) were collected from 7 healthy 
subjects undergoing cataract surgery at the Birmingham & Midland Eye Centre. All 
human samples were taken after informed consent approved by the Birmingham East, 
North and Solihull (BENS) Research Ethics Committee (LREC 08/H1206/165) and from 
the Black Country Research Ethics Committee (incorporating the Dudley Research 
Ethics Committee (LREC 06/Q2702/63). Concentrations of 1,25(OH)2D3 in AqH were 
measure by 1,25(OH)2D3 EIA as described below. 
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2.10 VDR SNPs 
VDR SNPs were selected according to HapMap (www.hapmap.org) and their 
relevance to the immune system according to epidemiological studies (Arjumand et al., 
2012;Orlow et al., 2012;Sanchez-de la Torre et al., 2008). 
SNPs FokI, BsmI, and A1012G were selected (Table 2.5). Three VDR SNP 
genotyping assays: FokI (rs2228570) (Poon et al., 2004;Sanchez-de la Torre et al., 
2008), BsmI (rs1544410) (Al-Daghri et al., 2012), and A1012G (rs4516035) (Sanchez-
de la Torre et al., 2008) were purchased from Applied Biosystems, Warrington, UK and 
were tested in 165 patient and 100 control Caucasian samples (Table 2.6). Study 
population was disease free and was not matched on other criteria. PCR was performed 
in 384-well plates with a 10 µl total reaction volume containing 20 pg/ml DNA (samples) 
or water (controls) and 2x LC-480  probe master (Roche, West Sussex UK) followed by 
endpoint genotyping analysis using the LC-480 system (Roche, West Sussex UK). 
Genotypes were determined as either homozygous (e.g. AA or GG) or heterozygous 
(e.g. AG) according to the presence or absence of fluorescence for each genotype.  
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Table ‎2.5. Selected VDR SNPs location and functional relevance. 
SNP Location Function References 
FokI Start 
codon 
Affects vitamin D protein size 
Modulates mRNA expression 
of NFAT, IL-12, and regulates 
pancreatic function 
(Mory et al., 2009;van Etten et 
al., 2007) 
BsmI 3’UTR mRNA expression and stability (Arai et al., 2001;Rukin and 
Strange, 2007;Uitterlinden et al., 
2002) 
A1012G Promoter associated with the 
transcription of GATA3, 
transcription factor for Th1 
(Halsall et al., 2004) 
 
Table ‎2.6. VDR SNP location, type, and Applied Biosystem assay ID#.  
SNP dbSNP Location Polymorphism Assay ID 
FokI* rs2228570 Coding region A/G Transition C__12060045_20 
BsmI rs1544410 3' UTRs C/T Transition C___8716062_10 
A1012G rs4516035 promoter 5' UTRs C/T Transition C___2880805_10 
*FokI (r2228570) is a C/T transition on the forward strand but the assay has been 
designed on the reverse strand. 
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2.11 Immunofluorescence 
Ocular barrier cells were cultured on glass chamber slides (BD Bioseciences, 
Oxford, UK), fixed for 20 min with cold methanol at 4º C and rinsed with PBS. Cells were 
blocked with 5% BSA in PBS for 1 hour, then treated with mouse-antihuman VDR clone 
H4537 (R&D Systems, Abingdon, UK), sheep-antimouse CYP27B1 PC290 (The Binding 
Site Ltd., Birmingham, UK)  mouse-antihuman CYP24A1 clone 1E1 (Novus Biologicals, 
Cambridge, UK), mouse-antihuman mannose-6-phosphate receptors (M6P) (Abcam, 
Cambridge, UK, clone 2G11), or mouse-antihuman trans-Golgi network 38 (TGN38) 
clone 2F7.1 (Novus Biologicals, Cambridge, UK) respectively (1:100 in PBS blocking 
solution) for 1 h at room temperature (RT). Cells were washed several times with PBS 
then incubated with FITC conjugated antimouse or FITC conjugated antisheep 
secondary antibody (The Binding Site Ltd., Birmingham, UK), or Texas Red (TR) 
conjugated antimouse antibody (Abcam, Cambridge, UK) diluted 1:250 in blocking 
solution for 1 hour at RT. Cells were briefly counter stained with 4',6-diamidino-2-
phenylindole (DAPI) (Invitrogen, Paisley, UK) and mounted (Vectashield, Vector 
Laboratories, Peterborough, UK). Staining was detected using a fluorescent microscope 
(AxioPlan2 Imaging, Ziess, Cambridge, UK). 
2.12 Statistical analysis 
Statistical analyses were performed using commercial statistical package software 
Graphpad Prism 5. Details of statistical calculations are explained in figure legends.
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3 CHARACTERISATION OF VITAMIN D3 PRODUCTION BY HUMAN 
OCULAR BARRIER CELLS 
3.1 Introduction  
Extra-renal synthesis of vitamin D3 has been reported in many tissues and cells 
including barrier sites. VDR and CYP27B1 have been described in epithelial cells of 
skin, lung, intestine, prostate, endometrium, and breast as well as cells of the immune 
system such as macrophages and dendritic cells (Agic et al., 2007;Brozyna et al., 
2011;Flanagan et al., 2006;Hansdottir et al., 2008;Hewison et al., 2003;Larriba et al., 
2011). Extra-renal vitamin D3 metabolism extends to the liver 25-hydroxylases involved 
in the first hydroxylation step in the activation of vitamin D3. CYP2R1 is suggested to be 
the major 25-hydroxylase in humans. It has higher affinity than CYP27A1 towards 
vitamin D3 and mutations in the CYP2R1 gene cause disturbance of vitamin D3 
metabolism (Zhu and Deluca, 2012). In the circulation, 25(OH)D3 is bound to vitamin D3 
binding protein (DBP) which facilitates its cellular uptake by multi-ligand endocytic 
receptors megalin/cubilin expressed on the apical surface of polarised epithelial cells in 
many tissues (Christensen and Birn, 2002).  
Local conversion of 25(OH)D3 into 1,25(OH)2D3 has been shown in respiratory, 
urinary bladder and colonic epithelial cells, osteoclasts, and macrophages (Gottfried et 
al., 2006;Hansdottir et al., 2008;Hertting et al., 2010;Kogawa et al., 2010;Lagishetty et 
al., 2010). Of note, VDR is critical for barrier formation in human skin and the integrity of 
the mucosal barrier in mouse intestine. In a mouse model of DSS induced colitis, VDR 
knockout (KO) mice (VDR-/-) compared to VDR+/+, suffered severe diarrhea and 
  Chapter 3  Characterisation of vitamin D3 production by human ocular barrier cells    76 
 
intestinal bleeding. Their intestines showed reduced TEER that progressed into 
ulceration and confocal microscopy revealed disrupted TJs. The addition of 1,25(OH)2D3 
in vitro to human colonic cancer epithelial cell lines SW480 and Caco-2 increased the 
expression of TJ proteins  ZO-1, claudin-1, claudin-2, and E-cadherin. TJ occludin was 
not induced by 1,25(OH)2D3 but it was completely absent from VDR
-/- intestinal mucosa 
after treatment with DSS. In the presence of 1,25(OH)2D3, a monolayer of Caco-2 cells 
was protected from damage by the addition of 5% DSS (Kong et al., 2008). Interestingly, 
silencing of VDR and steroid receptor coactivators (SRC) in primary normal human 
keratinocytes resulted in a compromised keratinocytes differentiation and hence barrier 
function. VDR-/-  mice also showed a compromised barrier formation as shown by 
decreased epidermal lamellar body density and reduced lipid secretion (Oda et al., 
2009).  
Recently, vitamin D3  has been recognised as an immunomodulatory hormone 
that regulates both innate and acquired immune responses (Hewison, 2012). One 
regulatory role of 1,25(OH)2D3 in the immune system (in vitro) involves the inhibition of 
proinflammatory cytokine production from CD4+ T cells and the induction of a regulatory 
T cell phenotype and a suppressive function (Jeffery et al., 2009). Endogenous 
conversion of 25(OH)D3 has been shown to inhibit DC antigen presentation and 
chemotaxis (Bartels et al., 2010). The ability to induce the production of HDPs in blood 
monocytes also supports an interaction between 1,25(OH)2D3 and the immune system. 
The HDPs LL-37 and hBD1-4 are antimicrobial and immunomodulatory molecules. They 
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can act as chemotactic agents for T and dendritic cells as well as their ability to induce 
Th 1 and 2 cytokines (Oppenheim et al., 2003). 
As stated in Chapter 1, ocular immune privilege is maintained by a set of 
anatomical and physiological processes that protect the eye from sight threatening 
infections and inflammatory responses (Streilein, 2003). The conjunctiva, composed of 
layers of epithelial cells and a sophisticated stroma forming a mucosal surface that 
contains a heterogeneous population of lymphoid cells playing an important role in the 
defense against infections (Fukuda et al., 2006). The sclera is the fibrous support to the 
global structure of the eye composed of a rich extracellular matrix (ECM) of collagen and 
elastic fibers together with fibroblasts that are responsible for tissue remodeling and the 
regeneration of the ECM (Rada et al., 2006). On the posterior surface of the cornea, 
endothelial cells contribute to barrier function by mediating sodium transport that 
maintains the cornea in a relatively dehydrated state thereby preserving corneal 
transparency (Mergler and Pleyer, 2007).  
Physical barriers that prevent the entry of immune cells from blood to the eye 
include BAB and BRB. The BAB is made of TJs between vascular endothelial cells of iris 
and ciliary body vessels and the non-pigmented ciliary body epithelial cells, while  the 
BRB is composed of TJs between endothelial cells in retinal blood vessels and those 
between the retinal pigment epithelial cells (Hornof et al., 2005). AqH is produced by the 
ciliary processes and is secreted into the posterior chamber. This active process is 
mainly a function of the blood-aqueous barrier which prevents the passage of proteins to 
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AqH to maintain its transparency (Kiel et al., 2011). AqH flows in a unidirectional 
movement from the posterior chamber through the pupil to the anterior chamber. It is 
drained through trabecular meshwork until it ends in episcleral veins (Goel et al., 2010).  
To date very few studies have examined the presence of vitamin D3 synthesising 
and metabolising pathways and whether human ocular barrier epithelial cells are 
capable of producing vitamin D3. This study shows the expression and functionality of 
the vitamin D3 system in human ocular barrier epithelial cells. Vitamin D3 may be 
important to the ocular barrier function and ocular immune privilege. 
3.2 Results 
3.2.1 Ocular barrier epithelial cells constitutively express mRNA for 
vitamin D3 metabolism 
Extra-renal expression of vitamin D3 synthesising and metabolising components 
has been described in many organs. To examine the presence of these elements in 
ocular barrier cells, mRNA expression was examined by RT-PCR. The VDR was 
strongly expressed in all ocular cells tested except in primary human corneal 
endothelium (PHCend). This could be due to the little amount of tissue and low RNA 
obtained from corneal rims (Figure 3.1 A). CYP27B1 was expressed markedly by 
CCL20.2, HCEC-12, ODM-2, and ARPE-19 cells and weakly by PHCend. The weak 
expression by PHCend could be due to the scarcity of sample size and low RNA 
concentration obtained. In contrast, CYP24A1 mRNA was strongly expressed only by 
CCL20.2 cells and weakly by all other cell types. CYP27A1 was weakly expressed in 
HCEC-12, ARPE-19 and ODM-2, and undetected in CCL20.2. Furthermore, CCL20.2, 
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HCEC-12, and ARPE-19 highly expressed CYP2R1 whereas ODM-2 showed weak 
expression. We also investigated the mRNA expression of cubilin and megalin, which 
are required for the internalisation of 25(OH)D3 through DBP. Cubilin was strongly 
expressed in all cells except CCL20.2 which had a weak expression, while only CCL20.2 
weakly expressed megalin (Figure 3.1 B). To summarise, ocular barrier epithelial cells 








Figure ‎3.1. Ocular barrier epithelial cells express mRNA for vitamin D3 elements. 
Total RNA was isolated from 80-90% confluent ARPE-19 (adult retinal pigment 
epithelial), ODM-2 (non-pigmented ciliary body epithelial), HCEC-12 (human corneal 
endothelial) cell lines, PHCend (freshly isolated RNA from primary human corneal 
endothelium), and CCL20.2 (conjunctival cell line). Conventional RT-PCR was 
performed for mRNA expression of VDR, CYP27B1, CYP24A1, CYP27A1, CYP2R1 (A), 
and for cubilin, and megalin (B) compared to 18S as an internal control. HKC-8 (human 
kidney cell line), M1 (classically activated macrophages), and M2 (alternatively activated 
[noninflammatory] macrophages) cells were used as positive controls for vitamin D3 
pathway molecules, RNA from primary thyroid cells was used as a positive control for 
cubilin and megalin, and H2O was used as a negative control. ND: not done. 
HKC-8    ARPE-19   ODM-2   HCEC-12    H2O     Thyroid 
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3.2.2 Ocular barrier epithelial cells express proteins for vitamin D3 
metabolism  
Immunofluorescent staining of all cell types for the different vitamin D3 elements 
was performed. The intensity of staining varied between cell types but all cells were 
positive for all vitamin D3 proteins. VDR showed a diffuse cytoplasmic and abundant 
speckled nuclear staining in all cells types. The expression was the strongest in HCEC-
12 and ODM-2 and weaker in CCL20.2 and ARPE-19 (Figures 3.2-3.5). CYP24A1 was 
also present in the cytoplasm where HCEC-12 and ODM-2 showed a strong signal 
(Figures 3.3 and 3.4), and there was a moderate signal in CCL20.2 (Figure 3.2). 
CYP27B1 showed an intense cytoplasmic pattern with denser staining in the peri-
nuclear area of ODM-2 and ARPE-19 (Figures 3.4 and 3.5), while CCL20.2 (Figure 3.2) 
showed moderate staining. Interestingly, in HCEC-12 cells, diffuse cytoplasmic staining 
was present but most of the enzyme appeared within a peri-nuclear vesicle (Figure 3.3).  















Figure ‎3.2.CCL20.2 cells express proteins for vitamin D3 pathway elements. Cells 
were grown to 40-50% confluency in 8-well chamber slides. Cells were fixed and 
processed for immunofluorescence staining. Cells were treated with antibodies against 
VDR, CYP27B1and CYP24A1 and visualised with FITC-conjugated secondary 
antibodies (green) compared to negative control (primary antibody omitted). DAPI was 
used as a counter nuclear stain (blue). VDR showed nuclear/cytoplasmic while 
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Figure ‎3.3. HCEC-12 cells express proteins for vitamin D3 pathway elements. Cells 
were grown to 40-50% confluency in 8-well chamber slides. Cells were fixed and 
processed for immunofluorescence staining. Cells were treated with antibodies against 
VDR, CYP27B1and CYP24A1 and visualised with FITC-conjugated secondary 
antibodies (green) compared to negative control (primary antibody omitted). DAPI was 
used as a counter nuclear stain (blue). VDR showed nuclear/cytoplasmic while and 
CYP24A1 showed cytoplasmic staining. CYP27B1 appeared as a vesicle near the 
nucleus. Pictures are shown as 40x magnification. 
HCEC-12 
CYP24A1 
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Figure ‎3.4. ODM-2 cells express proteins for vitamin D3 pathway elements. Cells 
were grown to 40-50% confluency in 8-well chamber slides. Cells were fixed and 
processed for immunofluorescence staining. Cells were treated with antibodies against 
VDR, CYP27B1and CYP24A1 and visualised with FITC-conjugated secondary 
antibodies (green) compared to negative control (primary antibody omitted). DAPI was 
used as a counter nuclear stain (blue). VDR showed nuclear/cytoplasmic while 
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 Figure ‎3.5. ARPE-19 cells express proteins for vitamin D3 pathway elements. Cells 
were grown to 40-50% confluency in 8-well chamber slides. Cells were fixed and 
processed for immunofluorescence staining. Cells were treated with antibodies against 
VDR, CYP27B1and CYP24A1 and visualised with FITC-conjugated secondary 
antibodies (green) compared to negative control (primary antibody omitted). DAPI was 
used as a counter nuclear stain (blue). VDR showed nuclear/cytoplasmic while 
CYP27B1 and CYP24A1 showed cytoplasmic staining. Pictures are shown as 40x 
magnification. 
ARPE-19 
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3.2.3 CYP27B1 co-localises with mannose phosphate receptors 
(MPRs) and trans-Golgi network (TGN) in HCEC-12 (human 
corneal endothelial cells). 
CYP27B1 is normally located in the inner membrane of the mitochondria (Adams 
and Hewison, 2012;Seliskar and Rozman, 2007). All the ocular epithelial cells tested 
demonstrated a staining pattern consistent with this expression i.e. cytoplasmic. The 
exception was HCEC-12 cells, which not only expressed CYP27B1 in the cytoplasm, but 
the majority of the enzyme appeared as a vesicle adjacent to the nucleus. To further 
identify the nature of this vesicle-like structure, HCEC-12 were stained for Mannose 6 
phosphate (M6P) receptors that are known to play a role in the transport of enzymes 
from the trans-Golgi network (TGN) to lysosomes (Ghosh et al., 2003) and typically 
shows peri-nuclear localisation. In addition, TGN38 protein, part of the TGN that directs 
proteins to secretory vesicles, lysosomes, or plasma membrane, was also examined (Gu 
et al., 2001). CYP27B1 co-localised to both M6P receptors and TGN38 in HCEC-12 
(Figure 3.6 A, B, and C). HECE-12 cells stained for CYP27B1 with FITC were also 
viewed by confocal microscopy which confirmed the peri-nuclear localisation of this 
enzyme (Figure 3.7). The cytoplasmic staining, together with the peri-nuclear punctuated 
presence confirms CYP27B1 presence in the TGN in HCEC-12 cells.  






Figure ‎3.6. CYP27B1 co-localises with Mannose-6-Phosphate (M6P) receptor and 
trans-Golgi network protein 38 (TGN38) in HCEC-12. HCEC-12 cells were grown to 
40-50% confluence in 8-well chamber slides. Cells were fixed with methanol at 4º C for 
20 min and processed for immunofluorescence staining. Cells were treated with 
antibodies against VDR, CYP27B1, and (A) M6P or (B) TGN38 and visualised with FITC 
(green) or Texas red (TR) (red) conjugated secondary antibodies compared to (C) 
negative control (primary antibody omitted). DAPI was used as a counter nuclear stain 
(blue). CYP27B1 co-localised with both M6P and TGN38 in HCEC-12. Pictures are 
shown as 100X (A and B) and 40X (C) magnification respectively.  
CYP27B1                           M6P                               TGN38                             Merge                         
A 
      CYP27B1                               M6P                              DAPI                             Merge 
C 
      CYP27B1                           TGN38                              DAPI                             Merge 
B 
           FITC                                 TR                                  DAPI                             Merge 
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Figure ‎3.7. CYP27B1 shows a peri-nuclear localisation in HCEC-12. HECE-12 cells 
were grown to 40-50% confluency in 8-well chamber slides. Cells were fixed and 
processed for immunofluorescence staining. Cells were treated with antibodies against 
CYP27B1 and visualised with FITC-conjugated secondary antibodies (green) compared 
to negative control (primary antibody omitted). DAPI was used as a counter nuclear stain 
(blue). CYP27B1 co-localised in the peri-nuclear space in HCEC-12. Images were 
obtained from confocal microscopy and are shown as 40x magnifications.  
FITC                 DAPI 
Merge 
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3.2.4 Ocular barrier epithelial cells can convert inactive vitamin D3 to 
the active form 1,25(OH)2D3 
Ocular barrier cells have the molecular components necessary to produce 
1,25(OH)2D3 locally. We next examined the functional capacity of CYP27B1 and its 
ability to convert inactive 25(OH)D3 (10
-7 M) into active 1,25(OH)2D3. The rate of 
conversion was variable amongst the different cells and can be broadly summarised with 
the highest rates in HCEC-12 and the lowest in ARPE-19 cells (Figure 3.9). 
To determine the best time point for 1,25(OH)2D3 measurement in culture 
supernatants, we started with time course conversion experiments using HKC-8 control 
cells and ARPE-19. Although ARPE-19 cells did not show significant conversion, the 
highest levels were at 24 h (Figure 3.8). Likewise, HKC-8 cells showed the highest 
1,25(OH)2D3 levels at 24 h, so a 24 h time point was chosen for all the succeeding 
conversion experiments. Substrate conversion was inhibited by pretreatment with 
itraconazole (10-5 M). Itraconazole did not give consistent inhibition so we changed it to 
ketokonazole (10-6 M). Conversion was inhibited by ketoconazole and the inhibition was 
statistically significant in cells that produced more than 200 pmol/L/mg protein of 
1,25(OH)2D3 (CCL20.2, HCEC-12, and ODM-2).  
CCL20.2 (conjunctiva) produced significant amounts of 1,25(OH)2D3 compared to 
untreated control cells (421.4 pmol/L/mg protein) (p<0.01) and double that made by 
HKC-8 positive control cells (195.4 pmol/L/mg protein) (p<0.05) (Figure 3.9). While 
ARPE-19 had minimal levels of conversion (25.0 pmol/L/mg protein), HCEC-12 were the 
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most efficient of all cell types at converting the substrate into the active form of 
1,25(OH)2D3 (2068.1 pmol/L/mg protein, p< 0.01) i.e. 10 times HKC-8 whereas ODM-2 











Figure ‎3.8. ARPE-19 and HKC-8 show the highest 25(OH)D3 conversion rates at   
24 h. ARPE-19 and HKC-8 (control) cells were grown to 80-90% confluence. Cells were 
either untreated (control) or treated with 25(OH)D3 (10
-7 M) for 12, 18, and 24 h with or 
without pre-treatment with CYP450 inhibitor (10-5 M) itraconazole (IC) for 2 h. Cell 
culture supernatants were collected and stored at -20º C until measurement. 
1,25(OH)2D3 was determined by enzyme immunoassay and the results were obtained 
from a standard curve as pmol/L. HKC-8 showed the highest conversion rate at 24 h. 
ARPE-19 did not show high conversion rates at all time points but the levels at 24 h 
were relatively higher and following from HCK-8, 24 h time point was selected for 
conversion experiments. HKC-8 and ARPE-19 n=1 except ARPE-19 24 h n=3. Graphs 
show mean 1,25(OH)2D3 concentration pmol/L for each treatment (except ARPE-19 at 
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Figure ‎3.9. Ocular barrier epithelial cells can convert 25(OH)D3 into active 
1,25(OH)2D3. Cells were grown to 80-90% confluence and were either untreated 
(control) or treated with 25(OH)D3 (10
-7 M) for 24 h in serum free conditions with or 
without pretreatment with CYP450 inhibitor (10-6 M) ketoconazole (KC) for 2 h. Cell 
culture supernatants were collected and stored at -20º C until measurement. 
1,25(OH)2D3 was determined by enzyme immunoassay and the results were obtained 
from a standard curve as pmol/L then corrected per mg of protein. HKC-8 cells were 
used as a positive conversion control. HCEC-12 cells showed the highest conversion 
rates followed by ODM-2 then CCL20.2, whereas the lowest rates were found in ARPE-
19 cells. The bottom right graph compares the conversion rates between cell types. 
Each experiment was performed at least 3 times. Graphs show mean±SD 1,25(OH)2D3 
per mg protein for each treatment.  * p<0.05, **p<0.01 and *** p<0.001 Kruskal-Wallis 
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3.2.5 Macrophages convert inactive vitamin D3 to the active form 
1,25(OH)2D3 
Macrophages express VDR and CYP27B1 and have been shown to upregulate 
genes downstream of 1,25(OH)2D3 activation (Liu et al., 2006).  Twenty years earlier, a 
study (Reichel et al., 1987) showed that activated macrophages were able to convert 
25(OH)D3 into active 1,25(OH)2D3. Macropahges can also contribute to local 
1,25(OH)2D3 production as either infiltrating inflammatory classically activated 
macrophages (M1) or resident noninflammatory alternatively activated macrophages 
(M2). To confirm the ability of macrophages to locally convert 25(OH) D3 into 
1,25(OH)2D3, M1 and M2 macrophages were isolated, differentiated (as described in 
section 2.2) and tested (Beyer et al., 2012;Schwartz and Svistelnik, 2012). Our results 
show that M1 and M2 cells can both metabolise 25(OH)D3 and convert it into 
1,25(OH)2D3 (Figure 3.10) although there was no statistically significant difference from 
control cells. The rates of conversion shown by HCEC-12 and ODM-2 above were even 
higher than the levels produced by M1 and M2 cells respectively. 
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Figure ‎3.10. Macrophages polarised to M1 and M2 phenotypes convert inactive 
vitamin D3 to the active form 1,25(OH)2D3. M1 and M2 macrophages prepared as 
described in section 2.2 were either untreated (control) or treated with 25(OH)D3 (10
-7 M) 
for 24 h in serum free conditions with or without pretreatment with CYP450 inhibitor (10-6 
M) ketoconazole (KC) for 2 h. Cell culture supernatants were collected and stored at -
20º C until measurement. 1,25(OH)2D3 was determined by enzyme immunoassay and 
the results were obtained from a standard curve as pmol/L then corrected per mg of 
protein. Both M1 and M2 macrophages show similar conversion rates although there 
was no statistically significant difference from control cells. Each experiment was 
performed at least 3 times. Graphs show mean±SD 1,25(OH)2D3 per mg protein for each 
treatment. * p<0.05 Kruskal-Wallis test.   
 
3.2.6 1,25(OH)2D3 can be detected in human AqH and serum samples 
To confirm the production of 1,25(OH)2D3 in the eye, 7 AqH samples from normal 
controls (age 46-84) were tested. AqH samples showed detectable levels of 
1,25(OH)2D3 (1.9-4.8 pmol/L). These levels were compared to matched serum samples 
(Figure 3.11). Serum levels were higher (49.9-89.9 pmol/L) than levels in AqH (p<0.01).  
Serum levels did not show a correlation to AqH i.e. the highest serum level does not 
necessarily match with the highest levels in AqH. Samples with zero values had a 
volume of <50µl (Table 3.1).  
M1 M2 









Figure ‎3.11. 1,25(OH)2D3 can be detected in human AqH. Matched AqH and serum 
samples from normal controls undergoing cataract surgery were collected, processed, 
and stored at -80º C until measurement. 1,25(OH)2D3 concentrations (pmol/L) were 
measured by enzyme immunoassay and the results were obtained from a standard 
curve as pmol/L. AqH showed detectable levels of 1,25(OH)2D3 but very low compared 
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Table ‎3.1. Concentrations of 1,25(OH)2D3 in aqueous humour (AqH) do not 
correlate with age or serum which supports local production. Matched AqH and 
serum from healthy controls undergoing cataract surgery (five females and two males) of 
ages between 46 and 84 were collected and tested for 1,25(OH)2D3 by enzyme 
immunoassay (pmol/L). Concentrations of 1,25(OH)2D3 in AqH did not correlate with age 











3.3 Discussion  
This study shows that human ocular barrier epithelial cells constitutively express 
mRNA and protein for the receptor and the metabolic enzymes required in the vitamin 
D3 pathway, and can endogenously produce 1,25(OH)2D3 when treated with 
physiological concentrations of its precursor 25(OH)D3 (Table 3.2).  
Until recently, vitamin D3 has not been reported in ocular surfaces. Previous 
studies have only shown that human primary RPE-choroid expressed mRNA for VDR 
and CYP27A1 while retinal tissue expressed CYP27B1 and CYP27A1 (Morrison et al., 
Gender Age 1,25(OH)2D3 (pmol/L) 
AqH Serum 
F 69 4.81 78.99 
F 46 1.99 49.92 
F 76 00 89.93 
F 84 00 77.85 
M 60 3.27 60.47 
F 81 3.31 84.35 
M 57 3.99 55.06 
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2011). Cultured primary rabbit, mouse, and human corneal epithelial cells expressed 
VDR and CYP27B1. Similar expression was seen in mRNA freshly collected from 
mouse and rabbit corneal epithelial tissues but there are no data on 25(OH)D3 
conversion (Lin et al., 2012). 
In agreement with the speckled cytoplasmic and nuclear VDR staining in ocular 
barrier cells, VDR has been described in cytoplasm and nucleus of urinary bladder 
epithelium (Hertting et al., 2010;Midorikawa et al., 1999). The cytoplasmic expression of 
CYP27B1 in most of the ocular barrier epithelial cell lines is in accordance with similar 
expression in urinary bladder epithelium (Hertting et al., 2010). Conversely, the 
punctuated peri-nuclear staining of CYP27B1 in HCEC-12 can be compared to the 
cytoplasmic localisation in the peri-nuclear space seen in human tumour prostate 
epithelial cell line (LNCaP) transfected with CYP27B1 (Chen and Holick, 2003). LNCaP 
cells express CYP27B1 as multiple vesicular structures. The expression of CYP27B1 in 
TGN could be part of this enzyme’s trafficking in these cells which are highly metabolic 
in nature supplying nutrients to the cornea and dehydrating the stroma (Bonanno, 2012). 
HCEC-12 were the most efficient in 25(OH)D3 conversion among ocular barrier epithelial 
cells tested. It could be that CYP27B1 localisation to TGN is part of its trafficking to get 
to the cell membrane making it readily available to bind and convert its substrate. 
Membrane bound CYP450 proteins can recycle through Golgi before reaching their 
destined locations. Some CYP450 enzymes can exist in the mitochondria and 
endoplasmic reticulum (ER), an example is rat CYP27B1. At the N-terminus (amino 
acids 20-36) of rat CYP27B1, there is a targeting signal for mitochondria and 
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endoplasmic reticulum. Phosphorylation of serine 128 (Ser128) activates a cryptic 
mitochondrial signal and modulates CYP27B1 destination to the mitochondria or ER 
(Seliskar and Rozman, 2007). A final possibility is that HCEC-12 cells are not primary 
and this expression could be an inherent characteristic of this cell line.  
Although ocular barrier epithelial cells show constitutive expression of mRNA and 
protein for CYP24A1, this mitochondrial enzyme is not constitutively expressed in all 
peripheral organs and tissues. Some cells such as skin keratinocytes, respiratory 
epithelial cells, and colonic epithelial cell line (Bar et al., 2007;Hansdottir et al., 
2008;Peric et al., 2009) only express CYP24A1 in response to 25(OH)D3 or 
1,25(OH)2D3. Keratinocytes demonstrate a strong upregulation following exposure to 
UVB light in the presence of 7DHC (Bar et al., 2007). CYP24A1 is also induced after 
treatment with 25(OH)D3 sufficient serum in macrophages (Liu et al., 2006).  
Our study also shows that human ocular barrier epithelial cells can convert 
inactive vitamin D3 to its active form. It also shows 1,25(OH)2D3 can be measured in 
human AqH samples. With the exception of ARPE-19, ocular barrier epithelial cells, are 
able to produce significant levels of active 1,25(OH)2D3 > 0.4x10
-9 M at 24 h. This rate of 
conversion is comparable to that of human primary respiratory epithelial cells, urinary 
bladder epithelial cell line, and mammary epithelial cells (Hansdottir et al., 2008;Hertting 
et al., 2010;Kemmis and Welsh, 2008). These rates are much higher than those 
produced by human kidney cortical collecting duct (HCD) cell line (Bland et al., 2001). 
Starting from the conjunctiva, ocular barrier conversion is higher in primary human 
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corneal epithelial cells (PHCEC) (Susarla et al. and Alsalem et al. manuscripts 
submitted), reaches a peak in corneal endothelium, and starts to decrease in non-
pigmented ciliary body epithelium reaching the lowest levels at retinal pigmented 
epithelium (Figure 3.12).  
Ocular barrier epithelial cells appear to be efficient in producing 1,25(OH)2D3 
provided they have the substrate available. Despite the requirement of 25(OH)D3 for 
CYP27B1 to convert it to 1,25(OH)2D3, ocular barrier cells can potentially initiate the 
vitamin D3 pathway as early as the first 25-hydroxylation step via CYP27A1 and 
CYP2R1. Extra-hepatic expression of CYP27A1 and CYP2R1 has also been reported 
previously in other tissues (Blomberg et al., 2010;Ellfolk et al., 2009;Matusiak and 
Benya, 2007;Shinkyo et al., 2004). CYP27A1 is expressed in human RPE tissue and 
with its broad substrate specificity, is also involved in cholesterol metabolism. and 
protects the retina from the toxic 7-ketocholesterol, a metabolite of 7-DHC as a result of 
photooxidation (Heo et al., 2012). CYP2R1 is expressed in primary human prostate 
epithelium and thyroid epithelium cell line and tissue, and primary renal kidney epithelial 
tissue (Bieche et al., 2007;Blomberg Jensen, 2012;Blomberg et al., 2010). Although 
CYP27A1 was weakly expressed by ocular barrier cells, the expression of microsomal 
CYP2R1 was considerably greater. Moreover, the 25-hydroxylation activity of CYP2R1 
is 26-fold higher than that of CYP27A1 (Shinkyo et al., 2004). This suggests that there is 
a possibility that ocular cells might be able to synthesise vitamin D3 directly after 
exposure to sunlight.   
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The expression of megalin and cubilin in ocular barrier cells indicate the 
importance of these receptors in vitamin D3 metabolism. Megalin has been identified in 
rat alveolar epithelial cell line, Caco-2 human intestinal epithelial cell line, and co-
localised with cubilin in rat epithelial cells of uterus and oviduct (Argraves and Morales, 
2004;Oda et al., 2011) but the relevance to the vitamin D3 pathway has not been 
investigated in these cells. In mouse gall bladder (GB) epithelium, the expression of 
megalin and cubilin was distorted in calcuclous GB epithelium. Megalin and cubilin are 
multi-ligand receptors and may contribute to cholesterol uptake and prevent bile 
accumulation. Therefore, their disrupted expression or absence may suggest their 
involvement in gallstone formation (Tsaroucha et al., 2008). Although megalin is more 
widely expressed in different tissues (Christensen and Birn, 2002), the expression of 
cubilin is much more pronounced in ocular barrier epithelial cells.  
An immune privileged organ such as the eye requires efficient strategies that can 
protect optical clarity from sight-threatening infections and damaging inflammatory 
responses. Decreased serum levels in humans of 25(OH)D3 have been correlated with 
increased early AMD and low visual acuity in the elderly (Beauchet et al., 2011;Millen et 
al., 2011). This was further investigated by calculating UVB exposure index which 
correlated with reduced neovascular AMD. Moreover, SNPs in human CYP24A1 have 




Table ‎3.2. A summary of gene and protein expression for vitamin D3 elements by ocular barrier cells as well as the rate 
of 25D3 conversion. Ocular barrier epithelial cell lines are shown with mRNA expression, immunofluorescence staining 
intensity, and rate of 25D3 conversion with the highest as +++ and the lowest as +. HKC-8 cell line was used as a positive 
control for the expression of vitamin D3 pathway components and 25(OH)D3 conversion. Thyroid mRNA was used a positive 












         * ND: not done 
 




















Figure ‎3.12. The rate of 25(OH)D3 conversion by ocular barrier epithelial cells 
according to their anatomical location from the outside to the inside of the eye. A 
schematic diagram showing 1,25(OH)2D3 concentrations in the different ocular barrier 
epithelial cells from the exterior to the interior following their anatomical location. 
25(OH)D3 conversion starts at the conjunctiva, increases at corneal epithelium, reaches 
a peak at corneal endothelium, decreases at the ciliary body and diminishes at the 
retina. 
To date, there is no mention of the presence of 1,25(OH)2D3  in human AqH. Yin 
et al. measured vitamin D3 metabolites including 25(OH)D3 and 1,25(OH)2D3 in rabbit 
AqH and vitreous samples (Yin et al., 2011). The levels of 1,25(OH)2D3 obtained in the 
current study in human AqH (0.004 nM) were lower than those shown in rabbit AqH 
(0.04 nM). Rabbit AqH levels were measured by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS), a more sensitive technique suitable for the measurement of 
vitamin D3 in a sample size as low as 100 µl (Vogeser, 2010).  
There are several reasons why human aqueous levels of 1,25(OH)2D3  are lower 
than serum; (i) the recommended sample volume for the enzyme immunoassay is at 
least 500 µl and the sample volume available from AqH was between 50-150 µl which 
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movement and has a high turnover (2.4 ± 0.6 μl/min) to provide nutrients to and remove 
waste from the avascular cornea and lens (Goel et al., 2010), therefore the large 
amounts of 1,25(OH)2D3 produced by corneal endothelium and ciliary body may be used 
up by the cells or washed away with AqH movement to keep a clear fluid consistency; 
(iii) as AqH contains less than 1% of proteins in plasma (Freddo, 2001) it may not cross 
the iris/ciliary body barrier efficiently. Nevertheless, the levels in AqH did not directly 
match their counterparts in serum which may suggest local synthesis of 1,25(OH)2D3 
that is secreted into AqH. Moreover, although vitamin D3 synthesis is believed to 
decrease with age (Laird et al., 2010), serum vitamin D3 levels of patients with ages 69-
84 were higher than patients with ages 46-56. 
The ability of ocular barrier epithelial cells to locally produce large amounts of 
1,25(OH)2D3 may be important for their barrier function. For example, corneal endothelial 
cells are highly metabolic and represent an important barrier at the anterior segment of 
the eye and producing large amounts of 1,25(OH)2D3 may help maintain this function. 
More than 200 genes were significantly upregulated or downregulated in response to 
stimulation of lymphoblastoid cell line with 1,25(OH)2D3 including several involved in the 
immune response (Ramagopalan et al., 2010). Similarly the induction of HDPs by 
1,25(OH)2D3 may be of importance to ocular barrier function (Liu et al., 2006). 
The main caveat in this work is the use of cell lines rather than primary cells. 
Some attempts were carried out to isolate and grow primary human corneal endothelial 
cells without success.  Several emails were sent to eye banks in Bristol and Manchester 
to obtain eyes not suitable for transplantation and use them to isolate non-pigmented 
ciliary body and retinal pigment epithelium without response. However the lines used are 
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well-established and regarded as good correlates for freshly –isolated ocular cells 
(Bednarz et al., 2000;Dunn et al., 1996;Martin-Vasallo et al., 1989;Racusen et al., 1997).  
In conclusion, this study has demonstrated the expression of vitamin D3 pathway 
molecular components by in vitro models of ocular barrier epithelial cells and that these 
cells can convert inactive 25(OH)D3 into active 1,25(OH)2D3. This study has also shown 
that 1,25(OH)2D3 is present in detectable levels in human AqH. Further work will show if 
these cells can create an environment rich in 1,25(OH)2D3  and if this has an effect on 
ocular immune protection and immune privilege. 
           Chapter 4    The role of 1,25(OH)2D3 in ocular barrier epithelial cells                103 
     
 
4 THE ROLE OF 1,25(OH)2D3 IN OCULAR EPITHELIAL BARRIER 
CELLS 
4.1 Introduction 
 Vitamin D3 directly or indirectly influences many immune cells. This is facilitated 
by the wide expression of VDR in immune cells including neutrophils, macrophages, 
DCs, as well as activated T and B cells. Vitamin D3 prevents DC maturation, skews T 
cell development into regulatory phenotypes, and inhibits B cell proliferation (Baeke et 
al., 2010). Stimulation of CD4+CD25- T cells with 1,25(OH)2D3  resulted in an inhibition of 
proinflammatory cytokines such as IFN- and IL-17. At the same time it increased the 
expression of CTLA4 and FoxP3 (Jeffery et al., 2009). Further investigations showed 
that endogenous production of 1,25(OH)2D3 caused the conversion of DC into 
tolerogenic phenotype and enabled them to alter T cell responses (Jeffery et al., 2012). 
B cell stimulation with 1,25(OH)2D3 prevented plasma cells differentiation and Ig class 
switching (Chen et al., 2007). This was translated in vivo where patients with SLE 
supplemented with vitamin D3 had decreased Th1 and Th17, restored regulatory T cells, 
and decreased memory B cells and anti-inflammatory antibodies (Terrier et al., 2012).  
 As stated in Chapter 1, HDPs are short cationic peptides produced by cells of the 
immune system and various cell types. They are known for exhibiting antimicrobial as 
well as immunomodulatory activities (Steinstraesser et al., 2011;Yeung et al., 2011).  
The immunomodulatory role of vitamin D3 became very clear in studies linking vitamin 
D3 deficiency to susceptibility to infection with Mtb (Gibney et al., 2008;Williams et al., 
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2008). When macrophages were stimulated with a TLR2/1 mycobacterial ligand in the 
presence of vitamin D3, there was an upregulation of LL-37 genes and increased 
antimicrobial activity against Mtb. African-Americans have higher melanin levels in their 
skin and thus become less capable of obtaining sufficient vitamin D3 from UV exposure 
(Macdonald, 2012). When macrophages were stimulated in the presence of vitamin D3 
insufficient African-American serum, there was a significant reduction in mRNA levels of 
LL-37 compared to Caucasians (Liu et al., 2006). This was mediated by TLR2/1 induced 
IL-15 which lead to the induction of CYP27B1 and cathelicidin (Krutzik et al., 2008).  
 The activation of TLR2/1 also induced IL-1β which together with VDR were 
required to induce DEFB4 (Liu et al., 2009b). In contrast to enhanced macrophage 
antimicrobial response to Mtb, vitamin D3 induced LL-37 increased virulence and 
promoted resistance to killing of Group A Streptococcus by oropharyngeal keratinocytes, 
macrophages and neutrophils (Love et al., 2012). IFN- produced by T cells needs 
vitamin D3 to result in subsequent autophagy, autophagosome-lysosome fusion and 
even the induction of HDPs such as cathelicidin and BD-4 (Fabri et al., 2011). 
  Skin injury is known to induce HDPs. Injury was induced using sterile incisions in 
healthy human skin and Streptococcal injections in C57BL/6 mice. Human cathelicidin 
(LL-37) and mouse cathelicidin-related HDP (CRAMP) proteins were expressed in the 
extracellular space and granulation tissues. This indicates their synthesis by 
keratinocytes and granulocytes migrating to the site of injury (Dorschner et al., 2001). 
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 This work was followed further. Injury of human skin induced mRNA expression of 
TLR2, CD14 (a TLR cofactor), and CYP24A1. Treatment of keratinocytes with TLR2 
ligand in the presence of TGF-β released in response to injury induced mRNA 
expression of CYP27B1. When keratinocytes were treated simultaneously with TGF-β1 
and 25(OH)D3, cathelicidin, CD14, and TLR2 were induced. TGF-β1 or 25(OH)D3 alone 
could not induce the same genes. CYP27B1 deficient mice were used to confirm the 
results in vivo.  Mouse CD14 is regulated by 1,25(OH)2D3 and it was absent compared to 
wild type. In contrast, mouse CRAMP was induced in both CYP27B1 deficient and wild 
type mice as this gene does not contain VDRE. Keratinocytes transfected with CAMP 
with disrupted VDRE could not induce cathelicidin in response to 1,25(OH)2D3. TLR2 
synegised with 1,25(OH)2D3 to induce mRNA expression of cathelicidin, an effect that 
diminished with VDR antagonist (Schauber et al., 2007).  
 The production of HDPs appears to be a key function of vitamin D3 in 
macrophages and epithelial cells. In respiratory epithelial cells, TLR2/1 has the same 
role as in macrophages. In addition, stimulation of TLR3 increased endogenous 
1,25(OH)2D3 production and both synergised to enhance the expression of LL-37 
(Hansdottir et al., 2008). In contrast, in urinary bladder epithelial cells, both exogenous 
and endogenous 1,25(OH)2D3 were able to upregulate LL-37 in the absence of TLR 
stimulation.  
Vitamin D3 proves to be important for barrier function. In a mouse model of IBD, 
oral supplementation with vitamin D3 abrogated the inflammatory response in the colon. 
           Chapter 4    The role of 1,25(OH)2D3 in ocular barrier epithelial cells                106 
     
 
Furthermore, vitamin D3 maintained intestinal barrier integrity by reducing permeability 
and upregulating the expression of TJ proteins (Zhao et al., 2012). Vitamin D3 also 
upregulated TJ proteins in corneal epithelium (Yin et al., 2011) but its role in the 
induction of HDPs in the eye has not been investigated. HDPs have been detected in 
ocular cells and fluids (Garreis et al., 2010b;Huang et al., 2007), but it is not clear if 
vitamin D3 plays a role in their induction. 
In this study, we investigated the role played by vitamin D3 in the induction of 
HDPs and if vitamin D3 synergises with TLR to upregulate proinflammatory cytokines.  
4.2 Results 
4.2.1 Ocular barrier epithelial cells upregulate vitamin D3 elements 
genes in response to 25(OH)D3 or 1,25(OH)2D3 
To confirm that ocular barrier cells have a functional system that can induce the 
upregulation of vitamin D3 induced genes such as VDR, CYP27B1, and CYP24A1, cells 
were treated with physiological concentrations of either inactive 25(OH)D3 (10
-7 M) or 
active 1,25(OH)2D3 (10
-8 M). HCEC-12, ODM-2, and ARPE-19 cells showed an induction 
of vitamin D3 element genes upon treatment with 25(OH)D3 and 1,25(OH)2D3 (Figures 
4.1-4.3) but this induction was not statistically significant except in HCEC-12 at 1 h.   
HCEC-12 cells showed a significant 4-fold increase in VDR at 1 h in response to 
1,25(OH)2D3 (p<0.01) that declined afterwards and about 2-fold increase with 25(OH)D3 
at 8 h. In ODM-2 cells, VDR showed a 2- fold increase at 1 h with 25(OH)D3. Stimulation 
with 1,25(OH)2D3 induced a 2-fold increase at 4 and 8h, a peak of 3 fold at 16 h and 
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back to 2 fold at 24 h. In contrast to HCEC-12 and ODM-2, VDR was not highly 
upregulated in ARPE-19 cells. There was a minimal increase at all time points with 
1,25(OH)2D3 but not with 25(OH)D3 (Figure 4.1).  
In HCEC-12 cells, CYP27B1 showed a 4-fold change at 4 h and decreased at 8 
and 16 h to 1.5 fold. At 24 h, CYP27B1 expression increased by 2 fold and 1.6 fold with 
25(OH)D3 and 1,25(OH)2D3 respectively. CYP27B1 showed a gradual increase in ODM-2 
cells until it reached 2 fold and 2.5 fold with 25(OH)D3 and 1,25(OH)2D3 respectively at 8 
h. At 16 h there was no induction of CYP27B1 but there was a slight increase of 1.5 fold 
at with 25(OH)D3 24 h. CYP27B1 showed a slight 1.5-fold increase in ARPE-19 at 1 h 
with both 25(OH)D3 and 1,25(OH)2D3. At 4 h there was a  2-fold change with 
1,25(OH)2D3 followed by a 1.5 fold change at 8 and 16 h that declined at 24 h. 25(OH)D3 
induced an upregulation of 1.5 fold at 1 and 4 h that declined at 8 h. At 8 h there was 2.5 
fold change which decreased at 24 h (Figure 4.2).  
CYP24A1 was gradually induced in HCEC-12 cells at 4 h (2 fold), 8 h (4 fold), and 
16 h (10 fold) in response to both 25(OH)D3  and 1,25(OH)2D3. This dropped at 24 h to 3 
and 4 fold with 25(OH)D3 and 1,25(OH)2D3 respectively. In ODM-2 cells, CYP2A1 
expressed a 1.5 and 2 fold change at 1 h with 25(OH)D3 and 1,25(OH)2D3 respectively. 
While at 4 h there was a 10-fold increase with both, stimulation with 25(OH)D3 
maintained about 4 fold increase at 8 and 16 h. There was no upregulation caused with 
1,25(OH)2D3 at 8 h but at 16 h there was a 4 fold increase at 16 h that declined again at 
24 h. ARPE-19 cells showed an induction of CYP24A1, 1.6 fold change, with both 
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25(OH)D3 and 1,25(OH)2D3 at 4 h. This increased to 3 fold for 1,25(OH)2D3 but remained 
about 1.6 fold for 25(OH)D3 at 8 h. At 16 and 24 h there was no induction of CYP24A1 
with both treatments (Figure 4.3). 
In conclusion, ocular barrier epithelial cells showed a trend towards an 
upregulation of vitamin D3 element genes in response to 25(OH)D3 and 1,25(OH)2D3. 
HCEC-12 cells appear to be the quickest to upregulate the expression of CYP27B1 at 4 
h while CYP24A1 is only induced after 24 h which gives them more time for synthesis of 
1,25(OH)2D3. ODM-2 cells showed a slight induction at 4 h increasing its highest 
expression at 8 h. CYP24A1 is induced as early as 4 h with its highest expression 
decreasing at 8 h and increasing again at 16 h. This may indicate a tighter regulation of 
1,25(OH)2D3 synthesis in these cells. ARPE-19 only showed a slight upregulation of 
CYP27B1 and a modest induction of CYP24A1 compared to the other cell lines. This fits 
in with the conversion rates obtained in these cells. We have shown that HCEC-12 cells 
had the highest 25(OH)D3 conversion rates followed by ODM-2 then ARPE-19 cells. 
However, due to the lack of statistical significance more repeats are required to provide 
conclusive results.  
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Figure ‎4.1. Ocular barrier epithelial cells show a higher upregulation of mRNA for 
VDR in response to 1,25(OH)2D3 than 25(OH)D3. HCEC-12, ODM-2, and ARPE-19 
cells were grown to 80-90% confluence and were either left untreated (control) or 
treated with 25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8 M) for 1, 4, 8, 16, or 24 h in serum 
free conditions. Total RNA was isolated and real-time PCR was used to measure 
relative fold change increase in treated samples compared to control (untreated cells) for 
VDR. VDR showed a significant upregulation only in HCEC-12 cells with 1,25(OH)2D3 at 
1 h and a slight upregulation with 25(OH)D3 at 8 h. ODM-2 cells showed a slight 
upregulation with 25(OH)D3 at 1 h and with 1,25(OH)2D3 16 h while ARPE-19 cells did 
not show an upregulation of VDR mRNA expression. This upregulation is not statistically 
significant. Graphs show mean±SD (at least 3 experimental repeats). Two-way ANOVA 
with Bonferroni’s post test were perfomed, ** p<0.01. 
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Figure ‎4.2. Ocular barrier epithelial cells upregulate mRNA for CYP27B1 in 
response to 25(OH)D3 and 1,25(OH)2D3. HCEC-12, ODM-2, and ARPE-19 cells were 
grown to 80-90% confluence and were either left untreated (control) or treated with 
25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8 M) for 1, 4, 8, 16, or 24 h in serum free 
conditions. Total RNA was isolated and real-time PCR was used to measure relative fold 
change increase in treated samples compared to control (untreated cells) for CYP27B1. 
CYP27B1 was upregulated with both 25(OH)D3 and 1,25(OH)2D3 in HCEC-12 cells at 4 
and 24 h. CYP27B1 showed a slight with 1,25(OH)2D3 at 4 h and with both 25(OH)D3 
and 1,25(OH)2D3 at 8 h. ARPE-19 cells slightly upregulated CYP27B1 mRNA expression 
with 1,25(OH)2D3 at 4 h and with 25(OH)D3 at 16 h. However, this upregulation is not 
statistically significant. Graphs show mean±SD (at least 3 experimental repeats). Two-
way ANOVA with Bonferroni’s post test were performed. 
HCEC-12 ODM-2 
ARPE-19 
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Figure ‎4.3. Ocular barrier epithelial cells upregulate mRNA for CYP24A1 in 
response to 25(OH)D3 and 1,25(OH)2D3. HCEC-12, ODM-2, and ARPE-19 cells were 
grown to 80-90% confluence and were either left untreated (control) or treated with 
25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8 M) for 1, 4, 8, 16, or 24 h in serum free 
conditions. Total RNA was isolated and real-time PCR was used to measure relative fold 
change increase in treated samples compared to control (untreated cells) for CYP24A1. 
CYP24A1 showed an upregulation in HCEC-12 with both 25(OH)D3 and 1,25(OH)2D3 at 
8 and 16 h and in ODM-2 cells at 4 and 16 h. ARPE-19 cells only upregulated CYP24A1 
with 1,25(OH)2D3 at 8. However, this upregulation is not statistically significant. Graphs 
show mean±SD (at least 3 experimental repeats). Two-way ANOVA with Bonferroni’s 
post test were performed. 
HCEC-12 ODM-2 
ARPE-19 
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4.2.2 Vitamin D3 does not synergise with TLR in the production of 
proinflammatory cytokines 
It has been shown in macrophages that TLRs synergise with vitamin D3 to induce 
downstream effects of VDR activation (Liu et al., 2006). To investigate if VDR behaves 
similarly in ocular barrier cells, we first screened the cells for the expression of TLR1-10, 
RIG-I, and MDA5 (Figure 4.4). TLR1, 3, 4, 10, RIG-I, and MDA5 were strongly 
expressed by all the cell lines. TLR2 was not expressed by HCEC-12 and very weakly in 
ODM-2 and ARPE-19. TLR5 was absent in HCEC-12 but expressed by ODM-2 and 
ARPE-19. While TLR6 was expressed in HCEC-12 and ARPE-19, it showed a weak 
expression in ODM-2. TLR7 and 8 were absent in all cell lines. Likewise, TLR9 was 
strongly expressed by ODM-2 and ARPE-19 but absent in HCEC-12.  
 Next the ability of TLR and 25(OH)D3 to induce proinflammatory cytokines such 
as IL-6, IL-8, TNF-, and IFN- was measured by ELISA. As 25(OH)D3 (10
-7 M) had to 
be added in serum free conditions (to avoid additional 25(OH)D3 present in serum), we 
questioned whether TLRs especially TLR4 would be able to respond in the absence of 
LPS-binding protein (LPS-LBP) present in serum (Figure 4.5).  
When ARPE-19 were treated with different concentrations of Pam3Cys, Poly I:C, 
and LPS in the presence or absence of serum, ARPE-19 cells responded variably to 
TLR stimulation through the production of IL-6 and IL-8. There was a 2-fold increase in 
IL-8 concentrations after treatment with Pam3Cys (1 and 10 µg) and Poly I:C (20 µg) 
while Poly I:C (100 µg) caused a 4-fold increase in serum free conditions. Stimulation of 
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ARPE-19 with LPS (10 ng and 1 and 5 µg) caused a 3-fold increase in IL-8 
concentrations compared to control cells. The addition of serum increased the 
background but did not prevent the cells from responding to LPS.  
Stimulation of ARPE-19 with Pam3Cys (1 and 10 µg), Poly I:C (20 µg), and LPS 
(10 ng and 5 µg) doubled IL-6 concentrations while Poly I:C (100 µg) caused a 3-fold 
increase. Similar to IL-8, the addition of serum increased the background without 
preventing the cells from responding to LPS. Based on these findings, we decided to 
carry out the experiments in serum free (SF) conditions.  
HCEC-12 cells showed a baseline production of IL-8 but the concentrations were 
only increased in response to Poly I:C (100 µg). Treatment with 25(OH)D3 does not 
seem to affect the response of these cells to TLR ligands. ODM-2 cells initially produced 
high concentrations of IL-8 which were not changed by 25(OH)D3. Untreated ARPE-19 
cells produced a higher baseline concentration of IL-8 than HCEC-12 but lower than 
ODM-2 cells. ARPE-19 cells showed the highest IL-8 production in response to Poly I:C 
and RIG-I/MDA5 both of which doubled IL-8 concentrations (Figures 4.6). 
Also HECE-12 cells produced IL-6 constitutively and there was a slight increase 
in response to Poly I:C (100 µg) but this was not influenced by 25(OH)D3. There was no 
increase in IL-6 in ODM-2 cells in response to any of the TLR ligands used and the 
addition of 25(OH)D3 did not alter this response. ARPE-19 cells produced very low levels 
of IL-6 compared to HCEC-12 and ODM-2. Consistent with HCEC-12 cells, ARPE-19 
           Chapter 4    The role of 1,25(OH)2D3 in ocular barrier epithelial cells                114 
      
 
cells showed the highest IL-6 amounts upon treatment with Poly I:C. The response to 
TLR ligands was not affected by the addition of 25(OH)D3 in ARPE-19 (Figure 4.7). 
To conclude, ocular barrier cells responded to TLR ligand treatment by the 
production of IL-8 and IL-6 (except ODM-2) but this response was not affected by the 
addition of 25(OH)D3. TNF- and IFN- were not detected in ocular barrier cells by 
ELISA. However, due to the low number of repeats and the lack of statistical 
significance, these results are inconclusive.  
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Figure ‎4.4. Ocular barrier epithelial cells express mRNA for TLRs, RIG-I, and 
MDA5. HCEC-12, ODM-2, and ARPE-19 cells were grown to 80-90% confluence, and 
total RNA was extracted. Conventional RT-PCR was performed for mRNA expression of 
TLR1-10, RIG-I, and MDA5. Expression bands are shown with their corresponding sizes 
(bp). HCEC-12 cells expressed all TLRs except TLR2, 7, and 9 while ODM-2 and ARPE-
19 cells expressed all TLRs except TLR2, 7, and 8. HCEC-12, ODM-2, and ARPE-19 
cells expressed RIG-I and MDA5. 18S or GAPDH were used as internal controls and 
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Figure ‎4.5 ARPE-19 cells produce IL-8 and IL-6 in response to TLR stimulation in 
the absence and presence of serum by ELISA with or without the addition of 
25(OH)D3. ARPE-19 cells were grown 80-90% confluence and were either left untreated 
(control) or treated with TLR ligands with or without serum in growth media in the 
presence or absence of 25(OH)D3 (10
-7 M) for  24 h. Supernatants were collected and 
cytokine were measured by ELISA. ARPE-19 cells produced IL-8 after treatment with 
Pam3Cys, Poly I:C, and LPS in serum free medium in the presence or absence of 
25(OH)D3. These levels increased in the presence of serum. IL-6 was also produced by 
ARPE-19 cells after treatment with Poly I:C (100 µg) and LPS (10 ng) in the presence or 
absence of 25(OH)D3. Similarly, the addition of serum increased IL-6 concentrations but 
the addition of serum did not alter this response. Graphs show mean cytokine 
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Figure ‎4.6. Vitamin D3 does not influence IL-8 production after stimulation with 
TLR and RIG-I/MDA5 ligands in ocular barrier epithelial cells. HCEC-12 (n=2), 
ODM-2 (n=2), and AREP-19 (n=3 except RIG-I/MDA5 n=1) were grown to 80-89% 
confluence and were either unstimulated (control) or stimulated with TLR and RIG-
I/MDA5 ligands in the absence or presence of 25(OH)D3 (10
-7 M) for 24 h in serum free 
conditions. Supernatants were collected and cytokine IL-8 production was measured by 
ELISA. IL-8 was produced by HECEC-12 in response to Poly I:C and ARPE-19 in 
response to Poly I:C and RIG-1/MDA5 which was not affected by the addition of 
25(OH)D3. ODM-2 showed a constitutive production of IL-8 and that was not influenced 
by TLR or RIG-I/MDA5 ligands or the presence of 25(OH)D3. Graphs show mean±SD 
cytokine production compared to untreated control cells (HCEC-12 and ODM-2 n=2 and 
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Figure ‎4.7. Vitamin D3 does not influence IL-6 production after stimulation with 
TLR and RIG-I/MDA5 ligands in ocular barrier epithelial cells. HCEC-12 (n=2), 
ODM-2 (n=2), and AREP-19 (n=3 except RIG-I/MDA5 n=1) were grown to 80-89% 
confluence and were either unstimulated (control) or stimulated with TLR and RIG-
I/MDA5 ligands in the absence or presence of 25(OH)D3 (10
-7 M) for 24 h in serum free 
conditions. Supernatants were collected and cytokine IL-6 production was measured by 
ELISA. HCEC-12 cells constitutively produced IL-6 and this was slightly increased in 
response to Ply I:C. ODM-2 cells initially produced high amounts of IL-6 but these levels 
were not upregulated by TLR stimulation. ARPE-19 cells produced lower levels of IL-6 
and these levels were increased after treatment with Poly I:C. Treatment with 25(OH)D3 
did not influence IL-6 levels. Graphs show mean±SD cytokine production compared to 
untreated control cells (HCEC-12 and ODM-2 n=2 and ARPE-19 n=2 except RIG-
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4.2.3 Ocular barrier epithelial cells upregulate genes for HDPs in 
response to locally produced as well as exogenous 1,25(OH)2D3 
by real-time PCR 
To further determine the ability of ocular barrier cells to use downstream 
signalling of VDR to produce HDPs (CAMP [cathelicidin, LL-37], BD1-4), these cells 
were tested in the presence of 25(OH)D3 (10
-7 M) and 1,25(OH)2D3 (10
-8 M) at 1, 4, 8, 
16, and 24 h by real-time PCR.  
HCEC-12 showed a gradual increase in the expression of CAMP starting from 4 h 
reaching a peak at 8 h, then declined at 16 h and low at 24 h. Treatment with 
1,25(OH)2D3 induced moderately higher CAMP than 25(OH)D3 at 4 h. ODM-2 did not 
show any induction of CAMP at 1, 4, 8 h. There was no induction with 25(OH)D3 and a 
decrease (0.5 fold) with  1,25(OH)2D3 at 16 h and a 1.5 fold-change at 24 h. ARPE-19 
showed a slight increase with both 25(OH)D3 and 1,25(OH)2D3 at 1 and 4 h but 4-fold 
increase induction of CAMP with 25(OH)D3 at 8 h that declined at 16, and 24 h (Figure 
4.8). 
In HCEC-12 cells, BD-1 was induced by 1,25(OH)2D3 (2.5-fold change) at 4 h, 
while both 25(OH)D3 and 1,25(OH)2D3 caused about 3-fold increase in its expression at 
24 h. ODM-2 cells showed a 2-fold increase by 1,25(OH)2D3 at 1 h, but no change was 
noticed upon treatment with 25(OH)D3 at all time points. In contrast, at 4 h ARPE-19 
cells showed a 3-fold change and 4-fold change in response to 25(OH)D3 and 
1,25(OH)2D3 respectively. For all other time points, 25(OH)D3 and 1,25(OH)2D3 showed 
around 1.5 fold-change (Figure 4.9). 
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In HCEC-12 cells, BD-2 was increased by 7 fold at 8 h and decreased to 2 fold at 
1 h and 5 fold at 16 h in response to 25(OH)D3. At 16 and 24 h, levels declined to 2.5 
and 2 fold respectively. Upon treatment with 1,25(OH)2D3, BD-2 was increased 2.5 fold 
at 4 h and 10 fold at 8 h then decreased to 3 fold at 16 h. ODM-2 cells showed a 2-fold 
change in BD-2 at 4 h with both 25(OH)D3 and 1,25(OH)2D3, a decline at 8 h, followed 
by a 3-fold increase by 25(OH)D3 at 16 h and 1,25(OH)2D3 at 24 h. ARPE-19 showed a 
1.5 fold change at 4 h with both 25(OH)D3 and 1,25(OH)2D3. At 8 h, treatment with 
25(OH)D3 maintained a 1.5 fold change while it decreased with 1,25(OH)2D3. There was 
a noticeable 10-fold change and 4 fold-change at 16 h in response to 25(OH)D3 and 
1,25(OH)2D3 respectively then levels declined at 24 h with both treatments (Figure 4.10). 
HCEC-12 cells showed about 1.5-fold and 2-fold change in the expression of BD-
3 at 24 h in response to both 25(OH)D3 and 1,25(OH)2D3 respectively while there was no 
induction at other time points. ODM-2 showed a 1.5 fold change with 25(OH)D3  at 4 and 
8 h that declined at 16 and 24 h. BD-3 was upregulated in response to 1,25(OH)2D3 at 8 
and 24 h while there was no induction at 16 h. In ARPE-19 cells, BD-3 induction was the 
highest with 5 fold in response to 25(OH)D3 at 4 h that declined to 3 fold at 8 h. 
Treatment with 1,25(OH)2D3 caused a 3-fold increase at 4 h that declined to about 1.5 
fold  at 8, 16, and 24 h (Figure 4.11).  
BD-4 showed a 2-fold increase in HCEC-12 cells at 1 and 4 h by 1,25(OH)2D3 that 
decreased at 8 h then increased again to 3 fold at 16 h and 4 fold at 24 h. BD-4 was not 
induced in response to 25(OH)D3 at early time points but showed a 3 fold change at 24 h 
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in HCEC-12 cells . ODM-2 cells also showed a 1.5 fold induction at 8 h that increased to 
6 fold at 16 h with 25(OH)D3. Treatment with 1,25(OH)2D3 induced a 3 fold-change at 1 
and 4 h followed by a decline at 8 and 16 h, and up to 2.5-fold change at 24 h. In ARPE-
19 cells, BD-4 expressed a 5.5 fold-change with 25(OH)D3 and decreased to 3 fold-
change at 16 h and declined at 24 h. Treatment with 1,25(OH)2D3 induced a 3 fold-
change at 8 h, increased to 5 fold-change at 16 h and declined at 24 h (Figure 4.12). 
To conclude, ocular barrier epithelial cells showed a trend towards the 
upregulation of mRNA expression of hBD1-4 but more repeats are required to draw 
conclusive results. Raw data are shown in the appendix. 
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Figure ‎4.8. Vitamin D3 upregulates mRNA expression of cathelicidin antimicrobial 
peptide (CAMP) in ocular barrier epithelial cells. HCEC-12, ODM-2, and ARPE-19 
cells were grown to 80-90% confluence and they were either left untreated (control) or 
treated with 25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8 M) for 1, 4, 8, 16, and 24 h in serum 
free conditions. Total RNA was isolated and real-time PCR was used to measure 
relative fold change increase in treated samples compared to controls for CAMP. CAMP 
was only upregulated in HCEC-12 cells in response to both 25(OH)D3 and 1,25(OH)2D3 
at 4, 8, and 16 h. ODM-2 cells did not upregulate CAMP but ARPE-19 cells slightly 
upregulated CAMP with 25(OH)D3 at 8h. This upregulation was not statistically 
significant (for raw data please see appendix). Graphs show mean±SD (results of at 
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Figure ‎4.9. Vitamin D3 upregulates mRNA expression of human beta defensin-1 
(hBD-1) in ocular barrier epithelial cells. HCEC-12, ODM-2, and ARPE-19 cells were 
grown to 80-90% confluence and were either left untreated (control) or treated with 
25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8  M) for 1, 4, 8, 16, and 24 h in serum free media. 
Total RNA was isolated and real-time PCR was used to measure relative fold change 
increase in treated samples compared to controls for hBD-1. HECE-12 cells slightly 
upregulated hBD-1 with 25(OH)D3 at 4 h and with both 25(OH)D3 and 1,25(OH)2D3 at   
24 h. ODM-2 cells did not upregulate hBD-1 whiles ARPE-19 cells showed an 
upregulation with both 25(OH)D3 and 1,25(OH)2D3 at 4 h. This upregulation was not 
statistically significant (for raw data please see appendix). Graphs show mean±SD 
(results of at least 3 experiments are shown). Two-way ANOVA and Bonferroni’s post 
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Figure ‎4.10. Vitamin D3 upregulates mRNA expression of human beta defensin -2 
(hBD-2) in ocular barrier epithelial cells. HCEC-12, ODM-2, and ARPE-19 cells were 
grown to 80-90% confluence and were either left untreated (control) or treated with 
25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8 M) for 1, 4, 8, 16, and 24 h in serum free media. 
Total RNA was isolated and real-time PCR was used to measure relative fold change 
increase in treated samples compared to controls for hBD-2. HCEC-12 cells showed an 
upregulation of hBD-2 with both 25(OH)D3 and 1,25(OH)2D3 at 8 h and with 25(OH)D3 at 
a6 h. ODM-2 did not show an upregulation of hBD-2 but ARPE-19 cells upregulated 
hBD-2 with both 25(OH)D3 and 1,25(OH)2D3 at 16 h. This upregulation was not 
statistically significant (for raw data please see appendix). Graphs show mean±SD 
(results of at least 3 experiments are shown). Two-way ANOVA and Bonferroni’s post 
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Figure ‎4.11. Vitamin D3 upregulates mRNA expression of human beta defensin -3 
(hBD-3) in ocular barrier epithelial cells. HCEC-12, ODM-2, and ARPE-19 cells were 
grown to 80-90% confluence and were either left untreated (control) or treated with 
25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8  M) for 1, 4, 8, 16, and 24 h in serum free 
media. Total RNA was isolated and real-time PCR was used to measure relative fold 
change increase in treated samples compared to controls for hBD-3. HCEC-12 and 
ODM-2 cells did not upregualte hBD-3 while ARPE-19 cells showed an upregulation with 
25(OH)D3 at 4 and 8 h. This upregulation was not statistically significant (for raw data 
please see appendix). Graphs show mean±SD (results of at least 3 experiments are 
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Figure ‎4.12. Vitamin D3 upregulates mRNA expression of human beta defensin -4 
(hBD-4) in ocular barrier epithelial cells. HCEC-12, ODM-2, and ARPE-19 cells were 
grown to 80-90% confluence and were either left untreated (control) or treated with 
25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8  M) for 1, 4, 8, 16, and 24 h in serum free 
media. Total RNA was isolated and real-time PCR was used to measure relative fold 
change increase in treated samples compared to controls for hBD-4. HECE-12 and 
ODM-2 cells did not show any upregulation of hBD-4 while ARPE-19 cells showed an 
upregulation with 25(OH)D3 at 8 h and 1,25(OH)2D3 at 16 h. This upregulation was not 
statistically significant (for raw data please see appendix). Graphs show mean±SD 
(results of at least 3 experiments are shown). Two-way ANOVA and Bonferroni’s post 
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4.2.4 Ocular barrier cells do not increase HDP proteins in response to 
endogenous and exogenous 1,25(OH)2D3  by ELISA. 
To investigate whether ocular barrier cells can translate HDP mRNA into protein 
in response to 25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8 M), we measured HDPs in the 
culture supernatants after 24 h of treatment.  
HCEC-12 showed higher baseline production of BD-1 compared to ODM-2 and 
ARPE-19 cells but there was no significant difference between control cells or those 
treated with either 25(OH)D3 or 1,25(OH)2D3 in all cell types. Similar results were 
observed in M1 and M2 (Figures 4.13 and 4.16). HCEC-12 followed by ODM-2 produced 
higher amounts of BD-2 compared to ARPE-19 cells. Again there was no significant 
difference between control and treated cells in all cell types. M1 and M2 cells hardly 
produced any BD-2 (Figures 4.14 and 4.16). HCEC-12 and ODM-2 cells produced 
higher BD-4 than ARPE-19 cells. There was a slight increase in BD-4 in response to 
1,25(OH)2D3 in ODM-2 cells. Similar to BD-1 and 2, there was no significant difference 
between control and treated cells in all cell types (Figure 4.15). Macrophages seem to 
produce higher BD-4 than BD-1 and 2. There was a slight increase in BD-4 produced by 
M1 and M2 in response to 1,25(OH)2D3 (Figure 4.16).  
To conclude, there was a wide-range of protein expression between different 
experiments which is surprising for cell lines. However the data taken together shows 
that ocular barrier cells did not upregulate protein for HDPs in response to 25(OH)D3 or 
1,25(OH)2D3 respectively. 
HCEC-12 










































































































Figure ‎4.13. Ocular barrier epithelial cells do not upregulate human β definsin-1 
(hBD-1) protein in response to 25(OH)D3 or 1,25(OH)2D3. HECE-12, ODM-2, and 
ARPE-19 cells were grown to confluence and they were wither left untreated (control) or 
treated with 25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8  M) for 1, 4, 8, 16, and 24 h in serum 
free media. Supernatants were collected and ELISA was performed to measure the 
concentrations of hBD-1. Minimum amounts of hBD-1 were produced by ocular barrier 
epithelial cells and there was no difference in hBD-1 concentrations between control 
(untreated) cells or those treated with 25(OH)D3 or 1,25(OH)2D3. Graphs show 
mean±SD (each experiment was performed at least 3 times except HCEC-12 n=1). 
Kruskall-Wallis test with Dunn’s post test were performed. 
HCEC-12 ODM-2 
ARPE-19 











































































































Figure ‎4.14. Ocular barrier epithelial cells do not upregulate human β definsin-2 
(hBD-2) protein in response to 25(OH)D3 or 1,25(OH)2D3. HECE-12, ODM-2, and 
ARPE-19 cells were grown to confluence and they were wither left untreated (control) or 
treated with 25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8  M) for 1, 4, 8, 16, and 24 h in serum 
free media. Supernatants were collected and ELISA was performed to measure the 
concentrations of hBD-2. There was a constitutive protein expression of hBD-2 in 
HCEC-12, ODM-2, and ARPE-19 cells but this was not upregulated upon treatment with 
25(OH)D3 or 1,25(OH)2D3. Graphs show mean±SD (each experiment was performed at 







































































































Figure ‎4.15. Ocular barrier epithelial cells do not upregulate human β definsin-4 
(hBD-4) protein in response to 25(OH)D3 or 1,25(OH)2D3. HECE-12, ODM-2, and 
ARPE-19 cells were grown to confluence and they were wither left untreated (control) or 
treated with 25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8  M) for 1, 4, 8, 16, and 24 h in serum 
free media. Supernatants were collected and ELISA was performed to measure the 
concentrations of hBD-4. There was a constitutive protein expression of hBD-2 in 
HCEC-12, ODM-2, and ARPE-19 cells but this was not upregulated upon treatment with 
25(OH)D3 or 1,25(OH)2D3. Graphs show mean±SD (each experiment was performed at 




















































































































































































































Figure ‎4.16. Macrophages do not upregulate HDP proteins in response to 
25(OH)D3 or 1,25(OH)2D3. M1 and M2 were differentiated from CD14
+ monocytes. On 
day 6 they were wither left untreated or treated with 25(OH)D3 (10
-7 M) or 1,25(OH)2D3 
(10-8 M) for 24h in serum free media. Supernatants were collected and ELISA was 
performed to measure the concentrations of BD-1 (top panel), 2 (middle panel), and 4 
(bottom panel). M1 and M2 macrophages did not produce hBD1, 2, and 4 and these 
levels were not upregulated upon treatment with 25(OH)D3 or 1,25(OH)2D3. Graphs 
show mean±SD (Experiments with SD bars represents triplicates while the absence of 
SD indicates a single experiment). Kruskall-Wallis test with Dunn’s post test were 
performed. 
M1 M2 
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4.2.5 Proinflammatory cytokines did not induce HDP proteins in 
ocular barrier cells. 
In macrophages, IL-1β mediated the vitamin D3 induced upregulation of DEFB4 
(Liu et al., 2009b). Previous work in our lab has also shown the same results (Susarla et 
al. manuscript submitted). We tested the ability of IL-1β and TNF- to synergise with 
25(OH)D3 (10
-7 M) or 1,25(OH)2D3 (10
-8 M) to upregulate HDP proteins. As shown above, 
both ODM-2 and ARPE-19 cells did not produce high amounts of BD-1, 2, and 4 in their 
supernatants.  
Untreated HCEC-12 produced higher constitutive levels of BD-1 compared to 
ODM-2 and ARPE-19 cells. Treatment with IL-1β did not alter this production when 
added alone or with 25(OH)D3 or 1,25(OH)2D3 in all cell types. In contrast treatment 
TNF- doubled the concentration of BD-1 when added alone and in with 1,25(OH)2D3 
respectively and induced a slight increase when added with 25(OH)D3 in HCEC-12 cells. 
In ARPE-19 cells, TNF- showed a slight increase in BD-1 production alone or with  
25(OH)D3 respectively but no change with 1,25(OH)2D3. In ODM-2 cells, there was no 
change upon the addition of either IL-1β or TNF- alone or with 25(OH)D3 or 
1,25(OH)2D3 respectively (Figure 4.17).  
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ODM-2 and ARPE-19 produced a higher baseline production of BD-2 than 
HCEC-12 cells. BD-2 concentrations increased 2 and 3 fold upon treatment with IL-1β or 
TNF- alone in HCEC-12 cells. In the presence of 25(OH)D3, TNF- doubled the 
concentration of BD-2 while IL-1β did not show any change. Both cytokines did not alter 
BD-1 production in the presence of 1,25(OH)2D3 in HCEC-12 cells. When IL-1β or TNF-
 were added alone to ODM-2 and ARPE-19 cells, there was a slight decrease in the 
concentration of BD-2 compared to untreated cells. Both cytokines induced a slight 
decrease in BD-2 when added in the presence of 25(OH)D3 and a slight increase with 
IL-1β  and IL1,25(OH)2D3 respectively in ODM-2 cells (Figure 1.18).  
HCEC-12, ODM-2, and ARPE-19 cells produced similar levels of BD-4 and the 
treatment with IL-1β or TNF- in the presence or absence of 25(OH)D3 or 1,25(OH)2D3 
did not cause any change in BD-4 concentration (Figure 1.19).  
In conclusion, the results show only HCEC-12 upregulated BD-1 and 2 production 
in response to TNF- alone and BD-2 in response to IL-1β alone respectively. TNF- 
synergised with1,25(OH)2D3 to increase BD-1 levels and with 25(OH)D3 to upregulate 
BD-2. Due to the low number of repeats and the lack of statistical significance, more 
experiments are required to confirm these results. 














































































































Figure ‎4.17. IL-1β‎ and‎ TNF-α‎did not upregulate protein‎ production‎ of‎ human‎β‎
defensin-1 (hBD-1), in the presence of vitamin D3 in ocular barrier epithelial cells. 
HCEC-12, ODM-2, and ARPE-19 Cells were grown to confluence and were either 
treated with IL-1β (1 ng/ml) or TNF-α (5 ng/ml) in the presence or absence of 25(OH)D3 
(10-7 M) or 1,25(OH)2D3 (10
-8 M) for 24 h in serum free conditions. Supernatants were 
collected and hBD-1 concentrations were measured by ELISA. Treatment of ocular 
barrier epithelial cells with IL-1β or TNF-α did not alter hBD-1 production. Graphs show 



















































































































Figure ‎4.18. IL-1β‎ and‎ TNF-α‎did not upregulate protein‎ production‎ of‎ human‎β‎
defensin-2 (hBD-2), in the presence of vitamin D3 in ocular barrier epithelial cells. 
HCEC-12, ODM-2, and ARPE-19 Cells were grown to confluence and were either 
treated with IL-1β (1 ng/ml) or TNF-α (5 ng/ml) in the presence or absence of 25(OH)D3 
(10-7 M) or 1,25(OH)2D3 (10
-8 M) for 24 h in serum free conditions. Treatment of ocular 
barrier epithelial cells with IL-1β or TNF-α did not alter hBD-2 production. Supernatants 
were collected and hBD-2, was measured by ELISA. Graphs show mean±SD (HCEC-12 


















































































































Figure ‎4.19. IL-1β‎ and‎ TNF-α‎did not upregulate protein‎ production‎ of‎ human‎β‎
defensin-4 (hBD-4), in the presence of vitamin D3 in ocular barrier epithelial cells. 
HCEC-12, ODM-2, and ARPE-19 Cells were grown to confluence and were either 
treated with IL-1β (1 ng/ml) or TNF-α (5 ng/ml) in the presence or absence of 25(OH)D3 
(10-7 M) or 1,25(OH)2D3 (10
-8 M) for 24 h in serum free conditions. Treatment of ocular 
barrier epithelial cells with IL-1β or TNF-α did not alter hBD-4 production.Supernatants 
were collected and hBD-4, was measured by ELISA. Graphs show mean±SD (HCEC-12 










This study shows that ocular barrier cells can signal through VDR to upregulate 
the downstream vitamin D3 elements genes. It also shows that like exogenous 
1,25(OH)2D3, local activation of vitamin D3 by ocular barrier cells showed a trend 
towards the induction of mRNA of HDPs but not proteins at the time point tested. IL-1β 
and TNF- did not significantly upregulate hBD-1, 2 and 4 ocular barrier epithelial cells 
tested in the presence of vitamin D3. TLR signalling does not seem to synergise with 
vitamin D3 in the induction of proinflammatory cytokines.  
Extra-renal expression of vitamin D3 elements has been described in many 
epithelial cells such as primary respiratory epithelial cells, urinary bladder intestinal, 
mammary, endometrium, and prostate epithelial cell lines and skin keratinocytes (Chen 
and Holick, 2003;Hansdottir et al., 2008;Hertting et al., 2010;Kemmis and Welsh, 
2008;Kong et al., 2008). In the kidneys, synthesis of 1,25(OH)2D3 is tightly regulated by 
serum levels of calcium, phosphorous, and fibroblasts growth factor-23 (FGF-23). 
Additionally, 1,25(OH)2D3 provides its own negative feedback by decreasing the 
secretion of parathyroid hormone (PTH) from parathyroid gland (Holick, 2007).  
In contrast, extra-renal 1,25(OH)2D3 synthesis is regulated by inflammatory 
cytokines such as IFN- and IL-15 and through the induction of CYP24A1 (Adams and 
Hewison, 2012). In epithelial cells such keratinocytes, mammary, prostate and 
respiratory epithelial cells, CYP24A1 was only induced after local conversion of 
25(OH)D3 into 1,25(OH)2D3 or stimulation with 1,25(OH)2D3 (Flanagan et al., 
2006;Hansdottir et al., 2008;Welsh, 2011;Xie et al., 2002) . Ocular barrier epithelial cells 
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are no different from these cells where they appear to constitutively express CYP24A1 
which was upregulated in response to local synthesis of 1,25(OH)2D3.  
A growing body of evidence in literature has confirmed the importance of extra-
renal vitamin D3 system for host protection mainly through the induction of HDPs. In 
macrophages, skin, gingival, placenta, and respiratory epithelial cells, vitamin D3 acted 
with TLR to induce protective mechanisms (Hansdottir et al., 2008;Liu et al., 2009a;Liu 
et al., 2006;McMahon et al., 2011;Schauber et al., 2007). We know that ocular cells from 
the cornea to the retina express a range of PRR including TLR1-10 (Brito et al., 
2004;Chang et al., 2006;Kumar and Yu, 2006;Kumar et al., 2004;Ueta and Kinoshita, 
2010). RIG-I and MDA5 have been detected in human conjunctival epithelial and RPE 
cells (Ueta et al., 2010;Ueta et al., 2011;Wornle et al., 2011).  
Our results confirm the expression of TLR1-10, RIG-I, and MDA5 in ocular barrier 
cells and that these receptors are functional upon stimulation. We approached this by 
the measurement of IL-8 and IL-6 which are produced in response to TLR stimulation in 
the eye (Cook et al., 2005;Jin et al., 2010;Kumagai et al., 2005;Ueta et al., 2005). 
Human corneal endothelial cell line increased the production of IL-6 after stimulation of 
TLR9 (Takeda et al., 2011). Primary human non-pigmented ciliary body epithelial cells 
produced IL-6 in response to LPS (25 ng) (Brito et al., 2004).  
We could show that HCEC-12 and ARPE-19 cells produced the highest levels of 
IL-8 and IL-6 in response to Poly I:C. In contrast, ODM-2 cells did not upregulate IL-8 or 
IL-6 after treatment with TLR ligands including LPS. ARPE-19 cells produced high 
amounts of IL-6 in response to LPS (1ug) (Paimela et al., 2007). We could not replicate 
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these results with LPS as we used very low concentrations of LPS to try and simulate 
what can happen in real life.  ARPE-19 cells were the only cells that produced high 
amounts of IL-8 and slightly increased IL-6 in response to RIG-I/MDA5. This has been 
seen before in ARPE-19 cells that showed a similar increase in IL-8 and IL-6 expression 
after treatment with Poly I:C that can bind both TLR3 and RIG-I  (Wornle et al., 2011). 
We previously showed that TLR stimulation increased IL-8 and IL-6 but this was not 
influenced by vitamin D3 in primary human corneal epithelial cells (PHCEC) and corneal 
fibroblasts (HKF) (Susarla et al. manuscript submitted). Although some TLR are 
expressed strongly in ocular barrier cells, we could not detect any synergy between TLR 
signalling and vitamin D3 in the production of proinflammatory cytokines.  
Ocular barrier cells very poorly express TLR2 which is predominantly expressed 
in high levels in CD14+ monocytes (Flo et al., 2001;Foster et al., 2007). This may be part 
of vitamin D3 role as an immunomodulatory hormone to suppress destructive 
inflammatory responses to the eye. In PBMC, 1,25(OH)2D3 suppressed the expression 
of TLR2 and TLR4 and reduced their induction of IL-6 without reducing their ability to 
induce HDPs (Khoo et al., 2011a). Although one study showed that stimulation of TLR2 
in human corneal epithelial cell line increased the production of IL-8 and IL-6 (Kumar et 
al., 2006), another earlier study showed TLR2 and TLR4 expression was suppressed 
and stimulation with the corresponding ligands did not increase IL-8 or IL-6 production 
(Ueta et al., 2004).  
HDPs are essential players of innate immunity that imply protective and 
immunomodulatory properties to affected tissues. TLR2 stimulation induced mRNA and 
protein of hBD-2 in human corneal epithelial cell line (Kumar et al., 2006).  TLR3, 5,and 
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6/2 stimulation increased mRNA and protein expression of hBD-2 while TLR3 induced 
LL-37 in primary human corneal epithelial cells (Redfern et al., 2011). Furthermore pre-
exposure of human corneal epithelial cell line to TLR5 ligand impaired the signalling 
pathway downstream of TLR5 stimulation in a dose dependent manner. It reduced IL-8 
secretion but supported mRNA expression and secretion of hBD-2 and LL-37 (Kumar et 
al., 2007).  
Based on work from monocytes, TLR synergised with vitamin D3 in the induction 
of HDPs. Similar interaction was found in respiratory epithelial cells, colonic epithelial 
cell lines, and skin keratinocytes (Hansdottir et al., 2008;Lagishetty et al., 
2010;Schauber et al., 2007). We have shown previously that 1,25(OH)2D3 could induce 
HDPs in PHCEC. 1,25(OH)2D3 induced cathelicidin mRNA alone and in synergy with 
TLR3 and TLR4. It also induced hBD-1 and hBD-2 alone and in synergy with TLR3 and 
TLR3 and TLR4 respectively (Susarla et al. manuscript submitted). In this study, local 
synthesis of vitamin D3 was as good as exogenous supplementation in the induction of 
HDPs. This did not require TLR activation. This is in concordance with results from 
trophoblasts, gingival, sinonasal, bronchial, and urinary balder epithelial cells (Hertting et 
al., 2010;Liu et al., 2009a;McMahon et al., 2011;Schrumpf et al., 2012;Sultan et al., 
2013) where vitamin D3 alone can induce HDPs. Even in the skin, where vitamin D3 
synergised with TLR2/1, vitamin D3 could induce HDPs without TLR activation (Peric et 
al., 2010).  
In inflammatory conditions, cytokines such as IL-13 and IL-17 were found to 
enhance vitamin D3 mediated induction of HDPs such as hBD-2 and LL-37 in skin 
keratinocytes and bronchial epithelial cells (Peric et al., 2008;Schrumpf et al., 2012). 
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Conflicting data have been shown in TLR2/1 induced vitamin D3 dependent DEFB4 and 
LL-37 in monocytes. These responses were augmented by IFN- and IL-4 while IL-17 
had no effect (Edfeldt et al., 2010). In macrophages, it was previously shown that 
expression of DEFB4 required IL-1β (Liu et al., 2009b). HBD-1 is constitutively 
expressed in primary human ciliary body epithelium and ODM-2 while hBD-2 was 
induced by IL-1 β in ODM-2 and RPE cell line (Haynes et al., 2000). In ODM-2 and 
ARPE-19 cells we did not see a significant difference in the production of hBDs when we 
added IL-1β and TNF- alone or together with 25(OH)D3 and 1,25(OH)2D3.  
The discrepancy in my results between mRNA upregulation and serum 
concentrations could be due to the short half-life of hBD peptides (Yount et al., 1999) 
which means that earlier time points should be examined. It may also indicate that these 
cells produce HDPs constitutively as part of homeostatic function and they do not 
increase upon stimulation. Although more experiments are required, we can see that IL-
1β and TNF- could show some synergy with vitamin D3 to upregulate hBD-1 and 2 
protein production in HCEC-12 cells which may indicate the importance of vitamin D3 
during inflammation in these barrier cells at the back of the cornea. Cathelicidin has a 
longer half-life of 3.4 days (Bals et al., 1999), but we did not measure serum 
concentration in the current study. The mRNA expression of cathelicidin in HCEC-12 at 
8 h were equal to or higher than those shown in respiratory, urinary bladder, gingival 
epithelial cells at 24h (Hansdottir et al., 2008;Hertting et al., 2010;McMahon et al., 
2011). Human BD-2 and 3 were induced by 1,25(OH)2D3 in primary human keratinocytes 
to levels similar to ocular barrier epithelial cells but the expression was boosted by the 
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simultaneous stimulation of the pathogen recognition receptor NOD2/CARD15 (Wang et 
al., 2010).  
The eye is constantly exposed to sunlight. It has been shown in rabbits cornea 
exposed to UVB light could locally covert inactive to active vitamin D3 in the presence of 
7DHC. Vitamin D3 metabolites were also detected in tears, AqH, and vitreous (Lin et al., 
2012;Yin et al., 2011). In the Netherlands, vitamin D3 effects were influenced by 
seasonal variations. Treatment of PBMCs with 1,25(OH)2D3 in vitro, caused a reduction 
of IL-6 and TNF- induced by TLR2 and TLR4 stimulation. When tested in the summer, 
PBMCs showed a pronounced decrease in IL-β, TNF-, IFN-, IL-6, and IL10 after TLR4 
stimulation while moderate effects were seen for TLR2. Apparently high vitamin D3 
levels in the summer decreased TLR2 and TLR 4 expression and consequently their 
downstream effects upon stimulation (Khoo et al., 2011b). Vitamin D3 interestingly, in 
hypoxic conditions upregulated hBD-2 in macrophages (Nickel et al., 2012). Hypoxic 
conditions are created by the immune system in response to inflammation to allow a 
microenvironment that can resolve the infection and protect local tissue damage 
(Olender et al., 2003). 
In conclusion, although we could not detect an upregulation of HDPs with vitamin 
D3 at the protein level, the ability of the eye to locally utilise vitamin D3 provided the 
availability of circulating 25(OH)D3 or even 7DHC and to translate that into the 
expression of HDPs may indicate the important role of vitamin D3 in the eye. The 
constitutive expression of CYP24A1 indicates a tight regulation of this hormone to allow 
activation just long enough to mediate the required tasks before degradation. With all 
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the anti-inflammatory properties and the induction of antimicrobial responses, vitamin D3 
may be involved in the immune surveillance and homeostasis in the eye. 
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5 VDR POLYMORPHISM IN INTERMEDIATE UVEITIS 
5.1 Introduction 
Uveitis is a wide range of intraocular inflammatory conditions that accounts for  
about 5-20% of blindness in Western countries and 25% in the developing world (de 
Smet et al., 2011). Uveitis is classified anatomically by the Standardisation of Uveitis 
Nomenclature (SUN) uveitis according to the primary site of inflammation (Jabs et al., 
2005). Anterior uveitis involves the anterior chamber, while in IU the vitreous is affected. 
Posterior uveitis is the inflammation of the retina or choroid and panuveitis involves the 
anterior chamber, vitreous, retina, and choroid. (Chapter 1 Figure 1.11) 
IU can affect young and middle age adults which can create an economical and 
social burden. Patients present with blurry vision, floaters and distorted central vision. IU 
can occur without a known cause and is known as iodiopathic or pars planitis referring to 
snowbanks (white exudates) on pars plana in the ciliary body. IU can be associated with 
a systemic inflammatory diseases such as multiple sclerosis (MS), sarcoidosis, or 
infectious conditions like human T lymphotropic virus Type 1 (HTLV-1) and Lyme 
disease (Babu and Rathinam, 2010;Bonfioli et al., 2005;de Smet et al., 2011). In uveitis, 
IL-12, IFN-, TNF-α, and IL-17 are associated with pathogenesis while IL-4 and IL-10 
are found to be protective (Atan et al., 2010;Horai and Caspi, 2011). 
IU has been linked to HLA-DRB1*15 (Du et al., 2009;Wallace and Niemczyk, 
2011). HLA-DRB1*15 is also associated with MS (Gourraud et al., 2012;Zivkovic et al., 
2009) and this association has recently been suggested  to be female specific, but this 
will require validation in other disease cohorts (Irizar et al., 2012). Database analysis of 
                  Chapter  5    VDR polymorphism in intermediate uveitis                             145 
 
French patients with MS showed that 0.65% had uveitis. In 46% of patients uveitis 
preceded onset of MS, in 18% it was diagnosed simultaneously and 36% after the onset 
of MS (Le Scanff et al., 2008).  
MS is an inflammatory disease that affects the central nervous system (CNS) and 
many environmental and genetic factors are believed to be involved (Koch et al., 2013). 
Uveitis is not regarded as gender specific but studies from different countries have 
shown a slight increase in females with male to female ratios 1:1.8 in Italy, 1:1.1 in 
Tunisia, 1.04:1 in Turkey, and 1.2:1 in India (Kazokoglu et al., 2008;Khairallah et al., 
2006;Modorati et al., 2004;Parchand et al., 2011). Among MS-associated uveitis, a 
study in Caucasians have shown that women were mostly affected with a male to female 
ration 1:2.1 (Le Scanff et al., 2008).  
SNPs in different regions of VDR have been linked with autoimmune diseases. As 
explained in chapter 1, FokI (rs2228570) is known as a start codon polymorphism where 
ATG is changed to ACG and this leads to a different VDR protein size. In the 3’ 
untranslated region (3’UTR), polymorphisms identified were BsmI (rs1544410), ApaI 
(rs7975232), and TaqI (rs731236). This is a regulatory region involved in mRNA stability 
and expression (Fernandes de Abreu et al., 2010;Uitterlinden et al., 2004a;Uitterlinden 
et al., 2004b;Valdivielso and Fernandez, 2006). Cdx2 and A1012G polymorphisms were 
identified in the 5’ promoter region. Cdx2 (G to A) polymorphisms affects intestinal 
calcium absorption and body mass density (Arai et al., 2001) while A1012G regulates 
the expression of GATA3, a transcription factor for the polarisation of T helper 1 (Th1) 
cells (Halsall et al., 2004).  
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As mentioned in Chapter 1, low serum 25(OH)D3 levels were associated with an 
increase in BD (Karray et al., 2012). This was associated with decreased Treg and 
predominating Th1 responses indicating an immunomodulatory role of vitamin D3 in the 
eye (Hamzaoui et al., 2010). VDR SNP FokI was associated with BD in a group of 
Tunisian patients (Karray et al., 2012;Morrison et al., 2011). FokI is a start codon SNP 
that affects the size of vitamin D protein and has been shown to modulate mRNA 
expression of NFAT, IL-12, and regulates pancreatic function (Mory et al., 2009;van 
Etten et al., 2007). BsmI is in the 3’UTR (regulatory region) that influences mRNA 
stability and expression (Arai et al., 2001;Rukin and Strange, 2007;Uitterlinden et al., 
2002). BsmI-CT genotype coincided with the presence of higher numbers of IL-12 
producing CD14+ cells in T2DM (Al-Daghri et al., 2012). T cells from T1DM patients 
homozygous for BsmI minor allele (TT) produced higher IFN- than other genotypes 
(Shimada et al., 2008). A1012G a promoter region SNP that has been linked to the 
expression of GATA3 and the differentiation of T helper 1 (Th1) cells (Halsall et al., 
2004).  
In this project we studied VDR SNPs FokI (rs2228570), BsmI (rs1544410), and 
A1012G (rs4516035) for association with IU in a cohort of patients with idiopathic IU. 
These SNPs have been chosen based on their functional relevance to the expression 
and production of vitamin D and effects on the immune response. Controls were disease 
free and were matched to patients according to ethnicity but not any other criteria. 
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5.2 Results 
5.2.1 Endpoint genotyping 
To study VDR SNPs, endpoint genotyping assay was performed. The assay allows 
an amplification of DNA followed by endpoint genotyping analysis that separates the 
different genotypes in clusters according to the fluorescent probe in an X-Y plot. 
Homozygous individuals cluster towards Y or X axis while heterozygotes cluster in the 
middle for SNPs FokI (rs2228570) (Figure 5.1), BsmI (rs1544410) (Figure 5.2), A1012G 














Figure ‎5.1. Endpoint genotyping allele distribution of VDR SNP FokI (rs2228570) in 
IU patients vs. healthy controls. The plots show the frequency of FokI (rs2228570) 
alleles A and G. Each dot represents one sample. Individual samples clustered towards 
the Y-axis are homozygous for A allele (green), X-axis are homozygous for G allele 
(blue), and in the middle are heterozygous for AG alleles (red). Gray dots are negative 
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Figure ‎5.2. Endpoint genotyping allele distribution of VDR SNP BsmI (rs1544410) 
in IU patients vs. healthy controls. The plots show the frequency of BsmI (rs1544410) 
alleles C and T. Each dot represents one sample. Individual samples clustered towards 
the Y-axis are homozygous for C allele (green), X-axis are homozygous for T allele 
(blue), and in the middle are heterozygous for CT alleles (red). Gray dots are negative 
control while Pink dots represent undetected samples by the assay.  
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Figure ‎5.3. Endpoint genotyping allele distribution of VDR SNP A1012G 
(rs4516035) in IU patients vs. healthy controls. The plots show the frequency of 
A1012G (rs4516035) alleles C and T. Each dot represents one sample. Individual 
samples clustered towards the Y-axis are homozygous for C allele (green), X-axis are 
homozygous for T allele (blue), and in the middle are heterozygous for CT  alleles (red). 
Gray dots are negative controls. 
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5.2.2 VDR genotype and allele frequencies 
The results in Table 5.1 show allele and genotype frequency in patients with IU 
compared to HC. VDR BsmI (rs1544410) is significantly different between patients with 
IU and HC. Allele rs1544410-T and genotype rs1544410-CT were significantly 
associated with IU (OR 1.56 95% CI 1.06-2.32, p=0.0325 and OR 1.88 95% CI 1.08-
3.27, p=0.0332 respectively). Conversely, VDR rs1544410-CC genotype was more 
frequent in healthy controls than IU patients (OR 0.44 95% CI 0.25- 0.78, p=0.007). 
There was no significant difference found in VDR FokI (rs2228570) and A1012G 
(rs4516035). The minor allele in FokI (rs2228570) is the A allele, (BsmI (rs1544410) is 
the T allele, and in A1012G (rs4516035) is the C allele. 
5.2.3 Gender difference between VDR genotypes and alleles 
To determine if there are differences between females and males in VDR SNPs, we 
compared between genotypes and alleles in IU patients and healthy controls (Table 
5.2). FokI (rs2228570) showed no differences between females and males in IU. In 
contrast, among healthy controls, genotype rs2228570-AG was significantly more 
frequent in males (OR 0.24 95% CI (0.01-0.60), p=0.0034) whereas genotype 
rs2228570-GG was significantly more frequent in females (OR 2.82 95% CI (1.09-7.27), 
p=0.0493). Although BsmI (rs1544410) was significantly associated with IU, there was 
no gender difference in both groups. Similarly, there was no difference between females 
and males in both groups in A1012G (rs4516035). 
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Table ‎5.1 VDR SNP BsmI (rs1544410) is associated with Intermediate uveitis (IU) in 
Caucasians. VDR SNPs FokI (rs2228570), BsmI (rs1544410), and A1012G 
(rs4516035) were analysed using real-time PCR and endpoint genotyping in a study 
population of Caucasians (only matched for ethnicity but no other criteria). Table shows 
genotype and allele frequency in IU patients vs. healthy controls (HC).  
SNPs 
Allele/Genotype 
IU  HC OR (95% CI) p value 
FokI (rs2228570) N=158 N=92   
A 112 (35.4) 73 (39.7) 0.83 (0.57-1.21)  
G 204 (64.5) 111 (60.3) 1.19 (0.82-1.74) 0.395 
AA 24 (15.1) 17 (18.5) 0.791 (0.39-1.56) 0.617 
AG 64 (40.2) 39 (42.4) 0.92 (0.55-1.6) 0.873 
GG 70 (22.0) 36 (39.1) 1.24 (0.73-2.1) 0.506 
BsmI (rs1544410) N=139 N=85   
C 150 (53.9) 110 (64.7) 0.64 (0.43-0.95)  
T 128 (46.0) 60 (35.3) 1.56 (1.06-2.32) 0.0325* 
CC 38 (27.3) 39 (45.8) 0.44 (0.25- 0.78) 0.007 ** 
CT 74 (53.2) 32 (37.65) 1.88 (1.08-3.27) 0.033* 
TT 27 (19.4) 14 (16.47) 1.22 (0.600-2.49) 0.706 
A1012G (rs4516035) N=140 N=86   
C 105 (37.5) 63 (36.62) 1.04 (0.70-1.54)  
T 175 (62.5) 109 (63.37) 0.96 (0.65-1.43) 0.9314 
CC 21 (15) 14 (16.28) 0.91 (0.43-1.89) 0.945 
CT 63 (45) 35 (40.70) 1.19 (0.69-2.05) 0.620 
TT 56 (40) 37 (43.02) 0.88 (0.51-1.52) 0.757 
Analysis was done using 2x2 tables and Chi-squared test with Yate’s correction: * 




Table ‎5.2 VDR SNP BsmI (rs1544410) shows no difference in between males and females in Caucasian IU patients and 
healthy controls (HC). VDR SNPs FokI (rs2228570), BsmI (rs1544410), and A1012G (rs4516035) were analysed using real-
time PCR and endpoint genotyping in a study population of Caucasians (only matched for ethnicity but no other criteria). Table 















                    
Analysis was done using 2x2 tables and Chi-squared test with Yate’s correction: * p<0.05 and ** p<0.01. 
SNPs Allele/Genotype IU  OR (95% CI) p value HC OR (95% CI) p value 
FokI (rs2228570) F (N=84 ) M (N=53 )   F (N=55 ) M (N=30 )   
A 65 (36.9) 42 (32.8) 1.18 (0.73-1.91)  44 (37.3) 29 (43.9) 0.76 (0.41-1.40)  
G 111 (63.1) 86 (67.2) 0.85 (0.52-1.37) 0.578 74 (62.7) 37 (56.1) 1.32 (0.71-2.43) 0.4670 
AA 15 (17.0) 8 (12.5) 1.44 (0.57-3.63) 0.587 13 (22.0) 4 (12.1) 2.05 (0.61-6.89) 0.371 
AG 35 (39.7) 26 (40.6) 0.96 (0.50-1.86) 0.9508 18 (30.5) 21 (63.6) 0.24 (0.01-0.60) 0.0034** 
GG 38 (43.2) 30 (46.8) 0.86 (0.45-1.65) 0.774 28 (47.5) 8 (24.2) 2.82 (1.09-7.27) 0.0493* 
BsmI (rs1544410) F (N=83 ) M (N=52 )   F (N=55) M (N=37 )   
C 88 (53.0) 58 (55.7) 0.89 (0.55-1.46)  73 (66.3) 44 (59.4) 1.34 (0.73-2.47)  
T 78 (47.0) 46 (44.2) 1.12 (0.68-1.83) 0.7513 37 (33.6) 30 (40.) 0.74 (0.40-1.37) 0.4248 
CC 23 (27.7) 14 (0.26) 1.04 (0.47-2.27) 0.9216 25 (45.4) 14 (37.8) 1.37 (0.58-3.20) 0.6102 
CT 42 (50.6) 30 (57.7) 0.75 (0.37-1.51) 0.5311 23 (41.8) 16 (43.2) 0.94 (0.41-2.19) 0.9366 
TT 18 (21.7) 8 (15.4) 1.52 (0.61-3.81) 0.4969 7 (12.7) 7 (18.9) 1.60 (0.51- 5.02) 0.6067 
A1012G (rs4516035) F (N=63 ) M (N=73 )   F (N=54) M (N=32 )   
C 54 (42.8) 50 (34.2) 1.44 ( 0.88-2.35)  36 (57.1) 27 (42.80 0.68 ( 0.36-1.29)  
T 72 (57.1) 96 (65.7) 0.69 ( 0.42-1.14) 0.1828 72 (66.1) 37 (33.9) 1.46 ( 0.77-2.76) 0.3167 
CC 10 (15.9) 11 (15.1) 1.06 ( 0.42-2.70) 0.9136 8 (14.8) 8 (18.8) 0.75 ( 0.24-2.41) 0.8606 
CT 34 (53.9) 28 (38.4) 1.88 ( 0.95-3.73) 0.0989 20 (37.0) 15 (46.8) 0.66 ( 0.27-1.62) 0.5025 
TT 19 (30.2) 34 (46.5) 0.49 ( 0.24-1.00) 0.0749 26 (48.1) 11 (34.4) 1.77 ( 0.72-4.38) 0.3069 
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5.3 Discussion 
Results in this chapter showed an association between BsmI (rs1544410) and IU 
in a cohort of Caucasians. Allele rs1544410-C and genotype rs1544410-CT were 
significantly increased in patients with IU compared to healthy controls. Conversely, the 
rs1544410-CC genotype was more frequent in healthy controls. There was no difference 
in genotype and allele frequency between females and males in BsmI (rs1544410).  
Extra-renal expression of vitamin D3 identified a wide range of immunomodulatory 
functions of this hormone in many organs. In the eye, we and others have shown that 
many ocular cells express vitamin D3 pathway components (Lin et al., 2012;Yin et al., 
2011) and can locally convert inactive vitamin D3 to its active form (Alsalem et al. this 
thesis and manuscript submitted). IU has been linked with MS through HLA-DRB1*15, a 
molecule that is regulated by vitamin D3 (Ramagopalan et al., 2009).  
FokI (rs2228570) and A1012G (rs4516035) did not show any difference between 
patients with IU and healthy control group in this thesis although FokI (rs2228570)-AG 
and FokI (rs2228570)-GG were significantly more frequent in healthy males and females 
respectively. BsmI is located in intron 8 in the regulatory region of VDR and it may affect 
mRNA stability (Uitterlinden et al., 2002). SNPs in this region might not have an effect 
individually but may do as a haplotype with the closely linked SNPs.  
Studies on haplotype constructs from 3’UTR of VDR in human osteoblast cell line 
MG63 showed that minor alleles of BsmI-ApaI-TaqI (CCT) haplotype, which is more 
common in Caucasians, resulted in a 30% faster decay of VDR protein and may result in 
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lower protein level of VDR available in the cells (Fang et al., 2005;Grundberg et al., 
2007). The same haplotype was associated with asthma and atopy in a familial cohort in 
Canada (Poon et al., 2004). 
In PBMCs from a study group in India, CCT haplotype was associated with 
decreased IL-12p40 and IFN- in response to challenge with complete Freund's 
adjuvant, and 1,25(OH)2D3 in vitro and increased IL-10 levels in response to live Mtb and 
1,25(OH)2D3 in the control group (Selvaraj et al., 2008). SNPs in VDR have been linked 
to susceptibility to both T1DM and T2DM in different populations. In a recent meta-
analysis on papers up to November 2011, there is a significant association between 
BsmI (especially in East Asia) and increased risk to T1DM whereas BsmI (only in East 
Asia) and FokI (especially in East Asia) was significantly associated with T2DM (Wang 
et al., 2012).  
In concordance with our results, BsmI (rs1544410)-CT genotype was associated 
with T2DM in Saudi patients, BsmI-CT genotype was associated with the presence of 
higher numbers of IL-12 producing CD14+ cells (Al-Daghri et al., 2012). T cells from 
T2DM patients with genotype BsmI-TT produced higher IFN- than other genotypes 
(Shimada et al., 2008).  
Inflammation in uveitis in mouse models is driven by Th1 cells leading to the 
production of IFN- (Horai and Caspi, 2011). This association may indicate a role of 
VDR polymorphism in the pathogenesis of human uveitis by upregulating inflammatory 
Th1 response. In contrast to our results, BsmI was not associated with BD uveitis in 
Tunisian patients, but FokI was significantly associated (Karray et al., 2012) and this 
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could be due to the fact that VDR polymorphisms vary with ethnic background . We 
could not detect any difference in FokI and A1012G between controls and patients with 
IU in our patients. FokI polymorphism has been found to influence VDR mRNA copy 
numbers and may regulate CYP27B1 expression to increase active vitamin D3 
production in deficient patients (Ogunkolade et al., 2002). The A allele of A1012G 
increases the expression of GATA3 and directs the polarisation of Th0 cells to Th2 
phenotype and it was protective against the inflammatory skin disease psoriasis (Halsall 
et al., 2004).  
Although vitamin D3 levels have been strongly linked to MS, VDR polymorphisms 
studies showed no association between SNPs in VDR or other vitamin D3 related genes 
such as metabolic enzymes CYP27B1 and CYP2R1, catabolic enzyme CYP24A1, or 
vitamin D3 binding protein (DBP) with the aetiology of the disease (Huang and Xie, 
2012;Irizar et al., 2012;Simon et al., 2010). Nevertheless, the coexistence of TaqI and 
HLA-DRB1*15 correlated with protection against MS, and only a rare variant of 
CYP27B1 was associated with MS (Agliardi et al., 2011;Ramagopalan et al., 2011). It 
would be worth while investigating the expression of HLA-DRB1*15 in our cohort and try 
to explain its role with VDR SNPs in the protection against and progression to MS.  
Other VDR SNPs and vitamin D3 related genes polymorphisms may have a role 
in eye diseases. Polymorphism (G allele at rs4752) in DBP increased risk for uveitis in 
with ankylosing spondylitis in Korean patients (Jung et al., 2011). Another association 
between SNPs in IL-2 receptor alpha (IL-2RA) and IL-7 receptor alpha (IL-7RA) and risk 
of MS (Weber et al., 2008). A SNP in IL-2RA has recently been reported to be 
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associated with IU (Lindner et al., 2011). Several SNPs in CYP24A1 SNPs were 
associated with neovascular AMD while VDR, CY27A1, and CYP27B1 were not 
associated (Morrison et al., 2011). In IU, the inflammation extends to ciliary body and 
peripheral retina (Babu and Rathinam, 2010). We have shown that non-pigmented 
ciliary body cells can locally convert 25(OH)D3 into active 1,25(OH)2D3 (Alsalem et al. 
manuscript submitted). BsmI polymorphisms may affect local production of 1,25(OH)2D3 
and increase the risk of developing a stronger Th1 response that can worsen the 
pathogenesis by the production of IL-12 and IFN-.  
In conclusion, we have shown that VDR BsmI is associated with IU but there was 
difference among alleles and genotypes between males and females. FokI and A1012G 
did not show any association with disease. Following the genetic basis that link uveitis to 
MS would help get a deeper insight into the pathogenesis and outcome of IU. BsmI 
might have a function in IU alone or in conjunction with closely linked SNPs in VDR or 
vitamin D3 related genes. 
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6 GENERAL DISCUSSION 
 In this thesis, results have shown (i) that human ocular barrier epithelial cells 
express the molecular components capable of local conversion of inactive 25(OH)D3 into 
active 1,25(OH)2D3; (ii) local vitamin D3 synthesis upregulated mRNA expression of 
HDPs but did not synergise with TLR to induce proinflammatory cytokines; and (iii) a 
significant association between VDR SNP BsmI (rs1544410) and genotype rs1544410-
CT was significantly increased in Caucasian patients with intermediate uveitis compared 
to healthy controls (Figure 6.1) 
 
Figure ‎6.1. A model for the role of 1,25(OH)2D3 in ocular barrier epithelial cells. 
Local synthesis of 1,25(OH)2D3 (from 25(OH)D3 or potentially 7DHC) by ocular barrier 
epithelial cells controls the production of HDPs during homeostasis to keep a state of 
immune surveillance. During inflammation, local 1,25(OH)2D3 controls the production of 
HDPs and cytokine production by infiltrating macrophages. Infiltrating macrophages also 
contribute to local 1,25(OH)2D3 synthesis and provide a positive feedback to the 
process. 
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6.1 Extra-renal vitamin D3 synthesis by ocular barrier epithelial cells 
Consistent with many human epithelial cells, ocular barrier epithelial cells express 
all the genes for the molecules and enzymes required for the uptake and local synthesis 
of vitamin D3. The activity of these genes is reflected by the ability of these cells to take 
up 25(OH)D3 and convert it into 1,25(OH)2D3, whereas the constitutive expression of 
CYP24A1 suggests a controlled negative feedback mechanism to regulate the levels of 
1,25(OH)2D3 produced. As stated earlier, there was a conversion gradient with HCEC-12 
cells having the highest rates followed by ODM-2 and ARPE-19. 
Corneal endothelium is at the front of the eye and from these data, we can see 
that endogenous 1,25(OH)2D3 production decreases as we go from the front to the back 
of the eye. We are not sure if this is related to the amount of UV light available for these 
cells. It could also be related to the role of corneal endothelium as an important barrier 
between AqH and corneal stroma followed by ciliary body in BAB and that constitutive 
1,25(OH)2D3 production may be required for their protective functions in the eye from 
front to back.  
The localisation of VDR and CYP24A1 was similar between ocular barrier 
epithelial cells, but CYP27B1 had a different expression pattern in HCEC-12 indicative 
of its localisation to the TGN. We still have no explanation for this pattern and as we 
mentioned in Chapter 3, that this enzyme may follow a different trafficking pathway 
inside these cells. Human breast cancer epithelial cells T-47D internalised Alexa-DBP in 
the peri-nuclear which colocalised with lysosomes which suggested that DBP traffics 
through endosomes and lysosomes (Rowling et al., 2006). This may indicate that due to 
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the presence of CYP27B1 in TGN in HCEC-12, these cells can readily and efficiently 
convert 25(OH)D3 delivered by DBP in endocytic vesicles.  
The expression of CYP27B1 was detected in untreated cells and it may be helpful 
to compare it to the expression in cells treated with 25(OH)D3 or 1,25(OH)2D3 or even to 
add labelled 25(OH)D3 and follow its fate inside the cell. Extra-renal vitamin D3 may be 
essential as ocular barrier epithelial cells and many others express CYP2R1 needed for 
the conversion of vitamin D3 from the circulation into 25(OH)D3. A more immediate 
source of 1,25(OH)2D3 is needed to resolve infection or inflammation to maintain optical 
clarity or homeostatic conditions independent of the liver and kidneys.  
The main function of 1,25(OH)2D3 is to support bone growth and health, and 
extra-renal synthesis of 1,25(OH)2D3 may also contribute to increase the concentrations 
of 1,25(OH)2D3 required for bone health. Serum 1,25(OH)2D3 concentrations range from 
50 to 150 pmol/L (Lips, 2007), however 1,25(OH)2D3 in culture supernatants from ocular 
barrier epithelial cells does not reflect in vivo levels of vitamin D3.  
To overcome this limitation, we measured 1,25(OH)2D3 in AqH from normal 
healthy individuals. The levels that we obtained (1.9-4.8 pmol/L) were much lower than 
in serum and cell culture supernatants. When 1,25(OH)2D3 was measured in synovial 
fluids, the levels were not very different from those in serum (50-100 pmol/L) (Inaba et 
al., 1997). In the cerebrospinal fluid (CSF) of normal people, levels above 50 pmol/L of 
1,25(OH)2D3 were detected (Balabanova et al., 1984). The levels of 1,25(OH)2D3 found 
in pleural fluid from Mtb patients were 100% higher than serum levels (Barnes et al., 
1989). It would be interesting to investigate uveitic AqH to identify whether similar 
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increases in vitamin D3 are seen in the eye in the context of intraocular inflammation, or 
tear film in ocular surface disease. This variation between the amounts of 1,25(OH)2D3 in 
the eye and other biological fluids may be a result of the difference in organ size and 
volume, turnover of these fluids, and the very limited amount of protein allowed into AqH 
(Freddo, 2001), as the other tissues are not protected by tissue barriers. 
Unlike monocytes/macrophages and epithelial cells, fibroblasts, are unable to 
convert inactive 25(OH)D3 into active 1,25(OH)2D3 although they express vitamin D3 
metabolic and catabolic enzymes. We have previously shown that primary human 
scleral fibroblasts express CYP27B1 but did not convert 25(OH)D3 into 1,25(OH)2D3 
(Susarla et al. manuscript submitted). Similarly, dermal fibroblasts express CYP2R1 but 
not CYP27B1 and can produce 25(OH)D3 upon UVB irradiation but not 1,25(OH)2D3 
(Vantieghem et al., 2006). Primary synovial fibroblasts also failed to endogenously 
synthesise 1,25(OH)2D3 in vitro. Synovial fibroblasts are thought to regulate synovial 
levels of 1,25(OH)2D3 with their CYP24A1 activity (Hayes et al., 1992;Smith et al., 1999).  
In contrast, primary human gingival fibroblasts express CYP2R1, CYP27A1, and 
CYP27B1 and can locally synthesise both 25(OH)D3 and 1,25(OH)2D3 upon treatment 
with vitamin D3 and 25(OH)D3 (Liu et al., 2012b;Liu et al., 2012c). With the exception of 
gingival fibroblasts, it seems that epithelial cells, which act as the first line of defence as 
barriers in different sites in the body, are designed with the ability to produce 
1,25(OH)2D3 that contributes to their protective function against pathogens. This includes 
epithelial cells in the lung, colon, skin, gingival, breast, placenta, and cornea (Bikle et al., 
2004;Halhali et al., 1999;Hansdottir et al., 2010;Kong et al., 2008;Markov et al., 
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2012;McMahon et al., 2011;Yin et al., 2011). At least in primary mouse mammary 
epithelium, mouse intestinal epithelium in vivo, Caco-2 cell line, and primary rabbit 
corneal epithelial cells, vitamin D3 promotes barrier function by upregulating TJ proteins 
and barrier formation (Bikle et al., 2004;Kong et al., 2008;Markov et al., 2012;Yin et al., 
2011). 
6.2 The immunomodulatory role of locally synthesised 1,25(OH)2D3 in 
ocular barrier epithelial cells 
The ability of ocular barrier epithelial cells to convert 25(OH)D3 into the active 
metabolite, 1,25(OH)2D3, prompted us to ask if locally synthesised 1,25(OH)2D3 has any 
immunomodulatory role in these cells. We first tested the ability of the cells to upregulate 
vitamin D3 genes (VDR, CYP27B1, and CYP24A1) in response to local conversion of 
25(OH)D3 or to 1,25(OH)2D3. Local 25(OH)D3 conversion was as efficient in upregulating 
downstream signalling of VDR activation as direct delivery of 1,25(OH)2D3. In line with 
the conversion rates, HCEC-12 cells showed the highest fold change increases in 
vitamin D3 genes followed by ODM-2 then ARPE-19. 
In this project, and due to the difficulties of obtaining and growing primary cells, 
well-established representative cell lines of ocular barrier epithelial cells were used. The 
use of cultured cells does not allow a full understanding of the mechanisms used by 
vitamin D3 in the eye tissue and does not give information on the interaction between 
different cell types in the context of local 1,25(OH)2D3 synthesis. However, these cell 
lines do provide a means of addressing biological pathways that would not be possible 
with primary cells. A second way to address this point is to use animal models. VDR KO 
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mice are available commercially and are used to understand the importance of vitamin 
D3 for different functions, but they have their own limitations.  
In humans, vitamin D3 is mainly synthesised in the skin through the conversion of 
7DHC by UVB exposure. Mice are nocturnal animals that live without sunlight exposure 
and their skin is covered with fur. To survive, mice need very small amounts of vitamin 
D3, which they may have evolved to obtain from diet (particularly chow diet in laboratory 
conditions) (Holick, 2008;McCann and Ames, 2008). As stated in Chapter 4, mouse 
CRAMP is not regulated by vitamin D3 (Dorschner et al., 2001). Homologues of hBDs 
have been identified in mouse models (mouse BD: mBD) and they contribute to 
protection and corneal barrier function in mice bacterial keratitis (corneal infection) 
caused by Pseudomonas aeruginosa (P. aeruginosa) in vivo and in vitro (Augustin et al., 
2011;Doss et al., 2010;Wu et al., 2009). It is still unclear if mBD production in mice is 
vitamin D3-dependent (Liu et al., 2009b). However, VDR KO mice develop many health 
and growth problems that mimic those in humans and are still used to understand 
human disease (Bouillon et al., 2008). 
VDR KO mice were smaller in size, developed alopecia, had wrinkled skin, and 
showed growth arrest when they were compared to wild type. As they grew older, they 
expressed lower levels of aging-related molecules including NF-B, FGF-23, insulin like 
growth factor-I (IGFI), IGFI-receptor (IGFIR), p53, and Klotho. These molecules are 
required for the immune system, tumour suppression, and determining life span. The 
decreased expression was only seen in old, but not young, mice suggesting the role of 
VDR absence in inducing premature aging (Keisala et al., 2009).  
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The relationship between vitamin D and aging is complex. FGF-23 is induced by 
25(OH)D3  but in turn inhibits renal phosphate reabsorption and 1,25(OH)2D3 synthesis, 
and induces CYP24A1 production. FGF-23 knock-out mice show a shortened lifespan, 
arteriosclerosis, and obstructive pulmonary disease. Therefore while FGF-23 production 
is almost entirely dependent on 25(OH)D3, it’s function as a longevity gene is based on 
control of 1,25(OH)2D3 (Haussler et al., 2010). VDR KO mice were found to develop 
hypocalcaemia, hyperparathyroidism, and reduced intestinal calcium absorption. 
Interestingly, VDR KO mice produced more serum 1,25(OH)2D3, expressed higher renal 
CYP27B1 mRNA, and showed reduced CYP24A1 mRNA expression compared to 
VDR+/- mice and Tg mice with VDR expression limited to the intestine. VDR KO mice 
showed skeletal abnormalities with shorter femurs and low bone mass density (Xue and 
Fleet, 2009). Although VDR KO mice have normal myelopoiesis, they develop several 
defects in the immune system including reduced T cell proliferation, reduced Th1 
cytokines, mature DC phenotype, and decreased T cell homing to inflammatory sites 
(Bouillon et al., 2008). To date, ocular disease in VDR KO mice has not been 
investigated. 
It is well established that although the eye has a unique structure and immune 
regulation, innate immune system in the eye plays an important function in immune 
surveillance and defence against ocular infections (Lambiase et al., 2011). We could 
show that TLR signalling is functional in ocular barrier epithelial cells, but there was no 
synergy between vitamin D3 and TLR activation to affect the proinflammatory cytokines 
IL-6 and IL-8. In respiratory epithelial cells, the synergy was between vitamin D3 and 
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TLR3, rather than TLR2, as in monocytes, to induce cathelicidin (Hansdottir et al., 2008). 
In ocular barrier epithelial cells we observed that the highest cytokine production was in 
response to TLR3 and RIG-I/MDA5 activation. As mentioned above, IL-6 and IL-8 are 
induced through MyD88 signalling and activation of NF-B (Yang and Seki, 2012). When 
respiratory epithelial cells were infected with human respiratory syncytial virus (RSV) 
which interacts with TLR3 or RIG-I/MDA5 in vitro, exogenous 1,25(OH)2D3 inhibited NF-
B signalling and reduced IFN-β and interferon-γ-inducible protein 10 (IP-10, CXCL10), 
a chemokine produced in response to viral infections that attracts Th1 and NK cells. The 
inhibition of NF-B and the reduction in IFN-β did not allow viral replication to increase, 
which indicates that 1,25(OH)2D3 reduces inflammation but maintains an antiviral 
response.  
The induction of HDPs, which are important for innate immunity, by 1,25(OH)2D3 
or by local conversion may also contribute to viral infection resolution (Hansdottir et al., 
2010;Spurrell et al., 2005). When a human keratinocyte cell line was infected with 
varicella zoster virus (VZV) and exposed to exogenous LL-37 or hBD-2, viral load was 
reduced. Moreover, pretreatment of the virus with LL-37 or hBD-2 before infecting the 
cells resulted in further reduction in viral load. This shows that HDPs have a direct effect 
on the virus (Crack et al., 2012). VDR KO mice showed increased in vivo NF-B 
expression and NF-B translocation to the nucleus in colonic epithelial cells after 
infection with Salmonella typhimurium (S. typhimurium) (Wu et al., 2010).  
NF-B is a key molecule in eye infections induced by TLR signalling in bacterial 
and viral (Herpes simplex-1: HSV-1) keratitis, for the modulation of immune response 
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(Lan et al., 2012). The fact that local 1,25(OH)2D3 synthesis by ocular barrier cells did 
not affect IL-6 and IL-8 production in the current thesis after TLR stimulation may explain 
that the level of 1,25(OH)2D3 induced is inhibitory for inflammatory signals, but permits a 
certain degree of inflammation to resolve infection. 
Although not statistically significant, we can see that local synthesis of 
1,25(OH)2D3 induces the expression HDPs in all ocular barrier epithelial cells used in 
this study. The mRNA expression levels of HDPs were higher in HCEC-12 and ARPE-19 
cells than in ODM-2 cells. This may support their role in corneal endothelium and RPE 
as barriers at the front and back of the eye. Haynes et al. detected hBD-1 in human AqH 
and vitreous samples in small concentrations (<16 ng/ml) but could not detect hBD-2 
(Haynes et al., 2000).  
It has been observed in humans that hBDs and LL-37 are sensitive to salt 
concentrations that might render them ineffective in ocular fluids with a high salt content, 
such as tears. They can be present in small concentrations but synergistic with each 
other to overcome the effect of salt. This could be an advantage to the eye as high 
concentrations can be toxic to ocular cells (Huang et al., 2007;McDermott, 2009). The 
ability of endogenous 1,25(OH)2D3 to induce HDPs may be beneficial to the eye where 
there is microbial clearance without inducing local damage by inflammation, thereby 
maintaining visual clarity.  
As mentioned in Chapter 1, HDPs are not only antimicrobial but have 
immunomodulatory functions. For example, human PBMCs stimulated with IFN- and 
LPS in the presence of LL-37, produced lower levels of TNF-α and IL-12 proteins even 
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at low concentrations of LL-37 which could resemble physiological conditions. Similar 
results were seen with lipoteichoic acid (TLR2 ligand), but not with Pam3Csk4 (synthetic 
TLR2/1 ligand), as there was a reduction of IL-6 production after stimulation of an 
intracellular PRR NOD2 (nucleotide-binding oligomerisation domain-containing protein 
2) with its ligand muramyl dipeptide (MDP). LL-37 downregulated the expression of 
CD80, CD86, and MHC II on monocytes and DCs after treatment with IFN- and LPS 
and reduced the expression of TNF-α and IL-12 (Nijnik et al., 2009). A similar reduction 
of proinflammatory cytokine transcription and production was observed when mouse BM 
derived monocytes and DCs were treated with LPS in the presence of hBD-3. The 
inhibitory effects of hBD-3 were mediated through the inhibition of MyD88 and TRIFF 
signalling (Semple et al., 2011).  
6.3 Association of VDR SNPs with IU 
In this thesis, we have shown an association between BsmI and IU in Caucasians 
but there was no difference between males and females in this association. Although in 
this project, ocular barrier epithelial cells, in particular the corneal endothelium and 
ciliary body, are able to efficiently synthesise local vitamin D3, the eye still gets diseases 
such as uveitis. In addition, with supplementation there was a reduction in retinal 
inflammation and accumulation of Aβ associated with aging, indicating that locally 
synthesised vitamin D3 does not prevent the effects of aging or is not produced in 
sufficient levels to prevent aging (Lee et al., 2012). Vitamin D3 played a protective 
immunomodulatory role in BD (Tian et al., 2012), but these results are only from in vitro 
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investigations; they do not accurately depict what happens inside the body in eye 
inflammation in relation to vitamin D3 levels or supplementation.  
Vitamin D3 metabolism is influenced by many genes including those in the 
metabolic pathways, DBP, and cubilin and megalin. A systematic review of the different 
SNPs in relation to the levels of 25(OH)D3 showed that the minor allele T of FokI was 
associated with higher concentrations of 25(OH)D3. Only one SNP in CYP27B1 and one 
in DBP were associated with 25(OH)D3 levels. Other SNPs in CYP24A1, CYP27A1, and 
CYP2R1 did not shown any association with 25(OH)D3 (McGrath et al., 2010).  
A genome wide study has shown a significant association between 25(OH)D3 and 
several genes involved in, or near genes involved in the vitamin D3 pathway. A positive 
association was found with a SNP in NADSYN1, a gene encoding nicotinamide adenine 
dinucleotide (NAD) synthetase was in high LD with one SNP in the skin precursor 
7DHC. Another association was found with a SNP in chromosome 10 near 
ACADSB (acyl-coenzyme A dehydrogenase), an enzyme involved in the synthesis of 
cholesterol and vitamin D3, in addition to a SNP in CYP2R1 (Ahn et al., 2010). Although 
one SNP in cubilin was more frequent among T1DB patients, it was not associated with 
circulating 25(OH)D3 or 1,25(OH)2D3 (Ramos-Lopez et al., 2010).  
A very recent study in European women investigating carotenoids in age-
related eye disease showed that two SNPs in DBP and four SNPs in CYP2R1 were 
associated with serum 25(OH)D3 levels in women taking supplementation of >400 
international units (IU)/day. There was an association only in the blood drawn in the 
summer but not in the winter (Engelman et al., 2013). 1,25(OH)2D3 interacts with so 
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many other genes which may have their own polymorphisms and the influence of these 
SNPs on vitamin D3 activity will have wide ranging implications well beyond the 
mechanism identified in the current study. These complex interactions will require future 
systems biology approaches to define outcome.  
Based on the availability of 25(OH)D3, ocular barrier epithelial cells can 
constitutively convert it into 1,25(OH)2D3. This may indicate an important role for 
1,25(OH)2D3 in maintaining homeostatic conditions in the eye. More than 120 gene 
polymorphisms have been detected in DBP. There are three major known alleles, 
named after their Gc-globulin (group-specific component or Gc) electrophoretic 
migration; Gc1f (fast), Gc1s (slow), and Gc2. Gc1 phenotype binds with higher affinity to 
vitamin D3 metabolites than Gc2. Gc1f is more frequent in black Africans and black 
Americans while Gc2 is markedly high in Caucasians (Gomme and Bertolini, 
2004;Speeckaert et al., 2006). Liu et al. detected low serum levels of 25(OH)D3 in 
African-Americans compared to Caucasians. When monocytes were activated with 
TLR2/1L in the presence of sera from African-Americans, cathelicidin mRNA expression 
was lower than in cells treated with sera from Caucasians (Liu et al., 2006).  
The role of DBP in vitamin D function is another area of complexity. Murine 
studies have shown that DBP null-mice have very reduced levels of serum 1,25(OH)2D3 
(less than 1%), but calcium levels were completely normal. Kidney tissue expressed 
double the mRNA of CYP27B1 compared to wild-type mice, but CYP24A1 was reduced. 
Although 1,25(OH)2D3 was significantly reduced, tissue accumulation and activation of 
1,25(OH)2D3 was not affected by the loss of DBP in null-mice compared to wild type. 
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These results suggest that DBP is not essential for the delivery of 1,25(OH)2D3 to certain 
target cells and it can be replaced by low-affinity binding proteins such as albumin (Zella 
et al., 2008).  
When human monocytes were treated with exogenous 25(OH)D3 or 1,25(OH)2D3 
in the presence of serum from DBP-/- mice there was an increase in the expression of 
cathelicidin and CYP24A1. This expression was reduced with serum from DBP+/- mice. 
When 25(OH)D3 or 1,25(OH)2D3 were added in serum free medium in the presence of 
albumin, cathelicidin and CYP24A1 were efficiently induced. Under the same conditions, 
the addition of as low as 0.1 µM of exogenous DBP significantly reduced the expression 
of cathelicidin and CYP24A1. Although monocytes lacked the expression of megalin, 
they were able to internalise DBP, but to a low level compared to control cells 
expressing megalin and cubilin. This study has also shown that when monocytes were 
treated with 25(OH)D3 in the presence of 5% serum from donors with six combinations of 
DBP major alleles; Gc1F, Gc1S, and Gc2, cells were more sensitive to 25(OH)D3 and 
induced higher expression of cathelicidin and CYP24A1 when Gc1f was absent. As 
genetic variants of DBP determine how much of 25(OH)D3 or 1,25(OH)2D3 is available 
for cellular uptake, the authors suggest to determine DBP genotype for individuals in 
addition to circulating 25(OH)D3 measurement (Chun et al., 2010). 
Similar findings were reported by Jeffery et al. where the addition of DBP to DCs 
co-cultured with T cells, inhibited the uptake of 25(OH)D3 by DCs and suppressed the 
antiinflammatory effects seen previously on CD4+CD25- T cells. The inhibitory effects of 
DBP were more pronounced in 25(OH)D3 than 1,25(OH)2D3 (Jeffery et al., 2012). 
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 Unlike monocytes and DCs, human mammary epithelial cells express cubilin and 
megalin coreceptors. Human immortalised mammary epithelial (HME) cells were able to 
upregulate CYP24A1 in response to 25(OH)D3 or 1,25(OH)2D3 in the presence or 
absence of DBP. They were able to internalise DBP by endocytosis and the 
internalisation was inhibited with the use of a megalin inhibitor. The breast cancer 
epithelial MCF-7 cell line expresses megalin but lacks the expression of cubilin. Despite 
the presence of CYP27B1 in these cells, they failed to induce CYP24A1 in response to 
exogenous 25(OH)D3 or 1,25(OH)2D3 (Rowling et al., 2006).  
Another molecule at the cytoplasmic tail of megalin, the mitogen-responsive 
phosphoprotein disabled-2 (Dab2) is believed to be essential for the endocytosis of 
cubilin and megalin. It has been identified in human primary tubular epithelial cells 
(PTEC) and in the breast cancer epithelial T-47D cell line after it was induced to 
differentiate (Chlon et al., 2008;Gallagher et al., 2004). In this context, ocular barrier 
epithelial cells expressed cubilin mainly, as megalin was expressed but very poorly, 
indicating that they are capable of internalising DBP-bound 25(OH)D3 shown by their 
efficiency, at least in HCEC-12 and ODM-2, to uptake and metabolise 25(OH)D3. The 
contribution of cubilin and megalin in DBP-25(OH)D3 internalisation by ocular barrier 
epithelial cells is worthy of further investigation, taking into consideration the lack of 
evidence on the presence of DBP in AqH or eye tissue.  
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6.4 Vitamin D3 in context of inflammation  
Vitamin D3 synthesis is known to be a major advantage of exposure to sunlight 
but several studies have suggested a protective role of UV light independent of vitamin 
D3. Pretreatment of a murine model with UV rays (UVR) did not prevent the onset of 
experimental autoimmune encephalomyelitis (EAE) induced by subcutaneous injection 
with myelin oligodendrocyte glycoprotein (MOG) peptide 33-35 (MOG33-35). This 
pretreatment caused a slight increase in circulating serum 25(OH)D3. By comparison, 
when UVR treatment was continuous before and after immunisation with MOG, there 
was a significant suppression in EAE clinical score and disease severity. There was a 
significant increase in 25(OH)D3, but it was only transient and did not keep increasing 
with continuous UVR exposure. Treatment of the animals with increasing doses of 
25(OH)D3 up to levels causing hypercalcaemia, failed to suppress EAE which suggests 
a protective role of UVR independent of 25(OH)D3 (Becklund et al., 2010).  
UVR exposure correlated inversely with risk of developing MS in a Swedish study 
population and positively with serum 25(OH)D3 levels. About 47% of the cases were 
included in the study within 2 years, and 64% within 4 years of MS onset. Taking the 
HLA-DRB1*15 genotype into account, there was no association between UVR exposure 
and HLA-DRB1*15 nor between HLA-DRB1*15 and 25(OH)D3 deficiency with risk of 
developing MS at study inclusion (Baarnhielm et al., 2012).  
Murine studies have shown that in addition to interacting with 7DHC in the skin, 
exposure to UVR interacts with other molecules in the skin such as DNA, lipids and 
resident APCs to induce immunosuppression. DCs with damaged DNA can migrate to 
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draining lymph nodes and induce CD4+CD25+Foxp3+ Tregs (Hart et al., 2011). In a 
murine study, male mice from vitamin D3 deficient mothers kept on a vitamin D3 deficient 
diet had significantly lower serum 25(OH)D3 than their female littermates. Vitamin D3 
deficient male mice have low levels of the vitamin D3 precursor 7DHC in their skin, and 
their kidneys expressed higher levels of CYP27B1 and CYP24A1 mRNA than females.  
To study the effect of vitamin D3 induced by UVR on serum 25(OH)D3 and 
immune response, these mice were exposed to different doses of UVR. Of the vitamin 
D3 deficient group, female mice showed an increase in serum 25(OH)D3 compared to 
males, although the levels remained <25 nmol/L. Dietary supplementation of vitamin D3 
increased serum 25(OH)D3 in both male and female mice, but male mice still showed 
levels lower than females, similar to levels in vitamin D3 sufficient male mice. UVR only 
increased skin production of 1,25(OH)2D3 in female, but not male mice in the vitamin D3 
deplete group. There was no difference between males and females in UVR’s local and 
systemic immunosuppressive effects upon sensitisation with 2,4-dinitrofluorobenzene 
(DNFB) in the ear lobes. DCs from UVR irradiated vitamin D3 deficient male and female 
mice were isolated and expanded in vitro. When injected subcutaneously with DNFB in 
the ears of naïve mice, they failed to induce a Th1/17 inflammatory response. 
Furthermore, UVR irradiation suppressed allergic reactions in both male and female 
vitamin D3 deficient mice shown by reduced eosinophil numbers and IL-15 in their 
bronchoalveolar lavage after inhaling ovalbumin (OVA) for three days. If vitamin D3 
protects from autoimmune diseases, the previous study does not explain why females 
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have more tendencies to autoimmune diseases although they make higher serum 
25(OH)D3 in response to UVR (Gorman et al., 2012).  
In sunny countries, such as Saudi Arabia, one would expect women with scarves 
and veils to be more vitamin D3 deficient than men who do not need to cover. One study 
in the east of Saudi showed a high prevalence of vitamin D3 deficiency in Saudi 
participants, however there was no difference between men and women although 
according to the questionnaire >65% and >90% had adequate sunlight exposure and 
dietary intake respectively (Elsammak et al., 2011). Another study from Jeddah on the 
west coast of Saudi reported 87.8% deficiency in Saudi men, in particular among obese 
and older participants with no education (Ardawi et al., 2012). Education can help 
increase their awareness of the importance of sunlight exposure and vitamin D3 dietary 
intake.  
However, a study in Jordan has found low circulating 25(OH)D3 levels among 
women covering all the body only showing the face and hands (54.8% in summer and 
77.6% in winter) and in those that cover all the body including the face and hands 
(83.3% in summer and 81.8% in winter) compared to ladies with a western dress style 
(30.8% in summer and 75% in winter). The differences between the three groups in 
25(OH)D3 were not statistically significant, but the two groups of covered women were 
significantly lower than men as low vitamin D3 is found in 18% and 45.5.% of Jordanian 
men in summer and winter respectively (Mishal, 2001). The tendency of people to spend 
most of their time indoors to avoid the heat, and to watch TV and play video games in 
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addition to air pollution caused by industry are all factors that contribute to widespread 
vitamin D3 insufficiency and deficiency (Mead, 2008).  
Based on the results and data presented in this thesis there is a clear case for 
vitamin D3 supplementation. Vitamin D3 is cheap, easily available, and is safe to use, 
except at very high levels, but there is big debate on how much is enough for an 
individual and whether it would really help. Vitamin D3 is also made in the skin and this 
complicates the decision on the doses of supplementation. The new report from the 
Institute of Medicine (IOM) recommends 600 IU/day for ages less than 70 years and 800 
IU/day for ages older than 70 (Ross et al., 2011). Osteoporosis Canada has also 
published new guidelines that recommend 400-1000 IU/day for adults below the age of 
50 and 800-2000 IU/day for those above 50 years old (Hanley et al., 2010). In a 
systematic review published recently that included papers through the period from 1973 
to 2011, in pathophysiological studies, it was found that vitamin D3 deficiency in 
genetically susceptible people can cause the loss of regulatory functions of DCs over 
Th1 responses.  
Cross-sectional studies have shown that serum 25(OH)D3 levels <30 ng/ml were 
found in both patients with autoimmune disease as well as healthy patients. Meta-
analysis of case-control studies revealed that vitamin D3 supplementation caused a 
significant reduction in the risk of developing T1DM. Interestingly, supplementation 
between the ages of 7-12 months reduced the chances of developing T1DM more than 
that between 0-6 months. This was explained by the fact that the adaptive immune 
system develops during that period of 7-12 months (Antico et al., 2012).  
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Month of birth has been linked to the risk of developing immune mediated 
diseases such MS, T1DM, Crohn’s disease, ulcerative colitis, and SLE where people 
born in the spring between April and October had more risk which correlated inversely 
with serum 25(OH)D3 during the second trimester of pregnancy (Disanto et al., 
2012;Kahn et al., 2009;Saastamoinen et al., 2012). In line with these data, we observed 
in patients with idiopathic IU, the highest incidence was among those born in the spring 
(Thomas et al. manuscript submitted).  
Mice born to mothers kept vitamin D3 deficient before and during pregnancy had 
less severe EAE after immunisation with MOG compared to control group. This was 
accompanied by an upregulation of VDR and heat shock proteins (involved in VDR 
mediated action in EAE) in the spinal cord up to day 30 after immunisation. Moreover, 
offspring fed postnatally on a vitamin D3 rich diet had a delayed and less severe EAE. 
This supports the concept that the in utero vitamin D3 environment has conditioned the 
foetus to be more sensitive to vitamin D3 ex utero. Surprisingly, the second generation of 
these mice had more severe symptoms and the symptoms were similar whether the 
mother or the father was vitamin D3 deficient. The study concluded that the mother 
imprints the foetus, and vitamin D3 status during pregnancy determines the child’s risk 
for developing an autoimmune disease (Fernandes de Abreu et al., 2010). However, De 
Luca and Plum have shown, using a different murine strain, that EAE was delayed and 
less severe in two generations of mice exposed to prolonged vitamin D3 deficiency 
(Deluca and Plum, 2011). 
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 It was observed that if people migrate before the age of 15 from an area with a 
high risk to an area with a low risk of MS, they acquire low susceptibility to MS but if they 
migrate from a low risk area to a high risk area, they maintain the low risk of their origin 
(O'Gorman et al., 2012). In contrast, a study on immigrants from the UK and Ireland to 
Australia showed no effect of age on the prevalence of MS suggesting other 
environmental factors that play a role before and after the age of 15 (Hammond et al., 
2000).  
Another study has shown that when people from the French West Indies (known 
as low MS prevalence) migrated to France and returned to the West Indies, there was a 
high prevalence among those who migrated to France before the age of 15. 
Unexpectedly, there was an increase in the prevalence of MS among non-immigrants in 
the West Indies and the authors suggest that immigrants may have acquired some 
environmental factors that act before the age of 15 and determine the susceptibility to 
MS (Cabre et al., 2005). Both studies suggest the involvement of genetic and 
environmental factors in determining the risk for developing MS. Taken together, we can 
see there is no clear evidence between vitamin D3 sufficiency/deficiency or location and 
autoimmune diseases. The genetic makeup, vitamin D3 status of the mother during 
pregnancy, environmental factors, and timing of immune system programming appear to 
all be involved in how individuals respond to vitamin D3 and how it can affect them. 
6.5 Summary and future studies 
In summary, results in this thesis have provided evidence for a complete and 
functional exra-renal vitamin D3 system in human ocular barrier epithelial cells capable 
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of locally converting vitamin D3 from its inactive to active form. We have also shown that 
local vitamin D3 production by these cells can induce the expression of mRNA for the 
HDPs cathelicidin and hBD1-4. Furthermore, we found an association between the VDR 
SNP BsmI and IU in Caucasians, which supports an immunomodulatory role of vitamin 
D3 in autoimmune disease in the human eye. Overall, our results suggest the potential of 
vitamin D3 to contribute to immune regulation in the eye during homeostatic as well as 
inflammatory conditions. Vitamin D3 might serve as a safe and cheap therapeutic agent 
to treat or even protect against the onset of an immune mediated inflammatory eye 
disease.  
Based on my results we can suggest that future studies should: 
1. Investigate vitamin D3 metabolism in corneal endothelial cells (primary and cell 
line) as they express a different staining pattern of CYP27B1 and they seem to be 
the most efficient in local conversion. 
2. Study the effect of vitamin D3 supplementation on HDP production in ocular fluids 
and their functional activities.  
3. Identify conditions for protein production of HDPs by ocular barrier epithelial cells 
to see if it matches mRNA expression 
4. To test other genetic variants in VDR and related genes to provide an insight of 
the functional relevance of these variants to vitamin D3 metabolism and 
association with eye diseases, such as uveitis, and disease outcome. Taking into 
consideration gender differences, these studies can be used to understand 
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differences between males and females in vitamin D3 metabolism and the 
modulation of immune response. 
5. To explore using animal models, how vitamin D3 can affect EAU both in males 
and females and how to correlate that to human uveitis. 
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8 APPENDIX  
Chapter 4 
Figure 4.8 

























1 2.14 0.03 0.004 1.49 0.03 0.06 
4 0.76 6.71 0.16 2.21 16.78 0.17 
8 2.05 25.667 1.340 1.784 29.90 1.02 
16 0.45 8.582 5.683 0.919 13.228 4.24 




1 0.41 0.46 1.40 1.01 0.59 0.99 
4 0.60 0.31 2.07 0.85 1.33 0.22 
8 0.96 0.86 1.09 0.89 0.58 1.64 
16 1.79 0.37 0.90 0.63 0.41 0.39 
24 0.16 0.81 2.83 1.41 0.77 2.36 
Time (h) 25D 1,25D 
1 2.24 0.42 0.28 5.19 3.29 0.27 0.26 0.24 
4 1.45 1.64   0.53 2.73   
8 2.15 1.17 2.07 13.53 1.89 0.47 1.13 0.65 
16 0.75 0.73 0.36 0.28  2.69 0.16 0.00 
24 0.86 0.22 0.68 0.001 1.003 0.36 1.46 0.98 
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Figure 4.9 

















Time (h) 25D 1,25D 
1 0.30 1.22 0.48 0.48 0.25 0.55 
4 1.06 0.63 1.44 1.18 1.54 4.96 
8 0.76 1.81 0.42 0.49 0.63 0.63 
16 0.67 0.30 1.91 1.52 0.57 1.33 
24 0.88 4.09 3.48 2.07 1.56 4.46 
Time (h) 25D 1,25D 
1 1.81 0.87 1.29 3.74 0.60 1.51 
4 2.22 0.79 0.94 0.91 0.48 0.70 
8 1.57 0.59 0.69 1.28 0.77 0.95 
16 2.23 0.78 0.59 2.24 0.88 0.69 
24 0.65 0.17 2.52 1.02 0.09 3.31 
Time (h) 25D 1,25D 
1 1.17 1.16 1.76 1.08 0.17 0.59 
4 0.96 4.92  1.28 6.07  
8 2.07 0.32 2.01 0.74 0.19 4.73 
16 0.55 2.08 2.72 0.65  2.29 
24 0.05 0.49 3.92 0.18 1.46  
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Figure 4.10 




























Time (h) 25D 1,25D 
1 1.94 0.41 4.27 0.56 0.84 1.94 
4 0.54 2.47 0.53 0.42 5.13 2.04 
8 1.53 1.51 16.20 0.93 0.78 30.25 
16 1.17 9.76 2.36 0.94 0.97 4.57 
24 3.88 2.70 0.01 1.62 0.98 0.04 
Time (h) 25D 1,25D 
1 0.58 0.72 0.62 0.79 0.74 1.01 
4 1.61 2.31 0.94 1.52 3.67 0.84 
8 1.19 1.38 0.81 0.87 1.72 0.77 
16 1.76 1.04 6.39 0.79 1.10 2.90 
24 1.76 0.85 2.62 1.56 0.72 7.76 
Time (h) 25D 1,25D 
1 0.41 0.61 1.66 0.34 0.46 0.86 
4 0.99  2.17 0.26  2.85 
8 1.01 1.49 2.23 0.50 0.82 0.23 
16 2.55 2.85 22.40 8.27 0.27  
24 0.99 1.17 1.14 1.76 0.44 1.25 
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Figure 4.11 

































Time (h) 25D 1,25D 
1 0.23 0.77 2.22 0.88 0.67 1.93 
4 3.40 0.62 0.35 1.74 0.96 0.37 
8 0.24 1.27 2.97 0.45 8.66 1.82 
16 1.12 0.87 1.25 1.59 2.04 0.56 
24 0.85 1.03 0.89 8.19 0.97 3.40 
Time (h) 25D 1,25D 
1 0.23 0.77 2.22 0.88 0.67 1.93 
4 3.40 0.62 0.35 1.74 0.96 0.37 
8 0.24 1.27 2.97 0.45 8.66 1.82 
16 1.12 0.87 1.25 1.59 2.04 0.56 
24 0.85 1.03 0.89 8.19 0.97 3.40 
Time (h) 25D 1,25D 
1 0.57 0.54 0.85 2.00 0.46 0.68 
4 7.32 2.80 
 
3.82 1.71 
 8 1.78 1.29 6.39 0.65 0.87 2.60 
16 0.59 1.53 0.50 
 
2.82 0.54 
24 2.58 0.54 1.49 1.54 0.66 1.66 
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Figure 4.12 





























Time (h) 25D 1,25D 
1 0.56 0.26 0.32 4.42 1.59 0.63 
4 1.53 0.92 1.79 3.70 0.57 2.19 
8 0.27 0.191 0.76 0.20 1.17 0.43 
16 2.13 0.510 0.88 5.67 0.06 2.98 
24 0.981 3.404 3.42 0.27 10.43 0.33 
Time (h) 25D 1,25D 
1 2.79 0.38 1.43 7.96 0.55 1.53 
4 1.19 2.27 0.43 4.03 3.72 0.65 
8 2.31 1.63 1.38 0.47 0.19 1.85 
16 9.43 0.03 8.18 0.40 0.01 2.84 
24 0.24 0.51 4.26 0.41 0.51 5.88 
Time (h) 25D 1,25D 
1 1.06 0.19 0.50 1.22 0.18 0.01 
4 1.85  0.01 1.01  0.59 
8 0.38 2.74 13.81 0.01 9.69 0.44 
16 7.72 0.55 1.09 10.08 0.17  
24 0.66 1.65 1.38 0.06 0.09 0.19 
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